pyrroles has been researched along with Carcinoma, Renal Cell in 1456 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 303 (20.81) | 29.6817 |
| 2010's | 1123 (77.13) | 24.3611 |
| 2020's | 30 (2.06) | 2.80 |
| Authors | Studies |
|---|---|
| Armitage, JN; Barrett, T; Connolly, S; Eisen, TGQ; Fife, KM; Gallagher, FA; Ingleson, V; Machin, AJ; Matakidou, A; Mullin, J; Priest, AN; Qian, W; Riddick, ACP; Stewart, GD; Thompson, N; Ursprung, S; Warren, A; Welsh, SJ; Zaccagna, F | 1 |
| Deniz, OC; Erdamar, S; Gündoğdu, Y; Köksal, İ; Saka, D; Şişman, G | 1 |
| Matsuda, T; Matsuo, T; Mitsunari, K; Miyata, Y; Mukae, Y; Nakamura, Y; Ohba, K; Sakai, H | 1 |
| Carbasse, C; Jacot, W; Leenhardt, F; Perrier, C; Pinguet, F; Viala, M | 1 |
| Danser, AHJ; Dechend, R; Dörr, A; Flörcken, A; Garrelds, IM; Kuehne, T; Linz, P; Markó, L; Müller, DN; van den Meiracker, AH | 1 |
| Gandhi, KA; Gota, V; Gurjar, M; Joshi, A; Mehta, P; Nookala, M; Noronha, V; Patil, A; Prabhash, K; Rane, P; Sharma, J | 1 |
| Fallah-Rad, N; Fleshner, L; Fleshner, N; Hersey, K; Nguyen, S; O'Halloran, S; Tiwari, R; Wise, J | 1 |
| Aarts, MJB; Brouns, SLN; de Bruijn, P; Heemskerk, JWM; Koolen, SLW; Kuijpers, MJE; Peters, NAJB; Sabrkhany, S; Swieringa, F; Tullemans, BME; van den Berkmortel, FWPJ | 1 |
| Kocak, I; Kocakova, I; Rihacek, M; Rihackova, E; Selingerova, I; Sterba, J; Valik, D | 1 |
| Amaro, F; Bastos, ML; Carvalho, M; Guedes de Pinho, P; Pinto, J; Pisoeiro, C; Valente, MJ | 1 |
| Afonso, J; Afonso, R; Alonso-Gordoa, T; Anguera, G; Asensio, Ú; Campayo, M; Casinello, J; Cassinello, NV; Climent, MA; de España, CG; de Velasco, G; Fernández-Calvo, O; Fernández-Parra, EM; Gallardo, E; García Del Muro, X; García Sánchez, L; García-Carbonero, I; González, IC; López-Martín, A; Méndez-Vidal, MJ; Núñez, NF; Ortega, EM; Pinto, Á; Polo, SH; Reig, O; Rodríguez-Vida, A; Rosero, A; Sánchez, ÁR; Santasusana, MD; Torregrosa, D; Valiente, PG | 1 |
| Aljubran, A; Alzahrani, A; Alzannan, N; Badran, A; Bazarbashi, S; Elhassan, T; Elshenawy, M; Gad, AM; Maraiki, F | 1 |
| Ashby, CR; Chen, ZS; Dai, SJ; He, Q; He, WF; Jin, J; Li, SY; Wang, JQ; Xie, Y; Zhang, JS | 1 |
| Carducci, MA | 1 |
| Ades, S; Ernstoff, MS; Gui, J; Highhouse, BJ; Labrie, BM; Lewis, LD; Ness, DB; Pooler, DB; Zhou, J | 1 |
| Del Bene, G; Faggiano, A; Gianfrilli, D; Giannetta, E; Lauretta, R; Lenzi, A; Longo, F; Pozza, C; Rizza, L; Sbardella, E; Tenuta, M | 1 |
| Cao, DL; Huo, DZ; Qu, YY; Shi, GH; Wang, J; Xu, WH; Ye, DW; Yin, GC; Zhang, HL | 1 |
| Agarwal, P; Krishna, M; Lang, M; Liao, PJ; Linehan, WM; Matsumoto, S; Mitchell, JB; Neckers, L; Railkar, R; Ricketts, CJ; Sourbier, C; Trepel, JB; Wei, D; Wei, MH; Yang, Y | 1 |
| Aljubran, A; Alzahrani, A; Badran, A; Bazarbashi, S; Eldali, A; Elshenawy, MA; Shahin, A | 1 |
| Akiyoshi, H; Mie, K; Miura, N; Nishida, H; Tanaka, T; Yamazaki, H | 1 |
| Bai, X; Chi, Z; Cui, C; Dai, J; Ding, L; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X; Zhou, L | 1 |
| Desar, IME; Krens, SD; Mulder, SF; Smilde, T; van der Graaf, WTA; van Erp, NP; van Herpen, CML; Westerdijk, K | 1 |
| Chen, N; Chen, Z; He, Q; Huang, Z; Jiang, H; Peng, D; Wan, P; Zhong, W | 1 |
| Das, A; Ganjoo, A; Ganjoo, S | 1 |
| Hatakeyama, S; Ohyama, C | 1 |
| Armstrong, AJ; Carmack, A; Eisen, T; Garcia, JA; George, DJ; Hainsworth, JD; Halabi, S; Hawkins, RE; Jones, RJ; Kollmannsberger, CK; Logan, TF; Nixon, AB; Pickering, LM; Picus, J; Protheroe, A; Puzanov, I; Ryan, CW; Stadler, WM; Vaishampayan, UN; Yang, Q | 1 |
| Balasubramanian, A; Bolton, D; Perera, M; Qu, L; Weickhardt, A | 1 |
| Antonuzzo, A; Artale, S; Barzaghi, S; Bertù, L; Bolzacchini, E; Bregni, M; Danova, M; Dentali, F; Galli, L; Giordano, M; Nigro, O; Pinotti, G; Torchio, M | 1 |
| Bendová, B; Büchler, T; Fiala, O; Filipovský, J; Fínek, J; Hora, M; Ostašov, P; Rozsypalová, A; Šorejs, O; Šustr, J; Trávníček, I | 1 |
| Cai, J; Guo, H; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xia, S; Xing, N; Ye, DW; Zhang, HL; Zhang, X; Zou, Q | 1 |
| Thomas, T | 1 |
| Dahlbäck, B; Fritz, HKM; Gustafsson, A | 1 |
| Barrios, CH; Beck, JT; Berkowitz, N; Chen, D; Cheung, F; Cosgriff, T; Flaig, TW; Geoffrois, L; Kim, TM; Knox, JJ; Marker, M; Motzer, RJ; Niolat, J; Page, RD; Patel, P; Pittman, K; Rha, SY; Sabbatini, R; Srimuninnimit, V; Yadav, S | 1 |
| Agarwal, N; Figlin, RA; Hariharan, S; Hutson, TE; Li, CX; Martini, JF; Motzer, RJ; Williams, JA | 1 |
| Kanehira, M; Kato, R; Kato, Y; Matsuura, T; Obara, W; Takata, R | 1 |
| Buda-Nowak, A; Dumnicka, P; Herman, RM; Kucharz, J; Kusnierz-Cabala, B; Kuzniewski, M; Zygulska, AL | 1 |
| Astsaturov, I; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Naito, S; Tulin, A; Uzzo, RG | 1 |
| Fujisawa, M; Harada, K; Hirai, M; Hirata, S; Ioroi, T; Miyake, H; Nakagawa, T; Watanabe, A; Yamamoto, K; Yano, I | 1 |
| Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L | 1 |
| Ezz El Din, M | 1 |
| Cosmai, L; Porta, C; Previtali, P | 1 |
| Cózar-Olmo, JM; Flores-Martín, JF; Moreno-Jiménez, J; Puche-Sanz, I; Vázquez-Alonso, F | 1 |
| Antón, L; Basterretxea, L; Castellano, D; Del Muro, XG; Dueñas, M; Esteban, E; Gallardo, E; Juan-Fita, MJ; Laínez, N; Lambea, J; León, L; Maroto, JP; Martinez-Fernández, M; Méndez-Vidal, MJ; Paramio, JM; Pérez-Valderrama, B; Puente, J; Samaniego, ML; Sanz, J; Suarez, C; Suárez-Paniagua, B; Vázquez, S | 1 |
| Crumbaker, M; Guminski, A; Gurney, H; Pavlakis, N; Sabanathan, D; Wong, S | 1 |
| Apellániz-Ruiz, M; Böhringer, S; Boven, E; Castellano, D; Diekstra, MH; García-Donás, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RHJ; Rini, BI; Rodríguez-Antona, C; Roldán, JM; Swen, JJ | 1 |
| Greco, F; Hadjinicolaou, AV; Moldenhauer, I; Nothacker, M; Peinemann, F; Roßmeißl, D; Seliger, B; Unverzagt, S | 1 |
| Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Zhang, J; Zhou, L | 1 |
| Blommestein, HM; De Groot, S; Kiemeney, LALM; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Antón-Aparicio, L; Arranz, JA; Bayona, C; Bolós, MV; Castellano, D; Climent, MA; Espinosa, E; Esteban, E; Fernández Parra, E; Gallardo, E; Gallegos, I; García Donas, J; González Del Alba, A; Grande, E; Llinares, J; Maroto, JP; Méndez, MJ; Samaniego, L | 1 |
| Belaud-Rotureau, MA; Bensalah, K; Bernhard, JC; Brunot, A; Dugay, F; Dupuis, F; Kammerer-Jacquet, SF; Laguerre, B; Lespagnol, A; Mathieu, R; Medane, S; Mosser, J; Peyronnet, B; Ravaud, A; Rioux-Leclercq, N; Verhoest, G; Yacoub, M | 1 |
| Iwamoto, H; Kugoh, H; Okada, F; Onuma, K; Osaki, M; Sejima, T; Takenaka, A; Yamaguchi, N; Yumioka, T | 1 |
| Bertolaso, P; Cochin, V; Daste, A; Gross-Goupil, M; Molimard, M; Ravaud, A | 1 |
| Agarwal, N; Gill, DM; Vaishampayan, U | 1 |
| Boult, JKR; Reynolds, AR; Robinson, SP; Vasudev, NS | 1 |
| Bergmann, L; Diekstra, MH; Fritsch, A; Gauler, T; Guchelaar, HJ; Hauser, S; Houtsma, D; Jaehde, U; Kanefendt, F; Kiemeney, LA; Kinzig, M; Moes, D; Moritz, B; Mross, K; Oosterwijk, E; Roessler, M; Schindele, D; Sörgel, F; Stelzer, C; Swen, JJ | 1 |
| Cha, TL; Chang, SY; Huang, SM; Lai, XM; Liu, SY; Sun, GH; Tsai, YT | 1 |
| Balestra, A; Bay, JO; Bernard, MA; Chevreau, C; Culine, S; Droz-Perroteau, C; Ferrière, JM; Fourrier-Réglat, A; Grelaud, A; Gross-Goupil, M; Lamarque, S; Lassalle, R; Moore, N; Moulin, F; Noize, P; Ravaud, A; Robinson, P; Rouyer, M | 1 |
| Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S | 1 |
| Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Laine, M; Ravaud, A | 1 |
| Bayat, S; Bensalah, K; Bernhard, JC; Brunot, A; Campillo-Gimenez, B; Dupuis, F; Edeline, J; Kammerer-Jacquet, SF; Laguerre, B; Lefort, M; Lespagnol, A; Mathieu, R; Mosser, J; Peyronnet, B; Ravaud, A; Rioux-Leclercq, N; Verhoest, G; Yacoub, M | 1 |
| Amdahl, J; Chandiwana, D; Delea, TE; Diaz, J; Park, J; Sharma, A | 1 |
| Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R | 1 |
| Chen, S; Gu, D; Wu, D; Xie, G; Zhang, L | 1 |
| Balakrishnar, B; Chan, M; Coulter, S; Fox, P; Gebski, V; Gurney, H; Liddle, C; Sabanathan, D; Zhang, A | 1 |
| Bao, L; Cao, Q; Chen, K; Chen, X; Gao, Y; Hu, W; Li, X; Liu, L; Qu, Y; Ru, Z; Ruan, H; Song, Z; Tong, J; Wang, K; Xiao, H; Xiao, W; Xiong, Z; Xu, G; Yang, H; Yuan, C; Zhang, X | 1 |
| Fukasawa, S; Hara, H; Horie, S; Kanao, K; Kimura, G; Kondo, T; Mizuno, R; Nakazawa, H; Oya, M; Shoji, S; Tanabe, K; Ueda, T | 1 |
| Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Fujii, Y; Ishioka, J; Kawamura, N; Kihara, K; Matsuoka, Y; Okuno, T; Saito, K; Uehara, S; Yamamoto, S; Yasuda, Y; Yokoyama, M; Yonese, J; Yuasa, T | 1 |
| Dalhaug, A; Nieder, C; Norum, J; Pawinski, A; Syed, MA | 1 |
| Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L | 2 |
| Goto, K; Hayashi, T; Inoue, S; Kitadai, Y; Kitano, H; Matsubara, A; Sentani, K; Shinmei, S; Teishima, J; Yasui, W; Yuge, R | 1 |
| Ambrosetti, D; Auberger, P; Bikfalvi, A; Borchiellini, D; Cassuto, O; Chamorey, E; Claren, A; Cooley, LS; Dufies, M; Escudier, B; Ferrero, JM; Frangeul, A; Gal, J; Giuliano, S; Grépin, R; Guyot, M; Jacquel, A; Milano, G; Ndiaye, PD; Negrier, S; Pagès, G; Parola, J; Porta, C; Rioux-Leclercq, N; Schiappa, R; Viotti, J | 1 |
| Ishikawa, S; Katagiri, A; Kazama, A; Mizusawa, T | 1 |
| Akslen, LA; Beisland, C; Bostad, L; Haug, Å; Heinrich, D; Hjelle, KM; Pilskog, M; Straume, O | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhong, H; Zhou, L | 1 |
| Bersanelli, M; Buti, S; Donini, M; Gattara, A; Leonardi, F; Passalacqua, R | 1 |
| Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S | 1 |
| Bjarnason, GA; Raphael, J; Thawer, A | 1 |
| Breza, J; Carteni, G; Casey, M; Chang, YH; Donskov, F; Escudier, B; George, DJ; Gerletti, P; Laguerre, B; Lechuga, M; Lin, X; Magheli, A; Motzer, RJ; Pandha, HS; Pantuck, AJ; Patard, JJ; Patel, A; Ravaud, A; Serfass, L; Staehler, M; Tomczak, P | 1 |
| Adelaiye-Ogala, R; Arisa, S; Arrington, J; Buck, M; Budka, J; Chintala, S; Ciamporcero, E; Damayanti, NP; Draetta, GF; Elbanna, M; Ferris, M; Hancock, B; Hollenhorst, P; Hsu, CC; Irudayaraj, J; Keilhack, H; Kota, J; McCarthy, BP; Miles, KM; Orillion, A; Persohn, SA; Pettazzoni, P; Pili, R; Radovich, M; Seshadri, M; Shen, L; Tao, WA; Territo, PR; Zang, Y | 1 |
| Cárcano, FM; da Silva Oliveira, RJ; de Lima, MA; Morini Matushita, MA; Reis, RM; Ribeiro, GG; Scapulatempo-Neto, C; Viana, CR; Zucca, LE | 1 |
| Casuscelli, J; Hsieh, JJ | 1 |
| Ariad, S; Douvdevani, A; Dresler, H; Keizman, D; Mermershtain, W; Neulander, EZ; Riff, R; Rouvinov, K; Shani-Shrem, N | 1 |
| Bao, L; Chen, K; Gao, Y; Hu, W; Liu, L; Lou, N; Qu, Y; Ru, Z; Ruan, H; Tong, J; Xiao, H; Xiao, W; Xiong, Z; Xu, G; Yang, H; Yuan, C; Zhang, X; Zhou, Y | 1 |
| He, HL; Yao, WX | 1 |
| Agarwal, N; Ghate, SR; Li, N; Meiselbach, MK; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 2 |
| Albersen, M; Beuselinck, B; Couchy, G; de Reynies, A; Job, S; Laguerre, B; Lerut, E; Meiller, C; Méjean, A; Oudard, S; Patard, JJ; Rioux-Leclercq, N; Schöffski, P; Verbiest, A; Verkarre, V; Zucman-Rossi, J | 1 |
| de Rochefort, L; Dubuisson, RM; Ingels, A; Lassau, N; Leguerney, I; Opolon, P; Pitre-Champagnat, S; Poirier-Quinot, M; Robert, P; Robin, S; Violas, X | 1 |
| Duplomb, S; Errihani, H; Layachi, M; Raiss, H; Tartas, S | 1 |
| Fukuda, H; Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| 'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ | 1 |
| Cao, P; Jiang, XJ; Xi, ZJ | 1 |
| DU, YQ; Hu, FZ; Liu, CL; Qin, CP; Sheng, ZZ; Xu, T; Yin, HQ; Zhao, YH | 1 |
| Buchler, T; Chloupkova, R; Dusek, L; Fiala, O; Finek, J; Kiss, I; Kopeckova, K; Kopecký, J; Lakomy, R; Melichar, B; Petrakova, K; Poprach, A; Slaby, O; Studentova, H; Zemanova, M | 1 |
| Laguna, MP | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y | 1 |
| Atri, M; Bailey, C; Bjarnason, GA; Burns, PN; Hudson, JM; Kiss, A; Milot, L; Stanisz, G; Williams, R | 1 |
| Asai, A; Matsunaga, N; Matsuo, T; Mitsunari, K; Miyata, Y; Mochizuki, Y; Ohba, K; Sakai, H; Yasuda, T | 1 |
| Pandey, M; Ramasamy, M; Shukla, M | 1 |
| Drakaki, A; Faiena, I; Pantuck, AJ; Salmasi, A | 1 |
| Golinelli, G; Pia, F; Rosa, MS; Toso, A; Valletti, PA | 1 |
| Cserháti, A; Kahán, Z; Kószó, R; Maráz, A; Révész, J; Szilágyi, É; Uhercsák, G; Varga, L; Varga, Z | 1 |
| Debbagh, A; Errihani, H; Ichou, M; Mahi, M; Sbitti, Y; Slimani, K | 1 |
| Arén Frontera, O; Barrios, CH; Barthélémy, P; Bracarda, S; Castellano, D; Chen, AC; Choueiri, TK; Doan, J; Donskov, F; Escudier, B; George, S; Grimm, MO; Gurney, H; Hammers, HJ; Hawkins, R; Kollmannsberger, CK; McDermott, DF; McHenry, MB; Mekan, S; Melichar, B; Motzer, RJ; Neiman, V; Plimack, ER; Porta, C; Powles, T; Ravaud, A; Rini, BI; Salman, P; Sharma, P; Tannir, NM; Tomita, Y; Wind-Rotolo, M | 1 |
| Bakouny, Z; Eid, R; Haddad, FG; Kattan, J; Kourie, HR | 1 |
| Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W | 1 |
| Stone, L | 3 |
| Iizuka, J; Ishihara, H; Iwamoto, K; Kondo, T; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Horie, S; Kanayama, M; Nagata, M; Nagaya, N | 1 |
| Buchler, T; Fiala, O; Juracek, J; Kopecky, J; Kovacova, J; Poprach, A; Slaby, O; Svoboda, M | 1 |
| Aki, R; Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K | 1 |
| Iizuka, J; Ishihara, H; Iwamoto, K; Kobayashi, H; Kondo, T; Omae, K; Tachibana, H; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Arai, Y; Ito, A; Kawasaki, Y; Kikuchi, M; Mano, N; Mitsuzuka, K; Noda, A; Saito, H; Sato, Y; Suzuka, M; Takasaki, S; Tanaka, M; Yamaguchi, H; Yamashita, S | 1 |
| Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
| Aitchison, M; Albiges, L; Beauval, JB; Beisland, C; Bensalah, K; Bernhard, JC; Chevreau, C; Colas, S; Cormier, L; Escudier, B; Geoffrois, L; Gravis, G; Gross-Goupil, M; Guy, L; Hubert, J; Laguerre, B; Lang, H; Lebret, T; Lechevallier, E; Linassier, C; Méjean, A; Oudard, S; Patard, JJ; Ravaud, A; Rolland, F; Theodore, C; Thezenas, S; Thiery-Vuillemin, A; Timsit, MO | 1 |
| Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL | 1 |
| Chen, N; Liu, J; Shen, P; Yao, J; Zeng, H; Zhang, X | 1 |
| Adashek, JJ; Bergerot, CD; Bergerot, PG; Dizman, N; Hsu, J; Pal, SK | 1 |
| Bajic, P; Clark, JI; Flanigan, RC; Joyce, CJ | 1 |
| Akiyama, N; Kogo, M; Kurihara, T; Murata, T; Nagatani, A; Naito, Y; Ogawa, Y; Sakamaki, H; Sasaki, H; Sasaki, T; Sunaga, T; Tomura, K; Usuda, M | 1 |
| Bargo, D; Bent-Ennakhil, N; Blackburn, S; Boegemann, M; Hubbe, M; Thomaidou, D; Wood, R | 1 |
| Escudier, B; Méjean, A; Thezenas, S | 1 |
| Kondoh, CN; Miura, Y; Yamanaka, T | 1 |
| Bex, A; Haanen, J; Powles, T | 1 |
| Adashek, JJ; Bergerot, PG; Boyd, T; Carret, AS; Chhabra, S; Forero-Torres, A; Gartner, EM; Hoimes, CJ; Li, H; Morris, JC; Pal, SK; Smith, DC; Thompson, JA; Vogelzang, NJ; Yu, X | 1 |
| Escudier, B | 2 |
| Flanigan, RC | 1 |
| Hama, Y; Hayata, N; Masuda, N; Satogami, N; Segawa, T; Sunada, T; Yoshida, T; Yoshikawa, T | 1 |
| Demkow, T; Demkow, U; Dumnicka, P; Giza, A; Kucharz, J; Kusnierz-Cabala, B; Wiechno, P | 1 |
| Bartnik, E; Brodziak, A; Czarnecka, AM; Dendek, C; Korniluk, J; Labochka, D; Sobczuk, P; Szczylik, C | 1 |
| Albiges, L; Bersanelli, M; Buti, S; Escudier, B; Fischer, R; Houede, N; Iacovelli, R; Laguerre, B; Lheureux, S; Negrier, S; Oudard, S; Porta, C; Procopio, G; Ravaud, A | 1 |
| Kim, H; Nagata, Y; Shoji, S; Terachi, T; Uchida, T; Usui, Y | 1 |
| Salup, RR | 1 |
| Cohen, SA; Derweesh, IH; Kane, CJ; Kopp, RP; Liss, MA; Mehrazin, R; Millard, F; Palazzi, KL; Park, SK; Patel, N; Patterson, AL; Raheem, OA; Stroup, SP | 1 |
| Berkers, J; Beuselinck, B; Claes, B; Couchy, G; Deplanque, G; Descazeaud, A; Elaidi, R; Gravis, G; Joly, F; Karadimou, A; Lambrechts, D; Lebret, T; Leclercq, NR; Lerut, E; Méjean, A; Molinié, V; Oudard, S; Paridaens, R; Patard, JJ; Schöffski, P; Teghom, C; van Poppel, H; Verkarre, V; Wolter, P; Zucman-Rossi, J | 1 |
| Bravo, J; Cañueto, J; de Unamuno, P; Mir-Bonafé, JM | 1 |
| Gelmann, EP; Lim, E | 1 |
| Bex, A; Haanen, J | 1 |
| Abadie-Lacourtoisie, S; Azzouzi, AR; Bigot, P; Chautard, D; Delva, R; Hoarau, N; Latteux, G; Lebdai, S | 1 |
| Boudou-Rouquette, P; Delongchamps, NB; Giroux, J; Goldwasser, F; Huillard, O; Mir, O; Peyromaure, M; Ropert, S; Tlemsani, C; Zerbib, M | 1 |
| Berger, J; Berkers, J; Beuselinck, B; Bigot, P; Claes, B; Couchy, G; de la Taille, A; Karadimou, A; Lambrechts, D; Lerut, E; Linassier, C; Méjean, A; Négrier, S; Oudard, S; Paridaens, R; Patard, JJ; Schöffski, P; Tourani, JM; Verkarre, V; Wolter, P; Zucman-Rossi, J | 1 |
| Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M | 1 |
| Jiang, XL; Luo, CL; Wu, XH; Zhang, Y | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J | 1 |
| Geissler, AK; Liu, Q; Mier, JW; Panka, DJ | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Maccaroni, E; Minardi, D; Montironi, R; Muzzonigro, G; Nicoletti, S; Scartozzi, M | 1 |
| Bydlowski, SP; Chierice, GO; Ferreira, AK; Filho, OM; Freitas, VM; Levy, D; Maria, DA; Rici, RE; Ruiz, JL | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, DH; Lee, JL; Park, I; Park, K; Park, SJ; Song, C | 1 |
| Inayama, Y; Kubota, Y; Makiyama, K; Nakaigawa, N; Nakayama, T; Sakata, R; Sano, F; Tatenuma, T; Yao, M | 1 |
| Győrffy, B; Likó, I; Pénzváltó, Z; Schäfer, R; Szász, AM; Szendrői, A; Sztupinszki, Z; Tegze, B | 1 |
| An, H; Hu, X; Lin, Z; Liu, H; Liu, L; Liu, Y; Lv, T; Xu, J; Xu, L; Yin, H; Zhang, H; Zhang, J; Zhu, Y | 1 |
| Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD | 1 |
| Brugia, M; Cerullo, C; Neri, B; Rangan, S; Rediti, M; Tassi, R; Vannini, A | 1 |
| Kabashima, K; Matsuda, A; Matsui, M; Matubara, K; Sasahashi, M; Ueharaguchi, Y | 1 |
| Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C | 1 |
| Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E | 1 |
| Caulfield, TR; Cooper, SJ; Copland, JA; Marlow, LA; Tan, WW; Tun, HW; von Roemeling, CA; Wei, JJ; Wu, K | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Bergerot, P; Carmichael, C; Figlin, RA; Hsu, J; Hsu, S; Hu, J; Lau, C; Liu, X; Pal, SK; Saikia, J; Twardowski, P; Yuh, BF | 1 |
| Arrowsmith, ER; Crane, EJ; Franco, LA; Hainsworth, JD; Khatcheressian, J; Rubin, MS | 1 |
| Albarrán-Planelles, C; Báez-Perea, JM; Jiménez-Gallo, D; Linares-Barrios, M; Martínez-Rodríguez, A | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Koeseoglu, M; Kucukzeybek, Y; Payzin, KB; Somali, I; Tarhan, MO; Yildiz, Y | 1 |
| Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM | 1 |
| Barrios, CH; Bukowski, R; Escudier, B; Fly, K; Gore, ME; Hutson, TE; Lin, X; Matczak, E; Motzer, RJ; Rini, BI | 1 |
| Feldman, DR; Ginsberg, MS; Hsieh, JJ; Jia, X; Molina, AM; Motzer, RJ; Patil, S; Velasco, S | 1 |
| Bono, P; Joensuu, H; Peltola, K; Rautiola, J; Utriainen, T | 1 |
| Dong, B; Jha, BK; Nguyen, CT; Polyakova, I; Silverman, RH | 1 |
| Chung, B; Tsimafeyeu, I; Zart, JS | 1 |
| Alemany, I; Arranz, JA; Bellmunt, J; Castellano, DE; Climent, MA; Esteban, E; Font, A; Gallardo, E; Garcia-Donas, J; González Del Alba, A; Hernando, S; Leandro-García, LJ; Mellado, B; Moreno, F; Morente, M; Puente, J; Robledo, M; Rodríguez-Antona, C | 1 |
| Brugarolas, J; Jacobs, C; Kim, DW; Pedrosa, I; Straka, C; Timmerman, RD | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Itoh, K; Komai, Y; Matsubara, N; Mukai, H; Naito, Y; Sakai, Y | 1 |
| Bamia, C; Bamias, A; Beuselinck, B; Chrisofos, M; de Guillebon, E; Dimopoulos, MA; Diosynopoulos, D; Elaidi, RT; Escudier, B; Fountzilas, G; Lang, H; Oudard, S; Papazisis, K; Stravodimos, K; Tzannis, K; Wolter, P | 1 |
| Ishida, R; Kobayashi, H; Nishikimi, T; Tsuzuki, T; Yamada, H; Yamauchi, Y; Yokoi, K; Yoshida, S | 1 |
| Bianco, R; Damiano, V; Formisano, L; Martignoni, G; Massari, F; Nappi, L; Rosa, R; Scarpa, A; Tortora, G | 1 |
| Abernethy, AP; Chen, C; George, DJ; Harrison, MR; Kirkendall, DT; Korytowsky, B; Stepanski, EJ; Walker, MS | 1 |
| Dai, B; Hong, YP; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Choi, YA; Ko, SY; Lee, KE; Park, JC; Park, SY; Seo, MJ; Sim, EH; Yang, YJ | 1 |
| Ingels, A; Nolley, R; Peehl, DM; Santos, J; Thong, AE; Valta, MP; Young, SR; Zhao, H | 1 |
| Soulières, D | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Gong, K; He, ZS; Huang, LH; Jin, J; Li, XS; Shen, C; Song, G; Song, Y; Yu, W; Zhang, CJ; Zhang, Q; Zhang, Z; Zhao, J; Zhao, PJ; Zhao, Z; Zhou, LQ | 1 |
| Atala, A | 1 |
| Chovanec, M; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Rajec, J | 1 |
| Boleti, E; Cella, D; Choueiri, TK; Crescenzo, R; De Giorgi, U; de Souza, P; Deen, K; Fife, K; Guo, J; Hackshaw, MD; Harmenberg, U; Hawkins, R; Hutson, TE; Jin, J; Jones, R; McCann, L; Merchan, JR; Motzer, RJ; Nathan, P; Pandite, LN; Reeves, J; Staehler, M; Sternberg, CN; Uemura, H; Wang, J | 1 |
| Fujiwara, K; Fukuda, N; Kawata, N; Nagase, H; Obinata, D; Sato, A; Soma, M; Takahashi, S; Yamaguchi, K | 1 |
| Heng, DY; Molina, AM; Motzer, RJ | 1 |
| Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
| Deng, L; Gao, H | 1 |
| Kubota, Y; Makiyama, K; Nakaigawa, N; Nakamura, M; Sakata, R; Sano, F; Tatenuma, T; Yao, M | 1 |
| Ahn, JB; Kim, HR; Kim, HS; Kwon, WS; Lee, JH; Lim, SM; Park, HS; Rha, SY; Shin, SJ; Tanigawara, Y | 1 |
| Atkinson, BJ; Bathala, T; Corn, P; Jonasch, E; Kalra, S; Tannir, NM; Wang, X | 1 |
| Phillips, R | 2 |
| Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ | 1 |
| Chang, C; Chen, X; Jiang, H; Lou, D; Qin, Q; Wang, J; Zhang, W; Zhong, D; Zhou, A | 1 |
| Brunelle, S; Cappiello, M; Gilabert, M; Gravis, G; Provansal, M; Salem, N; Tarpin, C; Thomassin, J; Walz, Y | 1 |
| Korytowsky, B; Lechuga, MJ; Lin, X; Matczak, E; Molina, AM; Motzer, RJ; Wiltshire, R | 1 |
| Bertheau, P; Bousquet, G; de Bazelaire, C; Faivre, S; Ferreira, I; Germain, S; Janin, A; Leboeuf, C; Mongiat-Artus, P; Raymond, E; Varna, M; Wang, L | 1 |
| Egawa, S; Endo, K; Hatano, T; Ishii, G; Kishimoto, K | 1 |
| Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C | 1 |
| Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P | 1 |
| Fujita, K; Hatano, K; Kawashima, A; Nakai, Y; Nakata, W; Nonomura, N; Sato, M; Takayama, H; Uemura, M; Yoshida, T | 1 |
| Cho, IC; Chung, J; Joung, JY; Kwon, WA; Lee, KH; Nam, BH; Seo, HK; Yu, A | 1 |
| Dornbusch, J; Erdmann, K; Froehner, M; Fuessel, S; Meinhardt, M; Wirth, MP; Wolff, I; Zacharis, A; Zastrow, S | 1 |
| Inoue, T; Kawakita, S; Kinoshita, H; Masuda, T; Matsuda, T; Murota, T; Nishida, T | 1 |
| Babaian, KN; Hu, X; Kenney, PA; Lin, X; Maity, T; Merrill, MM; Su, SC; Wood, CG; Yang, SF; Zhang, XY | 1 |
| Campbell, S; Dreicer, R; Elson, P; Garcia, JA; Medsinge, A; Rini, BI; Salem, ME; Shah, SN; Wood, LS | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Alkiş, N; Bal, O; Demirci, A; Durnali, A; Ekinci, AŞ; Eşbah, O; Oksüzoğlu, B | 1 |
| Ishii, H; Kadota, J; Kushima, H | 1 |
| Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H | 1 |
| Beuselinck, B; De Smet, R; Debruyne, PR; Depoorter, L; Dumez, H; Joniau, S; Karadimou, A; Lerut, E; Oudard, S; Paridaens, R; Schöffski, P; Strijbos, M; Teghom, C; Van Calster, B; Van Poppel, H; Vano, YA; Wolter, P; Zucman-Rossi, J | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Karshafian, R; Milot, L; Williams, R | 1 |
| DePrimo, SE; Eisen, T; Figlin, RA; Harmon, CS; Huang, X; Hudes, GR; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Négrier, S; Williams, JA | 1 |
| Bianconi, M; Burattini, L; Cascinu, S; Di Primio, R; Lucarini, G; Mazzucchelli, R; Minardi, D; Montironi, R; Muzzonigro, G; Pistelli, M; Santoni, M; Scartozzi, M | 1 |
| Arakawa-Todo, M; Hasegawa, T; Kajikawa, K; Kato, Y; Kobayashi, I; Matsuura, K; Nakamura, K; Nishikawa, G; Saito, H; Sumitomo, M; Tsukiyama, I; Yamada, Y; Yoshizawa, T; Zennami, K | 1 |
| Novara, G; Zustovich, F | 1 |
| Deen, K; McCann, L; Motzer, RJ | 1 |
| Copur, MS; Ramaekers, R; Tharnish, M | 1 |
| Wittes, J | 1 |
| Casper, J; Köhne, CH; Schumann-Binarsch, S | 1 |
| Chang, CX; Jiang, HY; Ma, JH; Qin, Q; Wang, JW; Zhang, W; Zhou, AP | 1 |
| Mihajlović, J; Pechlivanoglou, P; Postma, MJ; Sabo, A; Tomić, Z | 1 |
| Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J | 1 |
| De Braud, F; Iacovelli, R; Procopio, G; Verzoni, E | 1 |
| Amela, E; Blanc, E; Chevreau, C; Delva, R; Escudier, B; Ferlay, C; Négrier, S; Oudard, S; Ravaud, A; Rolland, F; Tosi, D | 1 |
| Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y | 1 |
| Dell'Aquila, E; Frezza, AM; Grasso, RF; Guida, FM; Lanzetta, G; Santini, D; Silletta, M; Silvestris, N; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P | 1 |
| Arlot-Bonnemains, Y; Belaud-Rotureau, MA; Dolley-Hitze, T; Goujon, JM; Jouan, F; Laguerre, B; Lorcy, N; Rioux-Leclercq, N; Verhoest, G; Vigneau, C | 1 |
| Chan, A; Chau, NM; Chong, XJ; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL | 1 |
| Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A | 1 |
| Berger, R; Boursi, B; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Hayat, H; Ish-Shalom, M; Keizman, D; Kovel, S; Maimon, N; Mermershtain, W; Neumann, A; Peer, A; Pili, R; Rouvinov, K; Sella, A; Sinibaldi, V; Weitzen, R | 1 |
| Schmutz, JL; Trechot, P | 1 |
| A, M; H J, H; L, M; M, K; N, M; P J, G; S, B | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Khalil, B; Kiss, A; Milot, LM; Williams, R | 1 |
| Kato, Y; Yamamoto, T | 1 |
| Bae, WK; Kim, HR; Kim, HY; Kim, KH; Lee, HJ; Lee, S; Lim, HY; Rha, SY; Sun, JM | 1 |
| Garcia-Roig, M; Lokeshwar, V; Ortiz, N | 1 |
| Hutchinson, L | 1 |
| Payton, S | 1 |
| Figlin, RA | 3 |
| Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T | 1 |
| Appleman, LJ; Bass, MB; Friberg, G; Friedland, D; Gordon, MS; Hong, DS; Kurzrock, R; Mendelson, DS; Rasmussen, E; Samlowski, WE; Tannir, N; Vogelzang, NJ; Wu, BM; Zhong, ZD | 1 |
| Berney, DM; Bharwani, N; Chowdhury, S; Dilks, P; Miquel, ME; Powles, T; Rockall, AG; Sahdev, A; Shawyer, A; Wilson, PD | 1 |
| Aieta, M; Amadori, D; Baldazzi, V; Basso, U; Burattini, L; Camerini, A; Chiuri, VE; De Giorgi, U; De Vincenzo, F; Ferrari, V; Fornarini, G; Lo Re, G; Luzi Fedeli, S; Masini, C; Moscetti, L; Rosti, G; Sacco, C; Sava, T; Scarpi, E | 1 |
| Dai, B; Hong, YP; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Chatterjee, P; Kumar, R; Sikka, K | 1 |
| Binger, KA; Bruce, JY; Carmichael, L; Eickhoff, J; Hammers, H; Heideman, JL; Jeraj, R; Johnston, SA; Kolesar, JM; Liu, G; Perlman, SB; Stein, MN | 1 |
| Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
| De Both, A; Kruse, V; Rottey, S; Somers, A; Van Belle, S; Van Bortel, L | 1 |
| Fujimoto, K; Momose, H; Morizawa, Y; Oyama, N; Takada, S; Toyoshima, Y | 1 |
| Huang, YL; Ping, SY; Shen, KH; Wu, CL; Yu, DS | 1 |
| Barrios, CH; Bukowski, RM; Escudier, B; Figlin, RA; Fly, K; Gore, ME; Hutson, TE; Larkin, JM; Lin, X; Martell, B; Matczak, E; Motzer, RJ; Rini, BI | 1 |
| Dalton, B; Peters, T; Piszczek, J; Ruether, D; Urbanski, S | 1 |
| Herman, RM; Krzemieniecki, K; Kucharz, J; Kuzniewski, M; Michałowska-Kaczmarczyk, A; Streb, J | 1 |
| Hashimoto, Y; Iizuka, J; Ikezawa, E; Kobayashi, H; Kondo, T; Nozaki, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Arranz, JA; Bellmunt, J; Calvo, A; Carles, J; Castellano, D; Climent, MA; del Alba, AG; Esteban, E; Font, A; Gallardo, E; Garcia-Donas, J; Gurpide, A; Guruceaga, E; Hernandez, AG; Lopez-Picazo, JM; Lozano, MD; Martínez, E; Mellado, B; Moreno, F; Perez-Gracia, JL; Prior, C; Puente, J; Rodriguez-Antona, C; Suarez, C | 1 |
| Ouzaid, I; Rini, B | 1 |
| Killock, D | 2 |
| Aieta, M; Amadori, D; Baldazzi, V; Basso, U; Burattini, L; Camerini, A; Chiuri, VE; De Giorgi, U; De Vincenzo, F; Ferrari, V; Fornarini, G; Lo Re, G; Luzi Fedeli, S; Masini, C; Moscetti, L; Rihawi, K; Rosti, G; Sava, T; Scarpi, E | 1 |
| Stadler, WM | 2 |
| De Lichtenberg, TH; Hermann, GG; Holm, ML; Højer Larsen, MJ; Mansourvar, Z; Rørth, M; Scheike, T | 1 |
| Haq, S; Hershman, JM; Liwanpo, L; Ro, C | 1 |
| Barbounis, V; Efremidis, A; Kostakis, ID; Koumakis, G; Lypas, G; Panopoulos, C; Tolia, M; Tryfonopoulos, D; Tsoukalas, N | 1 |
| Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B | 1 |
| Bergmann, L; Burkholder, I; Gauler, T; Grünwald, V; Kahl, C; Kube, U; Maute, L; Weikert, S | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Mittal, K; Najjar, YG; Rini, BI; Wood, L | 1 |
| Afshar, M; Islam, MR; Kunene, V; Miscoria, M; Pirrie, S; Porfiri, E | 1 |
| Baek, SH; Han, JS; Joo, KW; Kim, DK; Kim, H; Kim, TM; Kim, YS; Lee, J; Lee, SH; Oh, KH | 1 |
| Bang, YJ; Chang, JW; Chung, HC; Kwong, P; Lee, SH; Li, RK; Mainwaring, P; Ng, C; Pitman Lowenthal, S; Sriuranpong, V; Toh, CK; Yuan, J | 1 |
| Habuchi, T; Inoue, T; Maita, S; Narita, S; Numakura, K; Saito, M; Satoh, S; Tsuchiya, N; Yonese, J; Yuasa, T | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Akin, O; Berger, MF; Brannon, AR; Chen, YB; Cheng, EH; Cunha, LF; Hakimi, AA; Hsieh, JJ; Liu, H; Motzer, RJ; Pham, CG; Reuter, VE; Russo, P; Sander, C; Schultz, N; Scott, SN; Socci, ND; Takeda, S; Viale, A; Voss, MH | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Davis, MP; Figlin, RA; Korytowsky, B; Matczak, E; Michaelson, MD; Motzer, RJ; Négrier, S; Sandin, R | 1 |
| Karakiewicz, PI; Perrotte, P; Sun, M; Trinh, QD | 1 |
| Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC | 1 |
| Chambers, CR; Chu, MP; Ghosh, S; Ha, VH; Ngo, M; Sawyer, MB | 1 |
| Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F | 1 |
| Fujisawa, M; Furukawa, J; Harada, K; Miyake, H; Nishikawa, M; Tei, H | 1 |
| Cushen, SJ; MacEneaney, P; Maher, MM; McDermott, R; O'Sullivan, K; Power, DG; Ryan, AM; Teo, MY | 1 |
| Bono, P; Cella, D; De Giorgi, U; Diaz, J; Eisen, T; Escudier, B; Gschwend, JE; Hawkins, R; Khan, S; Mehmud, F; Négrier, S; Parikh, O; Porta, C; Powles, T; Redhu, S; Sevin, E; Sternberg, CN | 1 |
| Garnick, MB | 2 |
| Ando, Y; Funahashi, Y; Gotoh, M; Inada-Inoue, M; Matsukawa, Y; Sassa, N | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| Ahn, H; Cho, YM; Hong, JH; Jeong, IG; Kim, CS; Lee, JL; Song, C; Song, SH; You, D | 1 |
| Aik, OT; Htun, TH; Lim, NK; Meng, LL; Razack, AH | 1 |
| Fujikawa, A; Hayashi, H; Moriyama, M; Namura, K; Ohta, J; Ohtake, S; Sawada, T | 1 |
| Hamada, A; Kato, K; Kawanishi, H; Okumura, K; Sawada, A; Sunada, T | 1 |
| Nakamura, M; Sekiguchi, Z; Takeshima, T; Takizawa, A; Tsuchiya, F | 1 |
| Fu, W; Guo, G; He, Z; Jin, J; Li, X; Zhang, C; Zhang, X; Zhou, L | 1 |
| Boorjian, S | 1 |
| Bushmakin, AG; Cappelleri, JC; Charbonneau, C; Figlin, RA; Korytowsky, B; Michaelson, MD; Motzer, RJ; Négrier, S; Sandin, R | 1 |
| Biondani, P; DE Braud, F; Grassi, P; Porcu, L; Procopio, G; Testa, I; Torri, V; Verzoni, E | 1 |
| Choueiri, TK; Deen, K; Hutson, TE; McCann, L; Motzer, RJ | 1 |
| Aguilera, O; Borrero-Palacios, A; Caramés, C; Casado, V; Chamizo, C; Cristóbal, I; del Puerto-Nevado, L; García-Foncillas, J; Madoz-Gúrpide, J; Martínez-Useros, J; Rincón, R; Rodríguez-Remírez, M; Rojo, F; Rubio, G; Vega, R; Zazo, S | 1 |
| Fujisawa, M; Harada, K; Miyake, H; Miyazaki, A | 2 |
| Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN | 1 |
| Bates, S; Burotto, M; Fojo, T; Motzer, R; Stein, W; Wilkerson, J | 1 |
| Grünwald, V; Paglino, C; Porta, C | 1 |
| Luyken, J; Neuhaus, T; Stier, S | 1 |
| Anastasiou, I; Bamia, C; Bamias, A; Beuselinck, B; Chrisofos, M; Constantinides, C; Deliveliotis, C; Dimopoulos, MA; Elaidi, TR; Escudier, B; Liontos, M; Mitropoulos, D; Oudard, S; Papatsoris, A; Stravodimos, K; Tzannis, K | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Aitchison, M; Berney, D; Bex, A; Eory, L; Harrison, DJ; Laird, A; Lubbock, AL; Mackay, A; Martin, SA; McNeill, SA; Mullen, P; Nanda, J; O'Donnell, M; O'Mahony, FC; Overton, IM; Powles, T; Rashid, S; Riddick, AC; Stewart, GD | 1 |
| Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P | 1 |
| Dong, M; Fukuda, T; Fukudo, M; Inui, K; Kamba, T; Katsura, T; Matsubara, K; Mizuno, T; Ogawa, O; Terada, T; Vinks, AA; Yamasaki, T | 1 |
| Elledge, R; Elledge, RO; Raskauskiene, D | 1 |
| Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P | 1 |
| Fisher, R; Gutzeit, A; Koh, DM; Larkin, J; Lote, H; Sohaib, A; Thian, Y | 1 |
| Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M | 1 |
| Casserly, L; Gupta, R; Neenan, T; Quintyne, KI | 1 |
| Berger, J; Beuselinck, B; Cardinaels, N; Caty, A; Couchy, G; Joniau, S; Karadimou, A; Lambrechts, D; Lerut, E; Oudard, S; Paridaens, R; Patard, JJ; Ravaud, A; Schöffski, P; Sebe, P; Van Brussel, T; Verkarre, V; Wolter, P; Zerbib, M; Zucman-Rossi, J | 1 |
| Elkord, E; Gilham, DE; Hawkins, RE; Shablak, A | 1 |
| Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H | 1 |
| Go, S; Hanasaki, T; Hashimoto, T; Higuchi, Y; Ito, N; Kanamaru, S; Kanematsu, A; Kawakita, M; Kono, Y; Makino, Y; Matsumoto, K; Nagasawa, S; Nakanishi, Y; Nojima, M; Shimatani, K; Shimizu, Y; Shiraishi, Y; Suzuki, T; Taoka, R; Togo, Y; Tsuchihashi, K; Utsunomiya, N; Yamamoto, S; Yo, T | 1 |
| Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P | 1 |
| Beck, R; Burris, HA; Fandi, A; Garcia, JA; Infante, JR; Jungnelius, U; Li, S; Redman, B; Rini, B | 1 |
| Bolanča, A; Jakšić, B; Jazvić, M; Krilić, D; Kusić, Z; Kust, D; Murgić, J; Prpić, M | 1 |
| Malik, L | 1 |
| Fukasawa, S; Ichikawa, T; Kobayashi, M; Komaru, A; Namekawa, T; Ohzeki, T; Sato, Y; Takagi, K; Ueda, T; Uemura, H | 1 |
| Yokomizo, A | 1 |
| Agarwal, N; Bamias, A; Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Ernst, DS; Heng, DY; Kim, JJ; Knox, JJ; Kollmannsberger, CK; Lee, JL; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Vaishampayan, UN; Wells, JC; Wood, LA; Yuasa, T | 1 |
| Czarnecka, AM; Oborska, S; Rzepecki, P; Szczylik, C | 1 |
| Arlot-Bonnemains, Y; Belaud-Rotureau, MA; Bensalah, K; Collet, N; Dolley-Hitze, T; Jouan, F; Lavenu, A; Oger, E; Rioux-Leclercq, N; Verhoest, G; Vigneau, C | 1 |
| Kroeger, N; Pantuck, AJ | 1 |
| Blanchard, F; Di Fiore, F; Nouhaud, FX; Pfister, C; Rebibo, JD; Sabourin, JC | 1 |
| Yuasa, T | 1 |
| Fujita, T; Iwamura, M; Matsumoto, K; Tabata, K; Wakatabe, Y; Yoshida, K | 1 |
| Culver, K; Jonasch, E; Lin, PL; Liu, Z; Pal, SK; Scott, JA; Signorovitch, JE; Vogelzang, NJ | 1 |
| Cho, YC; Jang, BC; Jang, JH; Kim, DE; Kim, KH; Kim, S; Kwon, TK; Lee, J; Lee, KS; Park, JS; Park, JW | 1 |
| Bladé, JS; Boudin, L; Bourgouin, S; de Jauréguiberry, JP; Romeo, É | 1 |
| Chou, A; Field, M; Gill, AJ; Hasovits, C; Hugh, TJ; Paik, J; Pavlakis, N; Toon, CW | 1 |
| Agochukwu, N; Gautam, R; Linehan, WM; Merino, M; Ricketts, CJ; Shuch, B; Srinivasan, R; Vocke, CD | 1 |
| Beaumont, JL; Bhattacharyya, H; Cella, D; Hahn, EA; Jensen, SE; Korytowsky, B; Motzer, R | 1 |
| Bellmunt, J; Castellano, D; Diaz, J; Donnellan, P; Duh, MS; Hawkins, R; Levy, A; McCaffrey, J; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Porta, C; Vekeman, F; Wagstaff, J | 1 |
| Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
| Anak, O; Barrios, CH; Bavbek, S; Beck, JT; Cheung, FY; Cosgriff, T; Falcon, S; Flaig, TW; Harker, WG; Kim, TM; Knox, JJ; Motzer, RJ; Niolat, J; Page, R; Patel, P; Pittman, K; Rha, SY; Sabbatini, R; Schiff, EM; Sellami, D; Srimuninnimit, V; Wang, X; Yadav, S | 1 |
| Berger, R; Boursi, B; Gottfried, M; Hayat, H; Keizman, D; Kovel, S; Livne-Segev, D; Maimon, N; Mermershtain, W; Neumann, A; Peer, A; Rouvinov, K; Sella, A; Weitzen, R | 1 |
| Czarnecka, AM; Rini, B; Szczylik, C | 1 |
| Akman, T; Avci, N; Basaran, M; Bayoglu, IV; Dede, İ; Ekenel, M; Kanitez, M; Kaplan, MA; Kocar, M; Sürmeli, Z; Tural, D; Ulaş, A; Uysal, M; Varol, U; Yazici, O; Yildiz, I | 1 |
| Bianco, C; Bianco, R; Ciardiello, F; Cipolletta, A; D'Amato, C; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Fulciniti, F; Marciano, R; Nappi, L; Raimondo, L; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| English, PA; Figlin, RA; Huang, X; Hudes, GR; Hutson, TE; Martini, JF; Motzer, RJ; Valota, O; Williams, JA | 1 |
| Kosaka, T; Mikami, S; Mizuno, R; Okada, Y; Oya, M; Saya, H | 1 |
| Hongo, F; Kamoi, K; Miki, T; Naitoh, Y; Nakamura, T; Naya, Y; Oishi, M; Okihara, K; Ueda, T | 1 |
| Ishii, Y; Johnson, KE; Ozono, S; Sakahara, H; Sugiyama, M; Sugiyama, T; Takayama, T; Takehara, Y; Wakayama, T; Wieben, O | 1 |
| Acharyya, S; Chopra, A; Fay, AP; Haaland, B; Lopes, Gde L | 1 |
| Adam, M; Eichelberg, C; Fuehner, T; Ganser, A; Grünwald, V; Herrmann, E; Ivanyi, P; Merseburger, AS | 1 |
| Gurney, H; Zhang, A | 1 |
| Choe, MS; Ha, JY; Jung, HR; Kim, BH; Kim, CI; Park, CH; Sohn, JC | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Burattini, L; Caricato, M; Cascinu, S; Conti, A; Guida, FM; Santini, D; Santoni, M; Savini, A; Tonini, G; Zeppola, T | 1 |
| Kılıç, L; Şen, F; Varol, U; Yıldız, I | 1 |
| Chung, H; Dhanda, R; Forsyth, M; Halm, M; Hutson, TE; Schnadig, ID; Vogelzang, NJ | 1 |
| Beuselinck, B; Claus, F; Cornelissen, L; De Keyzer, F; Dumez, H; Lerut, E; Van Poppel, H; Wolter, P | 1 |
| Zigeuner, R | 1 |
| Bono, P; Donskov, F; Joensuu, H; Peltola, K; Rautiola, J | 1 |
| Géczi, L; Kovács, E; Küronya, Z; Lahm, E | 1 |
| Cserháti, A; Kahán, Z; Maráz, A; Szilágyi, E; Uhercsák, G; Varga, Z | 1 |
| Gao, H; Han, Y; Jiang, Q; Peng, J; Wang, C | 1 |
| Barni, S; Petrelli, F | 1 |
| Cella, D; Eisen, T; Escudier, B; Mehmud, F; Porta, C; Powles, T; Sternberg, CN | 1 |
| Karakiewicz, PI; Larcher, A; Schiffmann, J; Sun, M | 1 |
| Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y | 1 |
| Barthelemy, P; Caty, A; Cheverau, C; Laplaige, P; Mouillet, G; Pouessel, D; Ravaud, A; Sebbagh, S; Thiery-Vuillemin, A; Vanno, YA | 1 |
| Almeida, DR; Boldt, HC; Chin, EK; Sacher, BA | 1 |
| Bagcchi, S | 1 |
| Adelaiye, R; Barrera, G; Ciamporcero, E; Ku, S; Miles, KM; Pili, R; Pizzimenti, S; Ramakrishnan, S; Sennino, B; Shen, L | 1 |
| Basso, U; Bezzon, E; Brunello, A; Maruzzo, M; Opocher, G; Pomerri, F; Roma, A; Zagonel, V; Zamarchi, R; Zovato, S | 1 |
| Adelaiye, R; Attwood, K; Ciamporcero, E; Conroy, D; Gillard, B; Kuhnert, F; Lalani, AS; Miles, KM; Pili, R; Seshadri, M; Shen, L; Sotomayor, P; Thurston, G | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Sebbagh, S; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Casciano, R; Chua, A; Culver, K; Garrison, LP; Gorritz, M; Liu, Z; Pal, S; Perrin, A; Sherman, S; Wang, X | 1 |
| Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Kim, D; Makarević, J; Reiter, M; Tsaur, I | 1 |
| Aarts, MJ; Hamming, L; Joosten, SC; Soetekouw, PM; Tjan-Heijnen, VC; van Engeland, M; Veeck, J | 1 |
| Baldazzi, V; Carini, M; Lapini, A; Mazzanti, R; Tassi, R | 1 |
| Arano, Y; Gushimiyagi, K; Kashiba, T; Nomura, Y; Sato, H; Sekine, Y; Siddig, S; Suzuki, S; Uehara, T; Ueno, K; Uzu, M; Yamaura, K | 1 |
| Bani, MR; Bassi, A; Bisighini, C; Damia, G; Fiordaliso, F; Ghilardi, C; Giavazzi, R; Moschetta, M; Piccirillo, R; Pretto, F; Rovida, A; Scarlato, V; Talamini, L | 1 |
| Lee, CH; Motzer, RJ | 1 |
| Altinmakas, E; Aparicio, A; Campbell, MT; Corn, PG; Millikan, RE; Siefker-Radtke, AO; Tannir, NM; Wen, SJ; Xiao, L | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Iacovelli, R; Loriot, Y; Massard, C; Massari, F | 1 |
| Kume, H; Makino, K; Tomoishi, J; Yoda, K | 1 |
| Bongaerts, AH; Brouwers, AH; de Haas, S; de Jong, IJ; de Jong, JR; de Vries, EG; Dierckx, RA; Gietema, JA; Hollema, H; Lub-de Hooge, MN; Nagengast, WB; Oosting, SF; Oude Munnink, TH; Scherer, SJ; Sluiter, WJ; van Es, SC | 1 |
| Avril, N; Hoimes, C; Hu, L; Lee, Z; Muzic, R; Sher, A; Valls, L | 1 |
| Bousquet, G; Duval, A; Ferreira, I; Feugeas, JP; Gapihan, G; Germain, S; Janin, A; Leboeuf, C; Mongiat-Artus, P; Ratajczak, P; Setterblad, N; Tan, S; Varna, M; Verine, J | 1 |
| Chan, A; Chau, NM; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL | 2 |
| Bareggi, C; Dell'orto, PG; Galassi, B; Gambini, D; Gianelli, U; Locatelli, E; Massironi, S; Tomirotti, M; Visintin, R | 1 |
| Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P | 1 |
| Ando, Y; Fukunaga, K; Imamura, CK; Katsuyama, Y; Miura, Y; Mushiroda, T; Okaneya, T; Suyama, K; Takano, T; Tanigawara, Y | 1 |
| Adelaiye, R; Bard, J; Bjarnason, GA; Buck, M; Chintala, S; Ciamporcero, E; Conroy, D; Fetterly, G; Ku, SY; Miles, KM; Orillion, A; Pili, R; Prey, J; Ramakrishnan, S; Shen, L; Sotomayor, P; Tsompana, M | 1 |
| Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H; Muramaki, M; Terakawa, T | 1 |
| Aydin, S; Gizzi, M; Machiels, JP | 1 |
| Campbell, SC; Derweesh, IH; Ercole, CE; Kim, HL; Klink, J; Lane, BR; O'Malley, R; Palazzi, KL; Rini, BI; Thomas, AA | 1 |
| Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV | 1 |
| Benson, P; Carpenter, C; Choueiri, TK; de Souza, P; Deen, K; Fay, AP; Figueroa, DJ; Gagnon, R; Ho, TH; Liu, Y; Motzer, RJ; Pandite, L; Powles, T; Signoretti, S | 1 |
| Pwint, T; Tyrrell, HE | 1 |
| Chan, A; Chau, NM; Hong, YW; Kanesvaran, R; Li, H; Lopes, G; Ng, QS; Tan, HS; Tan, MH; Tang, T; Tay, MH; Toh, CK; Wong, A; Yao, X | 1 |
| Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, H; Wang, X; Yan, X | 1 |
| Bolanča, A; Jakšić, B; Jazvić, M; Jukić, T; Kusić, Z; Kust, D; Murgić, J; Prgomet, A; Prpić, M | 1 |
| Bessho, H; Huang, D; Iwamura, M; Matsumoto, K; Ong, CK; Siew, EY; Tan, J; Tan, SY; Teh, BT; Wong, B | 1 |
| Ciuleanu, TE; Géczi, L; Leyman, S; Mardiak, J; Sajben, P; Torday, L; Vrdoljak, E; Zhang, K | 1 |
| Broom, RJ; Fong, PC; Mitchell, N | 1 |
| Arondekar, B; Deen, KC; Hackshaw, MD; Hansen, RN; Nagar, SP; Ramsey, SD; Sullivan, SD | 1 |
| Amdahl, J; Delea, TE; Diaz, J; Hackshaw, MD; Nakhaipour, HR | 1 |
| Artibani, W; Bimbatti, D; Brunelli, M; Ciccarese, C; Fantinel, E; Martignoni, G; Massari, F; Modena, A; Scarpa, A; Simbolo, M; Tortora, G | 1 |
| Bortlicek, Z; Buchler, T; Coufal, O; Dusek, L; Fiala, O; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Becht, E; Beuselinck, B; Couchy, G; de Reyniès, A; Elaidi, R; Fridman, WH; Giraldo, N; Job, S; Karadimou, A; Méjean, A; Molinié, V; Oudard, S; Patard, JJ; Rioux-Leclercq, N; Sautès-Fridman, C; Sibony, M; Teghom, C; Verkarre, V; Zucman-Rossi, J | 1 |
| Bedogni, A; Bettini, G; Bonacina, R; Campisi, G; Di Fede, O; Fusco, V; Guglielmini, P; Lo Re, G; Merigo, E; Paglino, C; Porta, C; Saia, G; Scoletta, M; Vescovi, P | 1 |
| Basso, U; Bonetti, A; Bracarda, S; Calabrò, F; Capaccetti, B; Cartenì, G; Ciuffreda, L; Fea, E; Ferrari, V; Fly, K; Gasparini, G; Gasparro, D; Hariharan, S; Labianca, R; Lo Re, G; Masini, C; Porta, C; Ruggeri, EM; Sternberg, CN; Tassinari, D; Zhang, K | 1 |
| Ito, T; Kutikov, A | 1 |
| Bergh, J; Borregaard, J; Dalhus, M; Damkier, P; Ersbøll, J; Hofland, K; Mickisch, G; Pieters, R; Pignatti, F; Salmonson, T; Skibeli, V; Slot, KB; Sylvester, R; Thoresen, H; Tzogani, K; Westgaard, I | 1 |
| He, CS; Huang, JK; Lin, QZ; Xie, M | 1 |
| Bianconi, M; Cascinu, S; Minardi, D; Muzzonigro, G; Quaresima, L; Santoni, M; Scartozzi, M | 1 |
| Jonasch, E; Kalra, S; Rini, BI | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Giavazzi, R; Piccirillo, R | 1 |
| An, H; Lin, Z; Liu, H; Liu, W; Liu, Y; Xu, J; Xu, L; Zhu, Y | 1 |
| Bing, N; Choueiri, TK; Davis, ID; Deen, KC; Esteban, E; Garcia-Donas, J; Johnson, T; McCann, L; Motzer, RJ; Pandite, LN; Rodríguez-Antona, C; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, Z | 1 |
| Baba, M; Hira, D; Kageyama, S; Kawauchi, A; Morita, SY; Noda, S; Okada, Y; Okamoto, K; Onishi, H; Otsuji, T; Terada, T; Yoshida, T | 1 |
| Azad, A; Davis, ID; Espinoza, D; Goldstein, D; Harrison, M; Harvie, R; Hudson, AL; Jovanovic, L; Kannourakis, G; Kichenadasse, G; Long, A; Lowenthal, RM; Martin, A; Nelson, CC; Pavlakis, N; Shapiro, J; Steer, C; Stockler, MR; Thompson, JF; Yip, S | 1 |
| Bhatt, RS; Choueiri, TK; Hamnvik, OP; Kaymakcalan, MD; Lin, X; McKay, RR; Rodriguez, GE; Sabbisetti, VS; Simantov, R | 1 |
| Boerman, OC; de Weijert, MC; Franssen, GM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oosterwijk-Wakka, JC; van der Laak, JA | 1 |
| Fujii, Y; Ishiwata, Y; Kihara, K; Nagata, M; Saito, K; Takahashi, H; Takahashi, Y; Yasuhara, M | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Keizman, D; Kim, JJ; Leibowitz-Amit, R; Maimon, N; Mermershtain, W; Peer, A; Rouvinov, K; Sella, A; Sinibaldi, V; Weitzen, R | 1 |
| Abdelmalek, RR; Edesa, WA | 1 |
| Adam, A; Barry, ER; Beran, G; Cairo, S; Clark, EA; D'Cruz, CM; Déas, O; Fawell, SE; Frigault, MM; Hattersley, M; Henry, RE; Jones, RD; Linsenmayer, D; Nicolle, D; Reimer, C; Schuller, AG; Smith, A; Wilson, J; Zinda, M | 1 |
| Akashi, K; Annan, DA; Dosaka-Akita, H; Horlad, H; Jinushi, M; Kinoshita, I; Kitada, S; Komohara, Y; Morita, T; Nakayama, T; Ohnishi, K; Suzu, S; Takeya, M; Yamada, S | 1 |
| Albiges, L; Derosa, L; Escudier, B; Izzedine, H; Le Teuff, G | 1 |
| Chevreau, C; Culine, S; De Fromont, M; Escudier, B; Gravis, G; Jimenez, M; Laguerre, B; Ouali, M; Oudard, S; Ravaud, A; Rolland, F; Sevin, E; Theodore, C; Zanetta, S | 1 |
| Altuntaş, O; Güllü, İ; Petekkaya, İ; Süslü, N | 1 |
| Aurilio, G; Cossu Rocca, M; Cullurà, D; Iacovelli, R; Nolé, F; Verri, E | 1 |
| Bracarda, S | 2 |
| Chen, L; Cui, X; Gan, S; Hong, Y; Huang, H; Huang, Y; Li, L; Liu, B; Pan, X; Xu, D; Ye, J; Zhou, Q | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Prausova, J; Svoboda, M; Vyzula, R | 1 |
| Pilotte, AP | 1 |
| Bonnet, C; Sibon, I | 1 |
| Akaza, H; Aoki, K; Houzawa, H; Lee, SY; Naito, S; Pitman Lowenthal, S; Ueno, N | 1 |
| Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Trump, D | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Duzkopru, Y; Hacıbekiroglu, I; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M; Uysal, M | 2 |
| Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
| Thoma, C | 2 |
| Bensalah, K; Ouzaid, I | 1 |
| Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K | 1 |
| Burton, TM; Byfield, SA; Hackshaw, MD; McPheeters, JT; Nagar, SP | 1 |
| Bai, S; Bex, A; Ding, Z; Gao, J; German, P; Griffioen, AW; Hoang, A; Jonasch, E; Kalra, S; Karam, JA; Liu, XD; Matin, S; Rao, P; Sharma, P; Sircar, K; Sun, M; Tamboli, P; Tannir, N; Wood, C; Yetil, A; Zhang, X; Zhou, L; Zurita, A | 1 |
| Aitchison, M; Berney, D; Bex, A; Eory, L; Harrison, DJ; Laird, A; Lubbock, AL; Mackay, A; McNeill, SA; Mullen, P; Nanda, J; O'Donnell, M; O'Mahony, FC; Overton, IM; Powles, T; Riddick, AC; Stewart, GD | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Beuselinck, B; Jean-Baptiste, J; Schöffski, P; Van Keerberghen, CA; Wolter, P; Zucman-Rossi, J | 1 |
| Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
| Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG | 1 |
| Cancel-Tassin, G; Cussenot, O | 1 |
| Atkins, MB; Choueiri, TK; McDermott, DF; McKay, RR; Michaelson, MD; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L | 1 |
| Demlova, R; Hezova, R; Kovarikova, A; Merhautova, J; Poprach, A; Radova, L; Slaby, O; Svoboda, M; Vyzula, R | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
| Bianconi, M; Bittoni, A; Cascinu, S; Cheng, L; Del Prete, M; Faloppi, L; Giampieri, R; Lopez-Beltran, A; Montironi, R; Scarpelli, M; Scartozzi, M | 1 |
| Bjarnason, GA; Bracarda, S; Bukowski, R; Carteni, G; Castellano, D; Crinò, L; Eberhardt, WE; Fly, K; Gore, ME; Haanen, J; Hariharan, S; Hawkins, RE; Kim, TM; Lechuga, MJ; Lee, SH; Mainwaring, P; Matczak, E; Oudard, S; Porta, C; Schöffski, P; Szczylik, C; Vrdoljak, E; Zhang, K | 1 |
| Kamata, S; Yoshinaga, A | 1 |
| Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H | 1 |
| Arakaki, R; Inoue, T; Kamba, T; Kanno, T; Nakamura, E; Ogawa, O; Sakamoto, H; Shibasaki, N; Tsuruyama, T; Utsunomiya, N; Yamasaki, T | 1 |
| Gore, M; Kharkevich, G; Leyman, S; Mardiak, J; Sajben, P; Schöffski, P; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E; Zhang, K | 1 |
| Beuselinck, B; Zucman-Rossi, J | 1 |
| Schmidinger, M; Wittes, J | 1 |
| Armstrong, AJ; George, DJ; Kanesvaran, R; Turnbull, JD; Watt, K; Wolkowiez, MC | 1 |
| Dezentjé, VO; Feberwee, T; van Erp, NP; van Kinschot, CM | 1 |
| Albiges, L; Escudier, B | 1 |
| Bjarnason, GA; Butz, H; Dharsee, M; Ding, Q; Evans, KR; Khella, HWZ; Kupchak, P; Latif, A; Lianidou, E; Pasic, MD; Rotondo, F; Yousef, GM | 1 |
| Pertijs, J; Rongen, GA; Thijs, AM; van den Broek, PH; van der Graaf, WT; van Herpen, CM; Verweij, V | 1 |
| Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L | 1 |
| Altavilla, A; Boni, L; Bracarda, S; Camerini, A; Derosa, L; Di Lorenzo, G; Escudier, B; Galli, L; Iacovelli, R; Longo, F; Morelli, F; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santoni, M; Sisani, M | 1 |
| Huang, J; Shan, L; Song, Y; Zhang, HT | 1 |
| Fu, S; Hao, J; Liu, Y; Wang, B; Xu, Z; Yu, N; Zhang, A | 1 |
| Chau, NM; Choudhury, Y; Chowbay, B; Chu, YH; Kanesvaran, R; Koh, V; Lai, J; Li, H; Ng, QS; Phyo, WM; Tan, HS; Tan, MH; Tan, PH; Toh, CK | 1 |
| Atkins, MB; Choueiri, TK; Demkow, T; Drosik, K; Gravis, G; Michaelson, MD; Navale, L; Ravaud, A; Tomczak, P; Warner, D; Wong, SS; Wu, B | 1 |
| Hirai, M; Hirano, T; Mizumoto, A; Nakagawa, T; Nakayama, Y; Takara, K; Yamamoto, K | 1 |
| Bilen, MA; Chen, HC; Hodges, S; Huang, S; Ilias-Khan, NA; Jonasch, E; Kearney, AY; Khakoo, AY; Tannir, NM; Wang, X; Zurita, AJ | 1 |
| MacLean, EA; Mardekian, J; Sandin, R | 1 |
| Benedict, A; Ramaswamy, K; Sandin, R | 1 |
| Auberger, P; Belaid, A; Benhida, R; Colosetti, P; Cormerais, Y; Dufies, M; Giuliano, S; Grépin, R; Lacas-Gervais, S; Martin, A; Mazure, NM; Mograbi, B; Pagès, G; Parola, J | 1 |
| Čaržavec, D; Gaćina, P; Kruljac, I; Kust, D; Ostojić, J; Peternac, AŠ; Prpić, M | 1 |
| Hara, T; Inoue, R; Kawai, Y; Kobayashi, K; Matsumoto, H; Matsuyama, H; Nagamori, S; Nagao, K; Osawa, T; Sakano, S; Yamamoto, Y | 1 |
| Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS | 1 |
| Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Kim, MK; Lee, DH; Lee, JL; Park, I; Ryoo, HM; Song, C | 1 |
| Tomita, Y | 1 |
| Rexer, H | 3 |
| Bai, S; Ding, Z; German, P; Giaccia, AJ; Hoang, AG; Jonasch, E; Karam, JA; Laird, DA; Liu, XD; Matin, SF; Rankin, EB; Rao, P; Sircar, K; Sun, M; Tamboli, P; Tannir, N; Walker, CL; Wood, CG; Zhang, X; Zhou, L | 1 |
| Racsa, PN; Whisman, TR; Worley, K | 1 |
| Blanc, E; Chevreau, C; Elena-Herrmann, B; Escudier, B; Gravis, G; Jobard, E; Négrier, S; Trédan, O | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H | 1 |
| Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Liu, X; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Sidaway, P | 1 |
| Fujikawa, A; Moriyama, M; Namura, K; Ota, J; Otake, S; Sawada, T | 1 |
| Boers-Sonderen, MJ; De Geus-Oei, LF; Desar, IM; Fütterer, JJ; Mulder, SF; Mulders, PF; Oyen, WJ; Van Der Graaf, WT; Van Herpen, CM | 1 |
| Branžovský, J; Hes, O; Holubec, L; Hora, M; Kalusová, K; Pele, KB; Trávníček, I; Ürge, T | 1 |
| Atzori, F; Baghino, G; Boi, F; Ionta, MT; Mariotti, S; Pani, F; Tanca, L | 1 |
| Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C | 1 |
| Rongen, GA; Tack, CJ; Thijs, AM; van der Graaf, WT; van Herpen, CM | 1 |
| Bondarenko, I; Dressler, H; Eisen, T; Jones, RJ; Loembé, AB; MacLeod, N; Mazurkiewicz, M; Shparyk, Y; Temple, G | 1 |
| Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Rebibo, JD | 1 |
| Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS | 1 |
| Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X | 1 |
| Li, CL; Shi, HZ; Tian, J | 1 |
| Ettinger, S; Fazli, L; Frees, S; Gleave, ME; Han, KS; Hong, SJ; Li, N; Park, KC; Raven, PA; So, AI | 1 |
| Bridgeman, VL; Foo, S; Frentzas, S; Gore, M; Larkin, J; Nathan, MR; Nathan, PD; Powles, T; Preece, N; Reynolds, AR; Springer, CJ; Vasudev, NS; Vermeulen, PB; Wan, E; Welti, JC | 1 |
| Bahl, A; Brown, J; Buchan, S; Hawkins, R; Jones, R; Pickering, L; Porfiri, E; Wagstaff, J | 1 |
| Bjarnason, GA; Cohen, DP; Davis, MP; Donskov, F; Goldstein, D; Lin, X; Michaelson, MD; Motzer, RJ; Puzanov, I; Rini, BI; Wiltshire, R | 1 |
| Basso, U; Maruzzo, M | 1 |
| Fenner, A | 1 |
| Ahn, JH; Cho, YM; Lee, DH; Lee, JL; Park, I | 1 |
| Coakley, FV; Costantino, C; Ryan, C; Thomas, GV; Troxell, ML | 1 |
| Amdahl, J; Delea, TE; Diaz, J; El Khoury, MH; Nakhaipour, HR | 1 |
| Hackshaw, MD; Hansen, RN; Ramsey, SD; Sullivan, SD | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Grünwald, V; Ivanyi, P | 1 |
| Busch, JF; Ganser, A; Grünwald, V; Ivanyi, P; Koenig, J; Reuter, CW; Seidel, C; Trummer, A | 1 |
| Fujisawa, M; Miyake, H; Miyazaki, A | 1 |
| Cartenì, G; Vitale, MG | 1 |
| Bex, A; Ljungberg, B | 1 |
| Albiges, L; Altinmakas, E; Choueiri, TK; Dubauskas Lim, Z; Jonasch, E; Karam, JA; Matin, SF; McDermott, DF; Ng, CS; Qiao, W; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wang, X; Wood, CG | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Gardner, EE; Rudin, CM | 1 |
| Ettinger, S; Fazli, L; Frees, S; Gleave, ME; Gust, K; Han, KS; Hong, SJ; Kollmannsberger, C; Raven, PA; So, AI | 1 |
| Alekseev, B; Alyasova, A; Brechenmacher, T; Collins, L; Cosgriff, T; Karpenko, A; Karyakin, O; Kowalyszyn, R; Kurteva, G; Li, H; Lin, C; Morgan, L; Motzer, RJ; Neron, Y; Xie, L; Yang, L; Ye, D | 1 |
| Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ | 2 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
| Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR | 1 |
| Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Milot, L; Moshonov, H; Sinaei, M; Williams, R | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Bíró, K; Budai, B; Géczi, L; Gyergyay, F; Küronya, Z; Nagy, P; Nagyiványi, K; Németh, H; Noszek, L | 1 |
| Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B | 1 |
| Armstrong, AJ; Broderick, S; Eisen, T; Garcia, JA; George, DJ; Hainsworth, JD; Halabi, S; Hawkins, RE; Jones, RJ; Kollmannsberger, CK; Logan, TF; Lusk, CM; Oberg, S; Pickering, LM; Picus, J; Protheroe, A; Puzanov, I; Ryan, CW; Stadler, WM; Vaishampayan, UN | 1 |
| Belaustegui, A; Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Broxterman, HJ; De Haas, RR; Dekker, H; Halmos, B; Jiménez, CR; Knol, JC; Mier, JW; Pham, TV; Piersma, SR; Van Beusechem, VW; van der Mijn, JC; Verheul, HM | 1 |
| Bex, A; de Bruijn, RE; Haanen, JB; Horenblas, S; Nijkamp, J; Noe, A; Prevoo, W | 1 |
| Kelsey, R | 1 |
| Diekstra, MH; Gelderblom, H; Guchelaar, HJ; Swen, JJ | 1 |
| Dulfer, RR; Eechoute, K; Hamberg, P; Kloth, JSL; Kruit, WHJ; Mathijssen, RHJ; Mendelaar, PAJ; Sleijfer, S; van der Holt, B; Wiemer, EAC | 1 |
| Granovetter, M | 1 |
| Furukawa, S; Handa, H; Hashimoto, A; Hashimoto, S; Mikami, S; Oikawa, T; Okada, Y; Onodera, Y; Oya, M; Sabe, H; Sugino, H; Yoshikawa, A | 1 |
| Anai, S; Fujimoto, K; Hayashi, Y; Hori, S; Hosokawa, Y; Kuwada, M; Miyake, M; Morizawa, Y; Nakagawa, Y; Nakai, Y; Otani, T; Otsuka, K; Samma, S; Tanaka, N; Tatsumi, Y; Tomioka, A | 1 |
| Banzato, A; Basso, U; Brunello, A; Diminutto, A; Fiduccia, P; Maruzzo, M; Roma, A; Zagonel, V; Zattoni, F; Zustovich, F | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
| Delea, TE; Diaz, J; Latimer, N; Mehmud, F; Motzer, RJ; Pandite, L; Sternberg, CN | 1 |
| Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A | 1 |
| Chen, D; Hakimi, AA; Hsieh, JJ; Knox, JJ; Lee, CH; Marker, M; Motzer, RJ; Voi, M; Voss, MH | 1 |
| Enokida, H; Fujisawa, M; Fukasawa, S; Fukunaga, K; Hara, I; Hashine, K; Hongo, F; Inoue, T; Kato, Y; Kitamura, H; Kubo, M; Low, SK; Matsuda, K; Matsuyama, H; Miki, T; Mushiroda, T; Nakanishi, H; Nishimura, K; Takahashi, A; Tanaka, T; Tatsugami, K; Tomita, Y; Uemura, H | 1 |
| Bo, B; Hu, J; Jiao, M; Li, J; Su, H; Zhang, J; Zhou, X; Zhu, T; Zong, Y | 1 |
| de Jongh, FE; Guillen, SS; Meijer, M | 1 |
| Dornbusch, J; Fuessel, S; Gottschalk, A; Grimm, MO; Junker, K; Klug, SJ; Meinhardt, M; Obaje, A; Ohlmann, CH; Schoffer, O; Walter, M; Wirth, MP; Zacharis, A; Zastrow, S | 1 |
| Freyer, G; Le Saux, O; Négrier, S | 1 |
| Boers-Sonderen, MJ; Derikx, LA; Hoentjen, F; Mulder, SF; Mulders, PF; Nagtegaal, ID; van der Graaf, WT; van Herpen, CM; Wanten, GJ | 1 |
| Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG | 1 |
| Duensing, S; Hohenfellner, M | 1 |
| Aranegui, B; Bueno, C; Espinosa Lara, P; Jiménez Reyes, J; Vargas-Machuca, I | 1 |
| Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C | 1 |
| Akiyama, S; Fujishima, F; Imai, H; Ishioka, C; Kobayashi, A; Komine, K; Saijo, K; Sato, N; Shimodaira, H; Shirota, H; Shuin, T; Sugiyama, S; Takahashi, M; Takahashi, S | 1 |
| Barclay, JL; Gobe, GC; Johnson, DW; Li, L; Morais, C; Ng, KL; Oliver, K; Rajandram, R; Samaratunga, H; Small, DM; Vesey, DA; Wood, S | 1 |
| Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK | 1 |
| Beaumont, JL; Cella, D; Deen, KC; Diaz, J; Hackshaw, MD; McCann, L; Motzer, RJ; Powles, T; Salsman, JM | 1 |
| Alagh, A; Beksac, AT; Campbell, SC; Derweesh, IH; Gillis, K; Hamilton, Z; Jimenez, J; Kane, CJ; Lane, BR; Lee, HJ; Millard, F; Randall, JM; Tobert, C; Wang, S | 1 |
| Azumi, M; Hashizume, K; Hori, J; Iwata, T; Kakizaki, H; Kita, M; Kobayashi, S; Matsumoto, S; Okazaki, S; Watanabe, M | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K | 1 |
| Kononenko, OA; Stakhovskiy, EO; Stakhovskiy, OE; Vitruk, YV; Voylenko, OA; Vukalovych, PS | 1 |
| Chittoria, N; Dreicer, R; Elson, P; Garcia, JA; Haddad, H; Jonasch, E; Rini, BI; Tannir, NM; Wood, LS | 1 |
| De Meyer, T; Deforce, D; Harrison, DJ; Laird, A; Meynert, A; O'Mahony, F; Powles, T; Stewart, GD; Trooskens, G; Van Criekinge, W; Van Neste, C; Van Nieuwerburgh, F | 1 |
| Hwang, IG; Ji, JH; Lee, SJ; Lim, DH; Lim, HY; Lim, SH; Oh, SY; Park, SH; Yi, JH | 1 |
| Bergmann, L; Maute, L | 1 |
| Chen, L; Ding, C; Mai, H; Zhang, B | 1 |
| Gu, W; Lu, X; Shi, G; Ye, D; Zhang, H; Zhu, Y | 1 |
| Fukuda, H; Iida, S; Kondo, T; Takagi, T; Tanabe, K | 1 |
| Bono, P; Joensuu, H; Lampinen, A; Mirtti, T; Rautiola, J; Ristimäki, A; Saharinen, P | 1 |
| Asano, T; Hagiwara, M; Ito, K; Ito, Y; Kanao, K; Masuda, T; Masunaga, A; Mikami, S; Miyazaki, Y; Mizuno, R; Momma, T; Nakagawa, K; Oya, M; Oyama, M; Shirotake, S; Tanaka, N; Yasumizu, Y | 1 |
| Blanchet, B; Da Silva, F; Goldwasser, F; Huillard, O; Thomas-Schoemann, A | 1 |
| Bao, Y; Chen, C; Chen, W; Ding, J; Fang, ZY; Gao, L; Gao, Y; Li, XF; Li, YM; Liu, B; Liu, F; Miao, X; Qu, L; Sun, HY; Sun, W; Sun, YH; Wang, HY; Wang, LH; Wang, X; Wang, Y; Wu, DS; Wu, ZJ; Xu, B; Xu, ZP; Xu, ZY; Yang, Q | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Barkhodari, A; Harshman, L; Minamimoto, R; Quon, A; Srinivas, S | 1 |
| Bassani, N; Carles, J; Casanovas, O; García-Del-Muro, X; Graupera, M; Indraccolo, S; Jiménez-Valerio, G; Martínez-Lozano, M; Ochoa-de-Olza, M; Suárez, C; Vidal, A; Viñals, F | 1 |
| Brugarolas, J; Fedyshyn, S; Kucejova, B; Leong, HS; Pavia-Jimenez, A; Peña-Llopis, S; Power, N; Sivanand, S; Spence, P; Tran, TA; Xie, XJ; Yang, J | 1 |
| Fumagalli, E; Khosravan, R; Motzer, RJ; Rini, BI | 1 |
| Arrowsmith, ER; Crane, EJ; Flynt, A; Hainsworth, JD; Hamid, O; Mace, JR; Polzer, J; Reeves, JA; Roberson, S; Stille, JR | 1 |
| Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A | 1 |
| Bex, A; de Groot, S; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A | 1 |
| Abadie-Lacourtoisie, S; Amela, EY; Baciuchka, M; Boyle, H; Chevreau, C; Denechere, G; Deville, JL; Falkowski, S; Geoffrois, L; Gimel, P; Gross-Goupil, M; Guillot, A; Laguerre, B; Laramas, M; Legouffe, E; Oudard, S; Pfister, C; Rolland, F; Topart, D | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Ish-Shalom, M; Keizman, D; Maimon, N; Mermershtain, W; Neiman, V; Peer, A; Rosenbaum, E; Rouvinov, K; Sarid, D; Sella, A; Sinibaldi, V | 1 |
| Inoue, R; Kitamura, H; Masumori, N; Nishiyama, N; Shindo, T | 1 |
| Chen, W; Gratton, K; Kawakami, J; Lawson, KA; Morris, DG; Mostafa, AA; Shi, ZQ; Spurrell, J; Thakur, S | 1 |
| Eaddy, M; Hackshaw, MD; Holmes, M; Lankford, M; Ogbonnaya, A; Thomas, M | 1 |
| Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
| Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X | 1 |
| Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S | 1 |
| De Groot, S; Haanen, JB; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA | 1 |
| Bai, Q; Guo, J; Liu, L; Long, Q; Qu, Y; Wang, J; Xi, W; Xia, Y; Xiong, Y; Xu, J | 1 |
| Abe, H; Arai, K; Fukuda, T; Kamai, T; Masuda, A; Nukui, A; Yoshida, K | 1 |
| Fernández, C; Mariño, EL; Modamio, P; Segarra, I | 1 |
| Annala, M; Azad, AA; Chi, KN; Fazli, L; Mo, F; Nappi, L; Wyatt, AW | 1 |
| Kim, JH; Lee, JL; Park, I | 1 |
| Chen, X; Li, CL; Shi, HZ; Tian, J; Wang, D | 1 |
| Chen, M; Qi, L; Yang, Z | 1 |
| Abdallah, AO; Arnaoutakis, K; Mahmoud, F; Makhoul, I | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Keizman, D; Lee, JL; Mermershtain, W; Neiman, V; Neumann, A; Peer, A; Rosenbaum, E; Rouvinov, K; Sarid, D; Sella, A; Sinibaldi, V; Yildiz, I | 1 |
| Adamakis, I; Alamanis, C; Bamias, A; Christodoulou, C; Constantinidis, CA; Deliveliotis, C; Dimopoulos, MΑ; Karavasilis, V; Korkolopoulou, P; Kostouros, E; Koutsoukos, K; Lainakis, G; Liontos, M; Lykka, M; Mitropoulos, D; Papandreou, CN; Papatsoris, A; Patsouris, E; Saetta, A; Skolarikos, A; Stravodimos, K; Trigka, EA; Tzannis, K; Varkarakis, I | 1 |
| Aieta, M; Basso, U; Berardi, R; Conteduca, V; Crabb, SJ; De Giorgi, U; Derosa, L; Galli, L; La Russa, F; Lolli, C; Maruzzo, M; Massari, F; Santoni, M; Sava, T; Scarpi, E; Wheater, M | 1 |
| Allory, Y; Beuselinck, B; Couchy, G; Elaidi, R; Jean-Baptiste, J; Joniau, S; Lambrechts, D; Lerut, E; Meiller, C; Méjean, A; Oudard, S; Patard, JJ; Rolland, F; Roskams, T; Schöffski, P; Verkarre, V; Zucman-Rossi, J | 1 |
| Doehn, C; Rexer, H | 1 |
| Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Aigner, F; Heidegger, I; Horninger, W; Pichler, R; Tulchiner, G | 1 |
| Cisar, LA; Harnett, J; Hoang, CJ; MacLean, E; Mardekian, J | 1 |
| Choueiri, TK; Hamieh, L; Lin, X; McKay, RR; Moreira, RB; Simantov, R | 1 |
| Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J | 1 |
| Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK | 1 |
| Back, HM; Chae, JW; Chan, A; Ho, HK; Karlsson, MO; Kwon, KI; Lee, J; Teo, YL; Yun, HY | 1 |
| Goto, Y; Ichikawa, T; Ishida, Y; Kojima, S; Kurozumi, A; Matsushita, R; Naya, Y; Nohata, N; Seki, N; Yamazaki, K; Yoshino, H | 1 |
| Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Fraccon, AP; Heng, DY; Lee, JL; Pasini, F; Pezaro, C; Ptak-Chmielewska, A; Rini, BI; Ruiz-Morales, JM; Sim, HW; Sliwczynsk, A; Swierkowski, M; Szczylik, C; Teter, Z; Wells, JC; Wood, LA; Yuasa, T | 1 |
| Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C | 1 |
| Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A | 1 |
| M, Eel D | 1 |
| Golčić, M; Petković, M | 1 |
| Aarts, MJ; Griffioen, AW; Heemskerk, JW; Kuijpers, MJ; Mattheij, N; Oude Egbrink, MG; Pineda, S; Sabrkhany, S; Sanders, L; van Geffen, JP | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Hornova, J; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
| Aitali, A; Albouzidi, A; Benani, F; Debbagh, A; Errihani, H; Ichou, M; Mahi, M; Sbitti, Y; Seddik, H; Slimani, K; Tarchouli, M | 1 |
| Gao, Y; Jia, J; Li, J; Li, W; Meng, Q; Qiao, N; Qu, C; Wang, D; Wang, X; Yang, S; Zhang, M | 1 |
| Fujita, K; Kawashima, A; Miyagawa, Y; Nagahara, A; Nonomura, N; Uemura, M; Ujike, T | 1 |
| Barnard, J; Diaz-Montero, CM; Finke, JH; Lindner, DJ; Mao, FJ; Parker, Y; Pink, JJ; Rini, BI; Zamanian-Daryoush, M | 1 |
| Habuchi, T; Huang, M; Inoue, T; Kagaya, H; Miura, M; Narita, S; Niioka, T; Numakura, K; Satoh, S; Takahashi, M; Tsuchiya, N; Tsuruta, H | 1 |
| Bryniarski, P; Dumnicka, P; Giza, A; Herman, R; Krzemieniecki, K; Kucharz, J; Kusnierz-Cabala, B; Kuzniewski, M; Zygulska, AL | 1 |
| Alexandre, J; Bellesoeur, A; Blanchet, B; Goldwasser, F; Golmard, L; Huillard, O; Naji, F; Noé, G; Puszkiel, A; Rangarajan, S; Saidu, N; Thomas-Schoemann, A; Vidal, M | 1 |
| Brugarolas, J; Bruick, RK; Chang, J; Chen, W; Christie, A; Courtney, K; Frenkel, E; Gardner, KH; Geiger, H; Hao, G; Hill, H; Holloman, E; Homayoun, F; Hwang, TH; Josey, JA; Joyce, A; Kapur, P; Kim, MS; Ma, Y; McKay, RM; Patel, N; Pavia-Jimenez, A; Pedrosa, I; Reeves, C; Rizzi, JP; Sun, X; Wallace, EM; Wong, T; Xie, XJ; Xie, Y; Yell, P; Yousuf, Q; Zhang, H; Zojwalla, N | 1 |
| Bogusz, K; Brodziak, A; Czarnecka, AM; Korniluk, J; Labochka, D; Moszczuk, B; Owczarek, A; Sobczuk, P; Spychalska, M; Szczylik, C | 1 |
| Bryan, J; Griswold, M; Roda, M; Sirous, R; Smith, AD; Souza, F; Vasanji, A; Zhang, H; Zhang, X | 1 |
| Campanario, R; Juárez, A; Saiz, R; Soto, M | 1 |
| Munakata, S; Shiba, M; Takayama, H; Takeda, K; Wang, C | 1 |
| Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L | 1 |
| Figlin, RA; Lin, X; Matczak, E; Michaelson, MD; Sella, A; Simantov, R | 1 |
| Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP | 1 |
| Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
| Casuscelli, J; Graser, A; Hellbach, K; Hummel, N; Ingrisch, M; Karpitschka, M; Schlemmer, M; Sommer, W; Staehler, M; Sterzik, A | 1 |
| Breza, J; Carteni, G; Casey, M; Chang, YH; Donskov, F; Escudier, B; George, DJ; Gerletti, P; Laguerre, B; Lechuga, M; Lin, X; Magheli, A; Martini, JF; Motzer, RJ; Pandha, HS; Pantuck, AJ; Patard, JJ; Patel, A; Ramaswamy, K; Ravaud, A; Staehler, M; Tomczak, P | 1 |
| Bedke, J; Bracarda, S; Crabb, SJ; Eisen, T; Fritsche, J; Kirner, A; Kogan, M; Ludwig, J; Mahr, A; Maurer, D; Mendrzyk, R; Oudard, S; Reinhardt, C; Rini, BI; Shkolnik, M; Singh-Jasuja, H; Stenzl, A; Wagner, C; Walter, S; Weikert, S; Weinschenk, T; Zdrojowy, R | 1 |
| Berger, MF; Bhanot, U; Bouvier, N; Chen, D; Chen, YB; Cheng, EH; Chevinsky, MS; Hakimi, AA; Hsieh, JJ; Huberman, KH; Knox, J; Lee, W; Marker, M; Motzer, RJ; Patel, P; Pinciroli, P; Redzematovic, A; Selcuklu, SD; Socci, ND; Viale, A; Voi, M; Voss, MH; Wang, PI; Weinhold, N; Won, HH; You, D | 1 |
| Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolè, F; Verri, E | 1 |
| Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S | 1 |
| Baker, H | 1 |
| Chen, XL; Chi, ZH; Cui, CL; Guo, J; Kong, Y; Lian, B; Mao, LL; Sheng, XN; Si, L; Tang, BX; Wang, X; Yan, XQ | 1 |
| Escudier, B; Figlin, RA; Gannon, A; Motzer, RJ | 1 |
| Choi, HY; Chung, J; Jeon, SH; Kim, SH; Kim, WJ; Kim, YJ; Kwon, TG; Lee, HL; Lee, HM; Seo, SI | 1 |
| Payandeh, M; Sadeghi, E; Sadeghi, M | 1 |
| Brito, G; Dzik, C; Leite, KRM; Nahas, W; Paloppi, I; Reis, ST; Srougi, M; Viana, NI | 1 |
| Chen, J; Gao, R; He, J; Li, Y; Niu, Y; Yu, C; Zhang, L | 1 |
| Anai, S; Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
| Benoit, G; Benoudiba, F; Brizard, M; Caillet, V; Corréas, JM; David, P; Deveaux, S; Elaidi, R; Gaudric, A; Hammel, P; Joly, D; Le Rest, C; Méjean, A; Oudard, S; Richard, S; Timsit, MO | 1 |
| Beutel, G; Drewes, N; Ganser, A; Grünwald, V; Ivanyi, P; Kielstein, JT; Morgan, M; Pirr, J | 1 |
| Boven, E; Castellano, D; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Liu, X; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ | 1 |
| Bedke, J; Stühler, V | 1 |
| Fiocco, M; Guchelaar, HJ; Liu, X; Swen, JJ | 1 |
| Chu, Y; Guo, J; Hu, X; Wang, G; Zhao, Q | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Fournier, L; Mauge, L; Mejean, A; Nassif, E; Oudard, S; Tartour, E; Thibault, C; Timsit, MO; Vano, Y; Verkarre, V | 1 |
| Albiges, L; Bensalah, K; Bex, A; Dabestani, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Volpe, A | 1 |
| Ando, Y; Gyawali, B | 1 |
| Afshar, M; Bardoli, AD; Miscoria, M; Pirrie, S; Porfiri, E; Stubbs, C; Wheeley, I | 1 |
| Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C | 1 |
| Bracarda, S; Casper, J; Escudier, B; Gross Goupil, M; Larkin, J; Negrier, S; Porta, C; Schmidinger, M | 1 |
| Deininger, E; Moch, H; Razafinjatovo, CF; Rechsteiner, M; Schraml, P; Stiehl, D | 1 |
| Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL | 1 |
| Al Mansour, M; Darwish, W; Imtiaz, S; Zekri, J | 1 |
| Li, H; Li, J; Wu, X; Zhang, X; Zhang, Y; Zheng, G | 1 |
| Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A | 1 |
| Fitzgerald, SD; Harrison, T; Needle, D; Patterson, J; Thompson, KA | 1 |
| Bedke, J; Burchardt, M; Kroeger, N; Stenzl, A | 1 |
| Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J | 1 |
| Black, PC; Struss, WJ | 1 |
| Huang, L; Luo, C; Wen, T; Xiao, H; Xiong, M | 1 |
| Bex, A | 1 |
| Chen, M; Lei, Y; Yildiz, S | 1 |
| Chen, D; Hsieh, JJ; Marker, M | 1 |
| Allman, KD; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Grivas, P; Martin, A; Ornstein, MC; Rini, BI; Wood, LS; Zanick, BR | 1 |
| Bjarnason, GA; Ganeshan, B; Haider, MA; Khalvati, F; Kiss, A; Vosough, A | 1 |
| Basterrechea, L; Boni, V; Carrato, A; Castellano, D; Cebrián, A; Cruz-Jurado, J; Esteban, E; García-Alonso, M; García-Carbonero, I; García-Foncillas, J; Gómez Del Pulgar, T; González Del Alba, A; González-Larriba, JL; Gonzálvez, ML; Lainez, N; Mahillo-Fernández, I; Martin, Y; Méndez-Vidal, MJ; Moreno, F; Munárriz-Ferrándiz, J; Perez-Valderrama, B; Reynés, G; Rodríguez-Remírez, M; Sáez, MI; Suárez, C; Villatoro, R; Viqueira, A | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Xi, W; Xiong, Y; Xu, J; Yao, J | 1 |
| Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J | 1 |
| Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 1 |
| Arai, Y; Ito, A; Kawasaki, Y; Kikuchi, M; Mano, N; Takasaki, S; Yamaguchi, H | 1 |
| Klatte, T | 1 |
| Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R | 1 |
| Venkatesan, P | 1 |
| Huang, S; Jonasch, E; Msaouel, P; Tannir, NM; Zurita, AJ | 1 |
| Capri, S; Delea, TE; Porta, C | 1 |
| Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H | 1 |
| Choueiri, TK; Dakhil, S; Feldman, DR; George, DJ; Hahn, O; Halabi, S; Michaelson, MD; Morris, MJ; Olencki, T; Picus, J; Sanford, BL; Small, EJ; Walsh, MK | 1 |
| Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY | 1 |
| Abbas, T; Gesy, K; Iqbal, N; Iqbal, U; Lee, C; Lim, J; Suo, A | 1 |
| Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M | 1 |
| Bono, P; Hänninen, E; Joensuu, H; Peltola, KJ; Penttilä, P; Rautiola, J; Ristimäki, A | 1 |
| Ravaud, A | 2 |
| Zhang, Sh | 1 |
| Albiges, L; Champiat, S; Danlos, FX; Lambotte, O; Le Pavec, J; Marabelle, A; Michot, JM; Pradere, P | 1 |
| Dragomir, A; Edqvist, PH; Enblad, G; Niinivirta, M; Pontén, F; Ullenhag, GJ | 1 |
| Han, Q; Li, P; Tang, M; Zhang, K | 1 |
| Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C | 1 |
| Atkins, MB; Choueiri, TK; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Manola, J; Uzzo, RG | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Harisinghani, MG; Iliopoulos, O; McDermott, DF; McGovern, FJ; Michaelson, MD; Oliva, E | 1 |
| Akamatsu, S; Kanamaru, S; Soeda, A; Takenawa, J | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Breaker, K; Flaig, TW; Kim, FJ; La Rosa, FG; Russ, PD; Schoen, J | 1 |
| Kuczyk, MA; Merseburger, AS | 1 |
| Figlin, R; Moldawer, NP | 1 |
| Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Berkhof, J; Boven, E; de Gast, G; Haanen, JB; Helgason, HH; Mallo, H; Tillier, CN; van den Eertwegh, AJ; van der Veldt, AA; van Wouwe, M | 1 |
| Hes, O; Mardiak, J; Mego, M; Obertova, J; Rajec, J; Rejlekova, K; Rychly, B; Sycova-Mila, Z | 1 |
| Strumberg, D | 1 |
| Gakis, G; Kramer, MW; Kruck, S; Kuczyk, MA; Merseburger, AS; Stenzl, A | 2 |
| Bukowski, RM; Choueiri, TK; Cotta, C; Dreicer, R; Elson, P; Garcia, J; Khasawneh, MK; Mekhail, T; Rini, BI; Unnithan, J; Wood, L | 1 |
| Alexandrescu, DT; Dasanu, CA; Dawson, N; Farzanmehr, H; Popoveniuc, G; Wartofsky, L | 1 |
| Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M | 1 |
| Mueller, EW; Rashkin, MC; Rockey, ML | 1 |
| Bex, M; Carmeliet, P; Decallonne, B; Dumez, H; Schöffski, P; Stefan, C; Wolter, P | 1 |
| Bukowski, RM; Chen, I; DePrimo, SE; George, DJ; Harmon, CS; Hutson, TE; Kim, ST; Margolin, K; Michaelson, MD; Rini, BI; Rosenberg, JE; Sosman, JA; Stadler, WM | 1 |
| Bushmakin, A; Cappelleri, JC; Cella, D; Charbonneau, C; Chen, I; Kim, ST; Li, JZ; Motzer, RJ | 1 |
| Rini, BI; Vakkalanka, BK | 1 |
| Rübben, H | 1 |
| Culine, S; Patard, JJ; Pouessel, D | 2 |
| Chun, FK; Eichelberg, C; Heinzer, H; Heuer, R; Hinrichs, K; Huland, H; Zacharias, M | 1 |
| Bierer, S; Hertle, L; Nitschmann, S | 1 |
| Berneburg, M; Guenova, E; Hoetzenecker, W; Metzler, G; Mitev, V; Röcken, M; Voykov, B; Weber, HO | 1 |
| Charbonneau, C; Kim, ST; Motzer, RJ; Négrier, S; Remák, E | 1 |
| Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
| Bierer, S; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Baum, CM; Bukowski, RM; Figlin, RA; Hutson, TE; Kattan, MW; Kim, ST; Michaelson, MD; Motzer, RJ | 1 |
| Billemont, B; Boudou-Rouquette, P; Goldwasser, F; Loriot, Y; Ropert, S | 1 |
| Tuma, RS | 1 |
| Moch, H | 1 |
| Stergiopoulos, K; Wu, S; Zhu, X | 1 |
| Harshman, L; Srinivas, S | 1 |
| Casper, J; Freund, M; Hilgendorf, I; Kahl, C | 1 |
| Boven, E; Broxterman, HJ; de Gruijl, TD; Giaccone, G; Haanen, JB; Hoekman, K; Oosterhoff, D; Scheper, RJ; van Cruijsen, H; van den Eertwegh, AJ; van der Veldt, AA; Vroling, L | 1 |
| Fujioka, T; Obara, W | 1 |
| Kakehi, Y | 1 |
| Aguilar-Ponce, JL; Buzaid, AC; de la Garza, J; Fernandes, Gdos S; Kann, AG; Maluf, FC | 1 |
| Etienne-Grimaldi, MC; Izzedine, H; Milano, G; Renée, N; Vignot, S | 1 |
| Bensalah, K; Culine, S; Laguerre, B; Patard, JJ; Raffi, A; Thuret, R | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Jain, R; Mathew, P; Tannir, NM; Wood, CG | 1 |
| Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Chowdhury, S; Gore, ME; Larkin, JM | 1 |
| Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H | 1 |
| Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ | 1 |
| Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC | 1 |
| Billemont, B; Helley, D; Medioni, J; Meric, JB; Oudard, S; Rixe, O; Taillade, L | 1 |
| Basso, U; Bedogni, A; Brunello, A; Saia, G; Scaglione, D | 1 |
| Bukowski, R; Dreicer, R; Elson, P; Finke, JH; Garcia, J; Golshayan, A; Ireland, J; Rayman, P; Richmond, A; Rini, B; Wood, L | 1 |
| Hutson, TE | 2 |
| Bamias, A | 1 |
| Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J | 1 |
| Chow, E; Ehrlich, L; Hird, AE; Ko, YJ; Probyn, L; Sinclair, E; Yip, D | 1 |
| Kroog, GS; Motzer, RJ | 1 |
| Margulis, V; Wood, CG | 2 |
| Ellis, S; Marsh, JE; Sampson, S; Savage, P; Winn, SK | 1 |
| Dham, A; Dudek, AZ; Lindgren, BR; Szczylik, C; Zolnierek, J | 1 |
| Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M | 1 |
| Haseke, N; Ihrler, S; Karl, A; Schöppler, G; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 2 |
| Campbell, SC; Dreicer, R; Garcia, J; Klein, EA; Lane, BR; Novick, AC; Rini, BI; Thomas, AA | 1 |
| Beuselinck, B; Pans, S; Schöffski, P; Wolter, P | 1 |
| Bukowski, RM; Chi, KN; Garcia, JA; Heng, DY; Jin, T; Kollmannsberger, C; Murray, N; Rini, BI | 1 |
| Beniak, J; Kakalejcik, M; Reckova, M | 1 |
| Daniels, GH | 1 |
| Bex, A; Blank, C; Boven, E; Haanen, J; Horenblas, S; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Biswas, S; Eisen, T; Kelly, J | 1 |
| Ballanger, P; Bernhard, JC; Bram, R; Cornelis, F; Deminière, C; Gabbay, G; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Andrieu, JM; Azizi, M; Banu, E; Chedid, A; Fournier, L; Helley, D; Medioni, J; Mejean, A; Oudard, S; Scotte, F | 1 |
| Froehner, M; Novotny, V; Platzek, I; Wirth, MP; Zastrow, S | 1 |
| Berger, W; Lamm, W; Micksche, M; Pichelmeyer, O; Pirker, C; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
| Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L | 1 |
| Alken, P; Bolenz, C; Häcker, A; Herrmann, E; Honeck, P; Michel, MS; Schöppler, G; Trojan, L | 1 |
| Bergmann, L; Jäger, E; Jakse, G; Keilholz, U; Miller, K; Wirth, M | 1 |
| Nurzyński, P; Opolski, G; Szaluś, N; Szczylik, C; Szmit, S | 1 |
| Hill, KL; Lipson, AC; Sheehan, JM | 1 |
| Boven, E; Broxterman, HJ; de Haas, RR; Haanen, JB; Hoekman, K; Kuik, DJ; Schuurhuis, GJ; van Cruijsen, H; van den Eertwegh, AJ; van der Veldt, AA; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Bukowski, RM | 1 |
| Chu, D; Lacouture, ME; Weiner, E; Wu, S | 1 |
| Curiel, RE; Motzer, RJ; Patel, PH; Senico, PL | 1 |
| Fayyad, R; Figlin, RA; Hariharan, S; Hudes, G; Kempin, S; Motzer, RJ; Schwartz, LH; Wilding, G | 1 |
| Laber, DA; Mushtaq, M | 1 |
| Bas, CA; Gomez-Abuin, G; Karam, AA; Mezzadri, NA | 1 |
| Izzedine, H; Massard, C; Soria, JC | 1 |
| Baum, MS; Feldman, DR; Fischer, P; Flombaum, CD; Ginsberg, MS; Hassoun, H; Ishill, N; Motzer, RJ; Patil, S; Ronnen, E; Velasco, S | 1 |
| Schmidinger, M; Zielinski, CC | 1 |
| Du, Y; Figlin, R; Herrmann, A; Xin, H; Yu, H; Zhang, C | 1 |
| Porta, C; Szczylik, C | 1 |
| Bargman, JM; Oreopoulos, DG; Simons, M; Tapiawala, SN | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Bukowski, R; Cohen, P; Dreicer, R; Elson, P; Finke, JH; Garcia, J; Golshayan, A; Ireland, JL; Ko, JS; Rayman, PA; Rini, BI; Wood, L; Zea, AH | 1 |
| Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N | 1 |
| Mizutani, Y | 1 |
| Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
| Feyerabend, S; Schilling, D; Stenzl, A; Wicke, C | 1 |
| Jarkowski, A; Wong, MK | 1 |
| Betjes, MG; Rolleman, EJ; Weening, J | 1 |
| Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B | 1 |
| Soulières, D; Taussky, D | 1 |
| Hamada, Y; Shibata, A; Tahara, M; Yamaguchi, S | 1 |
| Cho, D; Choueiri, TK; Fournier, L; Medioni, J; Oudard, S; Zinzindohoué, F | 1 |
| Kurzyna, M; Opolski, G; Szczylik, C; Szmit, S; Zagrodzka, M | 1 |
| Ball, SA; Plowman, PN; Reznek, R; Richards, TM | 1 |
| Bellmunt, J; Flodgren, P; Oudard, S; Roigas, J | 1 |
| Bagner, JW; Bergmann, L; Ecke, TH; Eimer, C; Gerullis, H; Maute, L; Otto, T | 1 |
| Rini, BI | 6 |
| Ravaud, A; Sire, M | 1 |
| Secasan, CC | 1 |
| Sternberg, CN | 1 |
| Bukowski, R; Flodgren, P; Ravaud, A; Schöffski, P | 1 |
| Augereau, B; Gregory, T; Medioni, J; Mir, O; Oudard, S | 1 |
| Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP | 1 |
| Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
| Gan, HK; Knox, JJ; Seruga, B | 1 |
| Gillessen, S; Omlin, A; Rothermundt, CA | 1 |
| Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Nunzio, C; De Placido, S; Di Lorenzo, G; Ewer, M; Ficorella, C; Giordano, A; Giuliano, M; Gonnella, A; Montesarchio, V; Ricevuto, E; Rizzo, M; Romano, C; Tudini, M | 1 |
| Bjarnason, GA; Bukowski, RM; Chen, I; Figlin, RA; Garcia-del-Muro, X; Huang, X; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Pili, R; Solska, E; Sosman, JA; Szczylik, C; Thompson, JA; Tomczak, P; Wilding, G | 1 |
| Aliberti, C; Ballardini, P; Manfredini, R; Margutti, G | 1 |
| Berchem, G; Dewilde, S; Mahassen, P | 1 |
| Alasker, A; Guevremont, C; Karakiewicz, PI | 1 |
| Abel, EJ; Wood, CG | 1 |
| Bex, A; Boven, E; van der Veldt, AA | 1 |
| Benounna, M; Rivera, F; Sánchez de la Nieta, MD | 1 |
| Abrio, MV; Castellano, D; Cerezo, SD; del Muro, XG; González-Larriba, JL; Grande, E; Guzmán, C; Pardo, A; Pérez-Gracia, JL; Ruiz, MA | 1 |
| Bayz, U; Can, IH; Doğan, S; Ozer, E; Samim, EE; Sayn, M; Yazici, G | 1 |
| Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC | 1 |
| Bamias, A; Dimopoulos, MA; Gyftaki, R; Koroboki, E; Lainakis, G; Manios, E; Zakopoulos, N | 1 |
| Green, C; Hoyle, M; Liu, Z; Moxham, T; Rogers, G; Stein, K; Thompson Coon, JS; Welch, K | 1 |
| Melichar, B | 1 |
| Bjarnason, GA; Bracarda, S; Bukowski, R; Castellano, D; Gore, ME; Haanen, J; Hariharan, S; Lee, SH; Mainwaring, P; Nieto, A; Oudard, S; Porta, C; Schöffski, P; Szczylik, C; Vrdoljak, E; Yuan, J | 1 |
| Bellmunt, J; Choueiri, TK | 1 |
| Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M | 1 |
| Boix, E; Herrero, J; Meana, JA; Piñar, D | 1 |
| Bamias, A; Dimopoulos, MA; Fountzilas, G; Lainakis, G; Psimenou, E | 1 |
| Fokt, RM; Gillessen, S; Ohlschlegel, C; Schmid, HP; Templeton, A | 1 |
| Park, CY | 1 |
| Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Ficorella, C; Giannarini, G; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Pignata, S; Rescigno, P; Rizzo, M; Tudini, M | 1 |
| Chen, I; Escudier, B; Flodgren, P; Fountzilas, G; Gillessen, S; Harmenberg, U; Maneval, EC; Mulder, SF; Peschel, C; Roigas, J; Srinivas, S; Vogelzang, NJ | 1 |
| Dreyer, C; Faivre, S; Raymond, E; Theou-Anton, N | 1 |
| Ansari, J; Deshmukh, N; Doherty, A; McCafferty, I; Porfiri, E; Wallace, M | 1 |
| Benghiat, H; Collins, S; James, N; Karina, M; Oldroyd, A; Parry, H; Pascoe, J; Porfiri, E; Ray, D; Zachariah, A | 1 |
| Cella, D | 2 |
| Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J | 1 |
| Abrams, J; Al-Bashir, AK; Haacke, EM; Hillman, GG; Katkuri, Y; Li, M; Patel, AD; Singh-Gupta, V; Yunker, CK; Zhang, H | 1 |
| Cersosimo, RJ | 1 |
| Kosák, M; Koskuba, J; Kreze, A; Stáhalová, V; Zadrazilová, A | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
| Kalantari, HR | 1 |
| Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
| Kang, DY; Kim, S; Lee, HJ; Lim, JS; Song, IC; Yun, HJ | 1 |
| Garnock-Jones, KP; Keating, GM | 1 |
| Eigl, BJ; Hemmelgarn, B; Heng, DY; Vickers, MM | 1 |
| Choueiri, TK; Hirsch, MS; Mosquera, JM | 1 |
| Atkins, MB; Bukowski, RM; Cheng, T; Chi, KN; Choueiri, TK; Eigl, BJ; Golshayan, AR; Heng, DY; Knox, JJ; Kollmannsberger, C; McDermott, DF; North, S; Oh, WK; Regan, MM; Rini, BI; Ruether, JD; Sahi, C; Venner, P; Warren, MA; Xie, W | 1 |
| Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S | 1 |
| Dikilitas, M; Er, O; Karaca, H; Lale, A; Ozkan, M | 1 |
| Al Enazi, MM; Kadry, R; Mitwali, H | 1 |
| Edeline, J; Laguerre, B; Patard, JJ; Rolland, Y | 1 |
| Balvay, D; Chatellier, G; Cuenod, CA; Dromain, C; Escudier, B; Fournier, LS; Medioni, J; Oudard, S; Thiam, R; Trinquart, L | 1 |
| Goldschmeding, R; Overkleeft, EN; van Reekum, F; Verheul, HM; Voest, EE | 1 |
| Breau, RH; Leibovich, BC | 1 |
| Agata, N; Akaza, H; Fujimoto, H; Hasegawa, Y; Houk, B; Miki, T; Mugiya, S; Naito, S; Niwakawa, M; Nonomura, N; Shinohara, N; Takahashi, M; Tomita, Y; Uemura, H; Yuasa, T | 2 |
| Cappelleri, JC; Cella, D; Charbonneau, C; Chen, I; Kim, ST; Li, JZ; Luo, X; Motzer, RJ | 1 |
| Calvo, A; Gil-Bazo, I; Gonzalez, A; Grande-Pulido, E; Guillén-Grima, F; Gurpide, A; Melero, I; Panizo, A; Perez-Gracia, JL; Prior, C; Segura, V | 1 |
| Escudier, B; Gore, M; Mickisch, G; Nuijten, M; Procopio, G; Walzer, S | 1 |
| Cowey, CL; Fielding, JR; Rathmell, WK | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Staehler, M; Varga, Z | 1 |
| Atkins, MB; Choueiri, TK | 1 |
| Digue, L; Ravaud, A; Smith, D; Trufflandier, N | 1 |
| Thompson, JA | 1 |
| Wood, LS | 1 |
| Brade, AM; Chung, C; Dawson, LA; Joshua, AM | 1 |
| Carli, P; Ceravolo, R; Donach, M; Faggioni, G; Farina, M; Furini, L; Lombardi, G; Nicoletto, O; Pastorelli, D; Zovato, S; Zustovich, F | 1 |
| Gore, M; Larkin, J | 1 |
| Bello, CL; Demetri, GD; Houk, BE; Motzer, RJ; Poland, B; Rosen, LS | 1 |
| Li, X; Liu, J; Qiang, W; Yang, Y; Yao, J; Zeng, H; Zhu, Y | 1 |
| Goh, V; Juttla, J; Nathan, PD; Stott, D; Vinayan, A | 1 |
| Costero, O; Martinez-Ara, J; Picazo, ML; Romero, S; Selgas, R; Zamora, P | 1 |
| Wang, ZY | 1 |
| Autorino, R; Di Lorenzo, G | 1 |
| Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K | 1 |
| Lieber, ML; Shah, SN; Smith, AD | 1 |
| Mickisch, G; Nuijten, M | 1 |
| Gandhi, M; Guitart, JG; Kuzel, TM; Lacouture, M; Liu, SW | 1 |
| Heng, DY; Kollmannsberger, C | 1 |
| Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L | 1 |
| Peter, S; Rohde, D; Tong, TQ | 1 |
| Aubert, S; Copin, MC; Delehedde, M; Franquet, H; Kervoaze, G; Lassalle, P; Leroy, X; Villers, A; Zini, L | 1 |
| Ding, Y; Huang, D; Li, Y; Luo, WM; Qian, CN; Snider, J; Teh, BT; Vandenbeldt, K; Zhang, ZF | 1 |
| Ding, Y; Furge, KA; Futreal, PA; Huang, D; Kahnoski, R; Petillo, D; Qian, CN; Rini, BI; Teh, BT; Zhou, M | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Kim, ST; Li, JZ; Michaelson, MD; Motzer, RJ | 1 |
| Bex, A; Blank, C; Boven, E; Haanen, JB; Meijerink, MR; Van der Veldt, AA | 1 |
| Antón-Aparicio, LM; Calvo, OF; Carral, A; Durana, J; García-Campelo, R; Grande, E; López, MR; Quindós, M; Soto, JM; Vázquez, DD | 1 |
| Aparicio, LM; Calvo, OF; López, MR; Vázquez, DD | 1 |
| Guillén-Ponce, C; Mena, AC; Pulido, EG | 1 |
| Andrejak, M; Basille, D; Bentayeb, H; Boutemy, M; Dayen, C; Douadi, Y; Fournier, C; Garidi, R; Kanaan, M; Lecuyer, E | 1 |
| Oya, M | 1 |
| Baum, MS; Chen, I; Ginsberg, MS; Harmon, CS; Hudes, GR; Kim, ST; Motzer, RJ; Redman, BG | 1 |
| Decallonne, B; Op de Beeck, K; Rogiers, A; Schöffski, P; Thijs, M; Wolter, P | 1 |
| Albiges, L; Benatsou, B; Chami, L; Chebil, M; Escudier, BJ; Koscielny, S; Lassau, N; Roche, A | 1 |
| Boven, E; Haanen, JB; Meijerink, MR; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Canipari, C; De Amici, M; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L | 1 |
| Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C | 1 |
| Anastasiou, I; Andreadis, C; Bamias, A; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Karadimou, A; Kontovinis, L; Lainakis, G; Lampaki, S; Malettou, L; Papandreou, C; Papazisis, K; Razi, E; Skolarikos, A; Stravodimos, K; Syrigos, K; Timotheadou, E; Xanthakis, I | 1 |
| Bergmann, L; Miller, K | 2 |
| Bergmann, L | 1 |
| Gschwend, JE | 1 |
| Marschner, N | 1 |
| Miller, K | 1 |
| Jäger, E | 1 |
| Haseke, N; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Fournier, C; Tisman, G | 1 |
| Porta, C | 2 |
| Bierer, S; Herrmann, E; Wülfing, C | 1 |
| Hershman, JM; Liwanpo, L | 1 |
| Fujita, T; Iiri, T; Makita, N; Miyakawa, M | 1 |
| Fesler, MJ; Katta, A; Richart, JM; Tan, A; Vuong, G | 1 |
| Amato, AM; Atkins, MB; Cho, DC; Choueiri, TK; Clement, J; McDermott, D; Oh, WK; Regan, MM; Rosenberg, JE; Signoretti, S | 1 |
| Gajda, M; Kroeger, N; Petersen, I; Settmacher, U; Steiner, T; Wunderlich, H; Zanow, J | 1 |
| Kataja, V; Kellokumpu-Lehtinen, P; Nuttunen, P; Purmonen, T; Pyrhönen, S; Vuorinen, R | 1 |
| Barbastefano, J; Campbell, SC; Dreicer, R; Elson, P; Garcia, JA; Lane, BR; Rini, BI; Wood, LS | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Fukudo, M; Inui, K; Kamba, T; Katsura, T; Mizuno, T; Nakamura, E; Ogawa, O; Terada, T | 2 |
| Choueiri, TK | 1 |
| Devarajan, P | 1 |
| Bazzi, W; Derweesh, IH; DiBlasio, CJ; Downs, TM; Kane, CJ; Kopp, R; Mehrazin, R; Millard, F; Patterson, AL; Silberstein, JL; Yunus, F | 1 |
| Hansen, T; Jäger, E; Koch, FP; Wagner, W; Walter, C | 1 |
| Cuesta Alcalá, JA; De Pablo Cárdenas, A; Millán Serrano, JA; Sánchez Zalabardo, D | 1 |
| Bunting, KD; Cohen, PA; Finke, JH; Ireland, J; Ko, JS; Li, G; Rayman, P; Rini, B; Swaidani, S | 1 |
| Albouy, B; Escudier, B; Gross Goupil, M; Massard, C | 1 |
| Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E | 1 |
| Boyle, H; Fléchon, A; Négrier, S | 1 |
| Agarwal, N; Batten, J; Callis-Duffin, K; Narayanan, S | 1 |
| Kondo, M; Nieder, C; Norum, J | 1 |
| Beatty, K; Bokar, J; Chen, HX; Cooney, MM; Dowlati, A; Dreicer, R; Elson, P; Garcia, JA; Ivy, P; Rini, BI; Tyler, A | 1 |
| Dalhaug, A; Haukland, E; Nieder, C | 1 |
| Gong, K; He, ZS; Jin, J; Li, XS; Song, G; Song, Y; Wang, G; Yu, W; Zhang, Q; Zhang, Z; Zhao, Z; Zhou, LQ | 1 |
| Vaishampayan, U | 1 |
| Rini, BI; Shah, SN | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Kim, CS; Kim, JE; Lee, DH; Lee, JL; Lee, JS; Na, S; Song, C; Yoo, C | 1 |
| Grünwald, V; Kalanovic, D; Merseburger, AS | 1 |
| Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K | 1 |
| Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 2 |
| Dykema, K; Ellis, L; Furge, K; Hammers, HJ; Jaspers, J; Netto, G; Paesante, S; Pili, R; Rudek, M; Salumbides, B; Shah, P; Sharma, R; Shen, L; Teh, BT; Verheul, HM | 1 |
| Allory, Y; Bastien, L; Calvo, F; Cussenot, O; de La Taille, A; Deslandes, E; Menashi, S; Mourah, S; Naïmi, B; Paule, B; Podgorniak, MP; Porcher, R | 1 |
| Arnold, D; Ravaud, A; Schmidinger, M; Szczylik, C; Wagstaff, J | 1 |
| Arkadopoulos, N; Gennatas, C; Kondi-Pafiti, A; Michalaki, V | 1 |
| Bozas, G; Maraveyas, A; Ramasamy, V; Roy, A | 1 |
| Choueiri, TK; Dal Cin, P; Kelly, PJ; Perez-Atayde, AR; Sher, DJ; Weiss, SE | 1 |
| Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L | 1 |
| Chowdhury, S; Hutson, T; Jones, R; Lim, L; Mantle, M; Powles, T; Shamash, J | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Ansari, J; Collins, S; Fatima, A; Fernando, K; James, ND; Porfiri, E | 1 |
| Ghenev, P; Izumi, K; Kitagawa, S; Mouri, H; Ohtsubo, K; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Boven, E; de Boer, MP; Lankheet, NA; Serné, EH; van den Eertwegh, AJM; van der Veldt, AAM; Wijnstok, NJ | 1 |
| Herrmann, TR; Kramer, M; Kuczyk, MA; Merseburger, AS; Schrader, AJ; Waalkes, S | 1 |
| Bories, E; Caillol, F; Giovannini, M; Gravis, G; Jeanniard-Malet, O; Pesenti, C | 1 |
| Hellenthal, NJ; Kim, HL; Litwin, A; Penetrante, R; Teh, BT; Underwood, W; Wilding, GE; Zhang, S | 1 |
| Figlin, RA; Huang, X; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Négrier, S; Patil, S | 2 |
| Choueiri, TK; Corn, P; Dal Cin, P; Heng, DY; Hirsch, MS; Jonasch, E; Lim, ZD; McDermott, DF; Tamboli, P; Tannir, NM; Vaishampayan, U | 1 |
| Fisher, C; Fisher, R; Gore, M; Larkin, J; Livni, N; Pickering, L; Thway, K | 1 |
| Fujisawa, M; Haraguchi, T; Miyake, H; Takenaka, A | 1 |
| Eufinger, H; Hoefert, S | 1 |
| Hashimoto, Y; Iizuka, J; Kobayashi, H; Kondo, T; Nakano, M; Nishikawa, T; Tanabe, K | 1 |
| Ginsberg, MS; Molina, AM; Motzer, RJ | 1 |
| De Miguel Novoa, MP; Díaz Pérez, JÁ; Fuertes Zamorano, N; Molino González, A; Montañez Zorrilla, MC; Rojas-Marcos, PM | 1 |
| Rini, B; Rixe, O | 1 |
| Canfield, SE; Dahm, P; Sultan, S | 1 |
| Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Baum, MS; Feldman, DR; Georges, M; Ginsberg, MS; Jia, X; Kroog, G; Molina, AM; Motzer, RJ; Patil, S; Reuter, VE; Tickoo, SK | 1 |
| Ganser, A; Grünwald, V; Janssen, S; Karstens, JH; Morgan, M; Seidel, C; Welte, T | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Cecere, FL; Di Costanzo, F; Doni, L; Moscetti, L; Padalino, D; Ruggeri, EM | 1 |
| Dhaun, N; Webb, DJ | 1 |
| Danser, AH; Kappers, MH; Sleijfer, S; Sluiter, W; van den Meiracker, AH; van Esch, JH | 1 |
| Hiromatsu, Y; Matsuoka, K; Miyajima, J; Muraishi, K; Sasaki, Y; Sato, S; Suekane, S; Tajiri, Y; Tani, J; Tokubuchi, I; Yamada, K | 1 |
| Bukowski, RM; Cowey, CL; Dreicer, R; Elson, P; Garcia, JA; Gilligan, T; Hutson, TE; Nemec, C; Rini, BI | 1 |
| Albers, P; Beuselinck, B; Decoene, J; Oudard, S | 1 |
| Cagli, B; Intagliata, S; Onetti Muda, A; Perrone, G; Persichetti, P; Santini, D; Segreto, F; Tonini, G | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| del Muro, JG; Díaz, S; Grande, E; Paz-Ares, L | 1 |
| Andreadis, C; Antonakis, E; Christopoulou, M; Kontovinis, LF; Kortsaris, AH; Kouvatseas, G; Lafaras, C; Mouratidou, D; Papandreou, CN; Papazisis, KT | 1 |
| Bojic, M; Clodi, M; Haitel, A; Heinzl, H; Kramer, G; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
| Bjarnason, GA; Bracarda, S; Carteni, G; Gore, ME; Hariharan, S; Hawkins, R; Lee, SH; Nieto, A; Oudard, S; Porta, C; Szczylik, C; Yuan, J | 1 |
| Aglietta, M; Aieta, M; Buonerba, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Felici, A; Imbimbo, C; Longo, N; Milella, M; Mirone, V; Ortega, C; Palmieri, G; Rescigno, P; Ruggeri, EM | 1 |
| Baldazzi, V; Carini, M; Lapini, A; Mazzanti, R; Santomaggio, C; Tassi, R | 1 |
| Larkin, J; Mukherji, D; Pickering, L | 1 |
| Catlett, L; Eddy, S; Gordon, M; Healey, D; Huang, B; Rini, BI; Shannon, P; Stein, M; Stephenson, JJ; Tyler, A | 1 |
| Ayllon, J; Barrascout, E; Beuselinck, B; Blesius, A; Elaidi, R; Escudier, B; Lang, H; Medioni, J; Morel, A; Oudard, S; Rixe, O; Schöffski, P; Wolter, P; Zucman-Rossi, J | 1 |
| Barni, S; Cabiddu, M; Carpo, M; Ghilardi, M; Petrelli, F | 1 |
| Charbonneau, C; Sandin, R | 1 |
| Asakura, T; Fujinami, K; Goto, A; Komeya, M; Matsumoto, T; Senga, Y | 1 |
| Fujisawa, M; Miyake, H | 1 |
| Figlin, RA; Pal, SK | 1 |
| Basappa, NS; Dreicer, R; Elson, P; Garcia, JA; Golshayan, AR; Rini, BI; Wood, L | 1 |
| Augwal, S; Boleti, K; Bower, M; Chowdhury, S; Green, J; Lim, L; Peters, J; Powles, T; Sadev, A; Sarwar, N; Saunders, N; Shamash, J | 1 |
| Chang, SG; Jeon, SH; Lee, CH; Lee, JH; Lim, TJ; Min, GE; Yoo, KH | 1 |
| Frey, K; Giavazzi, R; Johannsen, M; Neri, D; Schliemann, C; Schwager, K | 1 |
| Chong, G; Hamilton, K; Yoong, J | 1 |
| Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; Lampard, JG; McDermott, DF; North, S; Rini, BI; Xie, W | 1 |
| Eechoute, K; Gelderblom, H; Gietema, J; Guchelaar, HJ; Haanen, JB; Mathijssen, RH; van den Eertwegh, AJ; van der Veldt, AA; van Erp, NP; Wessels, JA | 1 |
| Cho, JH; Kang, WK; Lee, J; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS | 1 |
| Chapelle, A; Guillot, B; Jacot, W; Kluger, N | 1 |
| Choueiri, TK; Cleary, JM; Elson, P; Escudier, B; Garcia, JA; Heng, DY; Hutson, TE; Knox, JJ; Michaelson, MD; Ramaiya, N; Rini, BI; Zama, IN | 1 |
| Breza, J; Eret, V; Ferda, J; Hes, O; Holečková, P; Hora, M; Hyršl, L; Klečka, J; Kreuzberg, B; Mego, M; Michal, M; Petersson, F; Stránský, P; Urge, T | 1 |
| Brinkhaus, G; Gebauer, B; Wust, P | 1 |
| Rini, B | 1 |
| Board, R; Hawkins, R; O'Dwyer, J; Shablak, A | 1 |
| Fjeld, JG; Fosså, SD; Hagen, G; Lilleby, W; Revheim, ME; Winge-Main, AK | 1 |
| Postema, PG; Regeer, MV; Richel, DJ; Stroes, ES; van der Valk, PR | 1 |
| Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B | 1 |
| Haseke, N; Karl, A; Muacevic, A; Nuhn, P; Siebels, M; Staehler, M; Stief, CG; Tüllmann, C; Wowra, B | 1 |
| Ikushima, H; Ishizu, A; Kamishima, T; Kanayama, H; Nonomura, K; Otsuka, N; Shimizu, C; Shinohara, N; Takahashi, M | 1 |
| Habuchi, T; Horikawa, Y; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H; Yuasa, T | 1 |
| Biró, K; Küronya, Z | 1 |
| Abel, EJ; Culp, SH; Karam, JA; Margulis, V; Tamboli, P; Wang, H; Wood, CG; Zhang, XY | 1 |
| Arnott, J; Bruce, JY; Carducci, M; Eickhoff, J; Liu, G; Logan, T; Pili, R; Treston, A; Wilding, G | 1 |
| Desar, IM; Fiedler, W; Grünwald, V; Haanen, J; Mouritzen, U; Olsen, MW; van Herpen, CM | 1 |
| Brion, N; Paule, B | 2 |
| Oudard, S | 1 |
| Eechoute, K; Mathijssen, RH; van Daele, PL; van Wijk, RG; van Zonneveld, M | 1 |
| Beutel, G; Ganser, A; Gruenwald, V; Haubitz, M; Ivanyi, P; Reuter, C; Schuch-Jantsch, S | 1 |
| Miller, MB; Nadauld, LD; Srinivas, S | 1 |
| Beltran, L; Berney, D; Bex, A; Blank, C; Boletti, K; Chowdhury, S; Haanen, J; Horenblas, S; Kayani, I; O'Brien, T; Peters, J; Powles, T; Sadev, A; Sarwar, N; Shamash, J | 1 |
| Choueiri, TK; Chowdhury, P; Chowdhury, S; Cowey, CL; Gore, ME; Harper, PG; Hutson, TE; Josephs, D; Karapetis, C; Larkin, JM; McDermott, DF; Pickering, LM; Powles, T; Van Hemelrijck, M | 1 |
| Christmas, T; Cordiner, RL; Fisher, RA; Ghosn, M; Gore, ME; Larkin, JM; Pickering, LM; Sohaib, SA | 1 |
| Amatulli, M; Claros, N; Corcoran, E; Duignan, IJ; Iacolina, M; Pennello, A; Plym, MJ; Samakoglu, S; Schwartz, J; Surguladze, D; Tonra, JR; Witte, L; Youssoufian, H | 1 |
| Dunn, RL; Filson, CP; Miller, DC; Redman, BG | 1 |
| Fenner, M; Ganser, A; Grünwald, V; Ivanyi, P; Länger, F; Merseburger, AS; Reuter, C; Seidel, C | 1 |
| Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A | 1 |
| Bex, A; Chowdhury, S; Hutson, T; Jones, R; Lim, L; Mantle, M; Nathan, P; Powles, T | 1 |
| Chay, WY; Choong, CV; Goh, C; Tan, MH; Tan, PH; Tang, T; Tay, MH; Zam, NA | 1 |
| Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P | 1 |
| Atkins, MB; Choueiri, TK; Guo, M; Heng, DY; Jagannathan, J; Krajewski, KM; McDermott, DF; Pedrosa, I; Ramaiya, N; Schutz, FA; Van den Abbeele, AD; Yap, J | 1 |
| Cohen, P; Finke, J; Ireland, J; Ko, J; Rayman, P; Rini, B | 1 |
| Fukui, I; Hatake, K; Inamura, K; Ishikwa, Y; Kodaira, M; Nakano, K; Takahashi, S; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Cho, DC; McDermott, DF; Mier, JW; Pandya, SS | 1 |
| Bradshaw, MJ; Cheville, JC; Croghan, GA | 1 |
| Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
| Branson, M; Hollaender, N; Neuenschwander, B; Rouyrre, N; Zuber, E | 1 |
| Demlová, R; Komínek, J; Ondrácková, B | 1 |
| Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ | 1 |
| Hashimoto, H | 1 |
| Abel, EJ; Brugarolas, J; Chapin, BF; Cost, NG; Culp, S; Delacroix, SE; Karam, JA; Margulis, V; Raj, GV; Sagalowsky, AI; Sleeper, JP; Smith, PJ; Wood, CG; Youssef, RF | 1 |
| Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K | 1 |
| Amato, RJ; de Belin, J; Goonewardena, M; Harrop, R; Hawkins, RE; Kaufman, HL; Kelleher, M; McDonald, M; Naylor, S; Shingler, WH; Treasure, P | 1 |
| Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Kimura, S; Maekawa, T; Maita, S; Mitobe, Y; Narita, S; Tsuchiya, N; Yuasa, T | 1 |
| Bello, CL; Ravaud, A | 1 |
| Lian, E; Merchan, J; Silva, O; Stefanovic, A; Talebi, TN | 1 |
| O'Donnell, PH | 1 |
| Bex, A; Clarke, N | 1 |
| Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T | 1 |
| Maráz, A | 1 |
| Ayllon, J; Barrascout, E; Beuselinck, B; Medioni, J; Morel, A; Oudard, S; Scotte, F | 1 |
| Fujisawa, M; Kusuda, Y; Miyake, H; Terakawa, T | 1 |
| Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST | 1 |
| Tanji, N; Yokoyama, M | 1 |
| Goyal, A; Gupta, YK; Padhy, BM; Shanmugam, SP | 1 |
| Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R | 1 |
| Ceresoli, GL; Colombo, P; De Sanctis, R; De Vincenzo, F; Gianoncelli, L; Graziotti, P; Lorenzi, E; Perrino, M; Santoro, A; Simonelli, M; Zucali, PA | 1 |
| Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J | 1 |
| Bjarnason, G; Bukowski, R; Burnett, P; Creel, P; Davis, M; Dawson, N; Feldman, D; George, S; Hershman, J; Kollmannsberger, C; Lechner, T; Potter, A; Raymond, E; Treister, N; Wood, L; Wu, S | 1 |
| Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K | 1 |
| Baum, MS; Chen, I; Cohen, DP; Figlin, RA; Gore, ME; Hariharan, S; Lu, DR; Motzer, RJ; Rini, BI | 1 |
| Abrahamova, J; Brabec, P; Buchler, T; Dusek, L; Klapka, R; Melichar, B; Vyzula, R | 1 |
| Bamias, A; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Karadimou, A; Lainakis, G; Manios, E; Michas, F; Zakopoulos, N | 1 |
| Perazzo, F; Rodríguez-Reimúndes, E; Vilches, AR | 1 |
| Atri, M; Bjarnason, GA; Burns, PN; Hudson, JM; Lloyd, BA; Lueck, G; Milot, L; Sureshkumar, AR; Williams, R | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z | 1 |
| Carrato, A; Ferreiro, R; Grande, E; Pachón, V; Vaz, MA | 1 |
| Nozawa, M | 1 |
| Demidov, LV; Petenko, NN; Timofeev, IV | 1 |
| Buonerba, C; Casciano, R; De Placido, S; Di Lorenzo, G; Liu, Z; Malangone, E; Sherman, S; Wang, X; Willet, J | 1 |
| Bajetta, E; Bearz, A; Calcagno, A; Cartenì, G; Chiappino, I; Guadalupi, V; Imarisio, I; Landi, L; Paglino, C; Porta, C; Procopio, G; Re, GL; Ricotta, R; Rizzo, M; Ruggeri, EM; Sabbatini, R; Verzoni, E; Zustovich, F | 1 |
| Antonarakis, ES; Carducci, MA; Eisenberger, MA; Hammers, H; Huang, P; Keizman, D; Kim, JJ; Pili, R | 1 |
| Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
| Beltran, L; Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Horenblas, S; Nathan, P; O'Brien, T; Peters, J; Powles, T; Sahdev, A; Sarwar, N; Shamash, J | 1 |
| Busch, J; Fenner, M; Ganser, A; Grünwald, V; Johannsen, A; Johannsen, M; Reuter, C; Seidel, C; Weikert, S | 1 |
| Ortega, C; Porta, C; Ravasio, R; Sabbatini, R | 1 |
| Bladou, F; Boher, JM; Brunelle, S; Deville, JL; Eymard, JC; Gravis, G; Marcy, M; Narbonne, H; Sabatier, R; Salem, N; Viens, P; Walz, J | 1 |
| Decker, R; Escudier, B; Faelker, T; Hamid, O; Kania, M; Kelly, CS; Schmidinger, M; Sternberg, CN; Szczylik, C | 1 |
| Bay, JO; Blanc, E; Chevreau, C; Delva, R; Escudier, B; Ferlay, C; Geoffrois, L; Gravis, G; Laguerre, B; Legouffe, E; Négrier, S; Pérol, D; Rolland, F; Sevin, E | 1 |
| Ciancio, G; Ekwenna, O; Gorin, MA; Soloway, MS | 1 |
| Kim, SP; Thompson, RH | 1 |
| Chatellier, G; Cuenod, CA; Faraggi, M; Fournier, L; Hindié, E; Huchet, V; Hugonnet, F; Itti, E; Medioni, J; Oudard, S; Smadja, C | 1 |
| du Parcq, J; Fisher, C; Larkin, JM; Livni, N; Thway, K | 1 |
| Duprez, O; Gao, F; Paes, MN; Visvardis, EE; Waxman, J | 1 |
| Chan, AL; Leung, HW | 1 |
| de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC | 1 |
| Bergmann, L; Gschwend, J; Keilholz, U; Miller, K | 1 |
| Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T | 1 |
| Bernhard, JC; De Clermont, H; Gross-Goupil, M; Quivy, A; Ravaud, A; Roca, S | 1 |
| Kunene, V; Porfiri, E | 1 |
| Avril, N; Bomanji, J; Chowdhury, S; Dickson, J; Ell, P; Kayani, I; Lim, L; Nathan, P; Powles, T; Reynolds, A; Rockall, A; Sahdev, A; Shamash, J; Sharpe, K; Wilson, P | 1 |
| Ahellal, Y; Errihani, H; Essadi, I; M'rabti, H; Tazi, EM; Tazi, MF | 1 |
| Busch, J; Grünwald, V; Hinz, S; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Weinkauf, L; Wolff, I | 1 |
| Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C | 1 |
| Abel, EJ; Culp, SH; Matin, SF; Tamboli, P; Tannir, NM; Wood, CG | 1 |
| Bai, L; Evans, CP; Kung, HJ; Mack, PC; Ok, JH; Yang, JC | 1 |
| Bex, A; Blank, C; Haanen, J; Horenblas, S; Meinhardt, W; van Tinteren, H | 1 |
| Busch, J; Grünwald, V; Hinz, S; Johannsen, M; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Wolff, I | 1 |
| Choueiri, TK; Dallabrida, SM; Heng, DY; Je, Y; Moslehi, JJ; Richards, CJ; Schutz, FA | 1 |
| Fukui, I; Hatake, K; Takahashi, S; Yonese, J; Yuasa, T | 1 |
| Danser, AH; de Krijger, RR; Eechoute, K; Kappers, MH; Leijten, F; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH; van Esch, JH; Visser, TJ | 1 |
| Greineder, CF; Kohnstamm, S; Ky, B | 1 |
| Atkins, M; Bukowski, R; Choueiri, TK; Dutcher, J; Eisen, T; Elson, P; Escudier, B; Heng, DY; Manola, J; Mazumdar, M; McCormack, JB; Motzer, R; Négrier, S; Royston, P | 1 |
| Ahn, JB; Bang, YJ; Chung, HC; Hong, MH; Jeung, HC; Kim, HS; Kim, K; Koh, Y; Lee, SH; Rha, SY; Shin, SJ | 1 |
| Purmonen, TT | 1 |
| Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J | 1 |
| Canter, D; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Uzzo, RG | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; Gnoni, A; Leo, S; Lombardi, L; Lorusso, V; Maiello, E; Morelli, F; Orlando, L | 1 |
| Danser, AH; Kappers, MH; Sleijfer, S; van den Meiracker, AH | 1 |
| Bazan, F; Bouchet, S; Curtit, E; Kalbacher, E; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Thiery-Vuillemin, A | 1 |
| Dreicer, R; Elson, P; Ganapathi, MK; Ganapathi, R; Garcia, JA; Kim, JJ; Rini, BI; Vaziri, SA; Wirka, R | 1 |
| Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Inoue, T; Nakano, K; Narita, S; Saito, M; Takahashi, S; Tsuchiya, N; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Ishihara, A; Kuroda, N; Takamori, H; Yamashita, Y | 1 |
| Rini, BI; Suarez, C | 1 |
| Michaelson, MD | 2 |
| Baum, MS; Brocks, DR; Feldman, DR; Fischer, PM; Ginsberg, MS; Molina, AM; Motzer, RJ; Patil, S; Trinos, MJ; Voss, MH | 1 |
| Barrios, CH; Bello, A; Brown, MP; Fein, L; Hariharan, S; Hernandez-Barajas, D; Lee, SH; Liu, JH; Martell, BA; Mundayat, R; Rha, SY; Wang, Z; Yuan, J | 1 |
| Joly, F | 1 |
| Endo, T; Hasegawa, H; Hoshino, Y; Ishii, Y; Kaneko, G; Kitagawa, Y; Mikami, S; Mukai, M; Ochiai, H; Okabayashi, K; Oya, M | 1 |
| Grünberger, B | 1 |
| Cao, K; Chen, J; Guo, S; Huang, B; Li, X; Mao, X; Mo, C; Pan, J; Qiu, S; Wang, Z; Zhuang, J | 1 |
| Baldazzi, V; Carini, M; Caruso, S; Garofoli, E; Lapini, A; Lunghi, A; Mazzanti, R; Tassi, R | 1 |
| Haygood, TM; Jonasch, E; Manoukian, GE; Qiao, W; Tannir, NM; Tu, SM | 1 |
| Chang, PM; Chen, MH; Liu, CY; Liu, YC; Pan, CC; Yang, CY | 1 |
| Assaraf, YG; Beerepoot, LV; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Griffioen, AW; Honeywell, RJ; Jansen, G; Labots, M; Musters, RJ; Peters, GJ; Pili, R; Rudek, MA; Verheul, HM | 1 |
| Henley, W; Hoyle, MW | 1 |
| Adriaansz, S; Beijnen, JH; Blank, CU; Huitema, AD; Lankheet, NA; Mallo, H; Rosing, H; Schellens, JH | 1 |
| Agaoglu, F; Basaran, M; Bavbek, S; Darendeliler, E; Ekenel, M; Ozcan, F; Sen, F; Tunc, HM; Yildiz, I | 1 |
| Arranz, JA; Bellmunt, J; Castellano, DE; Climent, MA; Esteban, E; Font, A; Gallardo, E; Garcia-Donas, J; González del Alba, A; Leandro-García, LJ; Martínez, E; Mellado, B; Moreno, F; Puente, J; Robledo, M; Rodríguez-Antona, C | 1 |
| Bearss, D; Carew, JS; Choy, G; Espitia, CM; Esquivel, JA; Giles, FJ; Kelly, KR; Mahalingam, D; Medina, EC; Nawrocki, ST; Taverna, P | 1 |
| Carducci, MA; Eisenberger, MA; Hammers, H; Huang, P; Ish-Shalom, M; Keizman, D; Pili, R | 1 |
| Bender, C; Ullrich, A | 1 |
| Carmichael, L; Chao, B; Eickhoff, J; Harrison, M; Ivy, P; Jeraj, R; Kolesar, J; Liu, G; Marnocha, R; Perlman, S; Simoncic, U; Vanderhoek, M; Wilding, G | 1 |
| Gong, K; He, ZS; Huang, LH; Jin, J; Li, XS; Shen, C; Song, G; Song, Y; Wang, G; Wu, X; Yu, W; Zhang, Q; Zhang, Z; Zhao, PJ; Zhao, Z; Zhou, LQ | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L | 1 |
| Appleman, LJ; Carlson, DM; Chen, J; Cho, D; Choueiri, TK; Coates, A; Ernstoff, MS; Gupta, N; Kollmannsberger, CK; Michaelson, MD; Perry, DJ; Posadas, EM; Pradhan, R; Qian, J; Ricker, JL; Scappaticci, FA; Tannir, NM; Wong, YN | 1 |
| Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I | 1 |
| Davis, DW; Fuller, GN; Gombos, DS; Jonasch, E; Matin, SF; McCutcheon, IE; Smith, LA; Tannir, NM; Waguespack, SG; Wen, S | 1 |
| Calvo Aller, E; Castellano, D; Díaz Cerezo, S; González Larriba, JL; Kreif, N; López-Brea, M; Maroto, P; Martí, B | 1 |
| Ghinea, N; Pichon, C; Radu, A; Siraj, MA | 1 |
| Dörken, B; Flörcken, A; Hopfenmüller, W; Pezzutto, A; Singh, A; Takvorian, A; Van Lessen, A; Westermann, J | 1 |
| Antón-Aparicio, L; Aparicio-Gallego, G; Blanco, M; Figueroa, A; García-Campelo, R; Grande-Pulido, E; Valladares-Ayerbes, M | 1 |
| Ishida, H; Ito, H; Itoh, H; Tsuchiyama, K; Yokoyama, O | 1 |
| Chen, X; Guan, W; Hu, Z; Li, Y; Liu, F; Peng, E; Ye, Z; Zhuang, Q | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H | 1 |
| Lanocita, R; Procopio, G; Verzoni, E | 1 |
| Ahn, H; Ahn, JH; Cho, YM; Hong, JH; Kim, CS; Kim, TM; Lee, DH; Lee, JL; Lee, SH; Lim, HY; Park, SH; Song, C | 1 |
| Albiges, L; Caty, A; Dietrich, PY; Duclos, B; Escudier, B; Geoffrois, L; Gravis, G; Guillot, A; Joly, F; Kohser, F; Laguerre, B; Legouffe, E; Negrier, S; Oudard, S; Rolland, F; Theodore, CA | 1 |
| Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Michaelson, MD; Motzer, RJ | 1 |
| Desar, IM; Hambrock, T; Heerschap, A; Mulders, PF; ter Voert, EG; van Asten, JJ; van der Graaf, WT; van Herpen, CM; van Laarhoven, HW; van Spronsen, DJ | 1 |
| Cortesi, E; Iacovelli, R; Mancini, ML; Palazzo, A; Risi, E | 1 |
| Edler, L; Kopp-Schneider, A; Wunder, C | 1 |
| Ohtsuka, T | 1 |
| Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E | 1 |
| Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B | 1 |
| Curvale, G; Deville, JL; Ducournau, A; Gross, E; Lechevallier, E; Rochwerger, A; Salas, S; Venton, G; Zink, JV | 1 |
| Ankersmit, HJ; de Martino, M; Haitel, A; Hoetzenecker, K; Klatte, T; Roth, GA; Waldert, M | 1 |
| Barriuso, J; Feliu, J; Lamarca, A | 1 |
| Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S | 1 |
| Byun, SS; Hong, SK; Joo, YM; Lee, BK; Lee, S; Lee, SE; Min, SH; Oh, JJ | 1 |
| Aparicio, L; Fernández, O; Grande, E; Lázaro, M; León, L; Vázquez, S | 1 |
| Buonerba, C; De Placido, S; Di Lorenzo, G | 1 |
| Bates, SE; Fojo, AT; Huang, X; Kim, ST; Motzer, RJ; Stein, WD; Wilkerson, J | 1 |
| Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K | 1 |
| Berger, R; Boursi, B; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Hayat, H; Ish-Shalom, M; Keizman, D; Kovel, S; Maimon, N; Peer, A; Pili, R; Sella, A; Sinibaldi, V | 1 |
| Haddad, H; Rini, BI | 1 |
| Campbell, S; Dreicer, R; Elson, P; Fergany, A; Garcia, J; Gong, M; Kaouk, J; Klein, E; Krishnamurthi, V; Rabets, J; Rini, BI; Salem, M; Shah, S; Stephenson, A; Wood, L | 1 |
| Galsky, MD | 1 |
| Agarwal, N; Bello, A; Burke, JM; Cella, D; Edenfield, WJ; Figlin, RA; Hariharan, S; Hudes, GR; Hutson, TE; Korytowsky, B; Martell, B; Motzer, RJ; Olsen, MR; Thompson, JA; Valota, O; Wilding, G; Yuan, J | 1 |
| Lim, ZD; Mahajan, A; Tannir, NM; Weinberg, J | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Autorino, R; Carteni, G; Castello, G; D' Alterio, C; Di Lorenzo, G; Facchini, G; Franco, R; La Mura, A; Nappi, O; Ottaiano, A; Perdona, S; Pignata, S; Portella, L; Rizzo, M; Scala, S | 1 |
| Zhou, A | 1 |
| Ejima, K; Matsuoka, K; Momozono, K; Moriya, F; Nagayoshi, R; Noguchi, M; Suekane, S; Ueda, K | 1 |
| Arai, Y; Kawashima, A; Mukai, M; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M; Yasunaga, Y | 1 |
| Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M | 1 |
| Adamy, A; Ehdaie, B; Favaretto, RL; Garg, T; Ghoneim, TP; Maschino, AC; Motzer, RJ; Russo, P; Silberstein, JL | 1 |
| Bex, A; de Graaf, AMA; de Hoog, CLMM; de Jong, TAM; Griffioen, AW; Jonasch, E; Mans, LA; Nowak-Sliwinska, P; van Beijnum, JR; Vyth-Dreese, FA | 1 |
| Ikeda, A; Iwasaki, H; Kawai, K; Kimura, T; Kojima, T; Miyazaki, J; Nishiyama, H; Oikawa, T; Shimano, H; Suetomi, T; Takaoka, E; Yoshino, T | 1 |
| Akarsu, E; Babacan, T; Balakan, O; Sevinc, A | 1 |
| Fingerle, A; Gschwend, JE; Hauner, K; Horn, T; Kübler, HR; Maurer, T; Retz, M; Schulz, S; Thalgott, MK | 1 |
| Wood, L | 1 |
| Beltran, L; Bycroft, J; Green, JS; Hussain, M; Nair, R; Peters, JL; Powles, T; Shaw, GL | 1 |
| Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K | 1 |
| Kuczyk, MA; Schnoeller, TJ; Schrader, AJ; Schrader, M; Steffens, S | 1 |
| Castellano, D; De Velasco, G; Ravaud, A; Schmidinger, M; Vazquez, F | 1 |
| Bojic, M; Schmidinger, M | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Bamias, A; Dimitriadis, G; Dimopoulos, MA; Economopoulos, T; Migkou, M; Nicolatou-Galitis, O; Pectasides, D; Psyrri, A; Raber-Durlacher, JE | 1 |
| Baba, S; Fujita, T; Ishii, D; Iwamura, M; Matsumoto, K; Tabata, K; Yoshida, K | 1 |
| Fleissig, Y; Lehman, H; Regev, E | 1 |
| Buchler, T; Cathomas, R; Chastonay, R; Haile, SR; Knuth, A; Liewen, H; Porta, C; Renner, C; Rothermundt, C; Samaras, P; Siciliano, RD; Stenner, F; Stoll, S | 1 |
| Khattak, MA; Martin, HL | 1 |
| Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R | 1 |
| Drudi, F; Giuliani, J | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R | 1 |
| Calvo, E; Esser, N; Fiedler, U; Graeser, R; Kim, D; Larkin, J; Tsuchihashi, Z | 1 |
| Hanovich, E; Hercbergs, AH; Kovel, S; Sella, A | 1 |
| Boleti, E; Chowdury, S; Crabb, SJ; Jones, R; Nathan, P; Powles, T; Protheroe, A; Rashid, S; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P | 1 |
| Aparicio, A; Araujo, J; Bekele, NB; Jonasch, E; Lim, Z; Matin, S; Ng, C; Pagliaro, L; Plimack, E; Smith, L; Tamboli, P; Tannir, NM; Wood, CG; Xiao, L | 1 |
| de Jesus-Gonzalez, N; Humphreys, BD; Moslehi, J; Robinson, E | 1 |
| Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P | 1 |
| Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M | 1 |
| Fukui, I; Kitsukawa, S; Saito, K; Takahashi, S; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T | 1 |
| Becker, JU; Grünwald, V; Kuczyk, MA; Merseburger, AS; Peters, I; von Klot, C | 1 |
| Saito, K | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Kappers, MH; Mathijssen, RH; Oosting, S; Reyners, AK; van der Veldt, AA; van Herpen, CM; Wessels, JA | 1 |
| Agrillo, A; Facchini, A; Filiaci, F; Nastro Siniscalchi, E; Ungari, C | 1 |
| Kondo, T | 1 |
| Anderson, J; Bier, N; Cherian, A; Chowdhury, T; O'Meara, A; Prichard-Jones, K; Sebire, NJ; Sullivan, MO | 1 |
| Puche-Sanz, I; Vázquez-Alonso, F | 1 |
| Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M | 1 |
| Gong, K; Li, T; Ning, X; Wang, X; Wu, P; Zhang, C; Zhang, N | 1 |
| Atkinson, B; Chen, A; Sevin, A | 1 |
| Bodnar, L; Duchnowska, R; Miciuk, B; Szczylik, C; Waśniewski, L | 1 |
| Bruera, E; Busaidy, NL; Cabanillas, ME; Del Fabbro, E; Dev, R; Rodriguez, EC | 1 |
| Barile, C; Basso, U; Brunello, A; Camerini, A; De Vivo, R; Falci, C; Maruzzo, M; Roma, A; Sacco, C; Sava, T; Zagonel, V | 1 |
| Abbas, M; Herrmann, TR; Jüttner, B; Kramer, M; Kuczyk, MA; Merseburger, AS; Peters, I; Reichelt, A; Teebken, OE; von Klot, C; Winkler, M | 1 |
| Ariad, S; Lazarev, I; Mermershtain, W; Shani-Shrem, N | 1 |
| Hirooka, N; Iwasaki, A; Matsuyama, S; Sekiguchi, Z; Takeshima, T; Takizawa, A; Tsuchiya, F | 1 |
| Arai, Y; Kakimoto, K; Matsuzaki, K; Nakata, W; Nakayama, M; Nishimura, K; Takeda, K; Ueda, N; Yamamoto, Y | 1 |
| Albiges, L; Escudier, B; Iacovelli, R; Lanoy, E | 1 |
| Bian, W; Ge, Z; Li, J; Qiu, F | 1 |
| Brugia, M; Cerullo, C; Muto, A; Neri, B; Rangan, S; Rediti, M; Tassi, R; Vannini, A | 1 |
| Karakiewicz, PI; Sun, M; Trinh, QD | 1 |
| Chiba, H; Hirose, T; Kanagawa, K; Shimoda, N | 1 |
| Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P | 1 |
| Boleti, E; Chowdury, S; Crabb, S; Jones, R; Lim, L; Nathan, P; Powles, T; Protheroe, A; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P | 1 |
| Catalá-López, F | 1 |
| Bex, A; de Bruijn, R; Horenblas, S; Kroon, BK; Powles, T; Prevoo, W | 1 |
| De Amici, M; Ganini, C; Giunta, V; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L | 1 |
| Abouelkhair, KM; Bayer, AM; Elmasri, OA; Ibrahim, EM; Kazkaz, GA | 1 |
| Hoekstra, R; Honeywell, RJ; Peters, GJ; van Erp, NP; Verheul, HM; Westgeest, HM | 1 |
| Albersen, M; Berkers, J; Beuselinck, B; Govaere, O; Joniau, S; Lerut, E; Roskams, T; Schöffski, P; Swinnen, J; Van den Oord, J; van Kempen, LC; Van Poppel, H; Wolter, P | 1 |
| Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L | 1 |
| Blanc, E; Escudier, B; Ferlay, C; Genin, C; Gigante, M; Li, G; Negrier, S; Paul, S; Perol, D; Tostain, J; Zhao, A | 1 |
| Bregant, C; Ganini, C; Imarisio, I; Morbini, P; Paglino, C; Porta, C; Vercelli, A | 1 |
| Brown, J; Collinson, FJ; Gregory, WM; Hanlon, P; Hewison, J; Howard, H; Lowe, C; McCabe, C; McParland, L; Potrata, D; Selby, PJ; Tubeuf, S; Wah, T | 1 |
| Aieta, M; Bochicchio, AM; Capobianco, A; Coccaro, M; Gallucci, G; Improta, G; Maurea, N; Tartarone, A; Tocchetti, CG; Zupa, A | 1 |
| Arima, K; Kanda, H; Masui, S; Sugimura, Y; Yamada, Y | 1 |
| Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U | 1 |
| Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M | 1 |
| Borker, R; Fonseca, E; Hess, G | 1 |
| Pal, SK; Vogelzang, NJ | 1 |
| Downey, FP; McDermott, RS; Teo, M | 1 |
| Harada, S; Kitsukawa, S; Kozuka, T; Kudo, K; Miyazawa, K; Sukegawa, G; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Huang, J; Huang, Y; Wang, T | 1 |
| Fujisawa, M; Miyake, H; Sakai, I | 1 |
| Corso, G; Di Mare, G; Lambert, Y; Marrelli, D; Mastrogiacomo, D; Neri, A; Roviello, F; Volterrani, L | 1 |
| Antón-Aparicio, LM; Bayona, C; Bolós, MV; Borrega, P; de Portugal, T; Espinosa Arranz, E; Fresno Vara, JA; Gallegos Sancho, MI; Gámez-Pozo, A; García-Domínguez, R; Madero, R; Pérez-Carrión, R; Ramos-Vázquez, M; Sánchez-Navarro, I | 1 |
| Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z | 1 |
| Alsop, DC; Atkins, MB; Bahamon, B; Bhatt, RS; Goldberg, SN; Mier, JW; O'Neill, A; Signoretti, S; Wang, X; Wood, CG; Zhang, L | 1 |
| Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F | 1 |
| Ahn, H; Ahn, JH; Ahn, Y; Choi, HJ; Hong, JH; Jeong, IG; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y | 1 |
| Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P | 1 |
| Buti, S; Donini, M; Lazzarelli, S; Passalacqua, R | 1 |
| Bates, SE; Blagoev, KB; Fojo, AT; Motzer, RJ; Stein, WD; Wilkerson, J | 1 |
| Hoekman, K; Kakkar, AK; Kostense, PJ; Kuenen, BC; Levi, M; Meijers, JC; Pinedo, HM; van Hinsbergh, VW | 1 |
| Baker, CH; Dinney, CP; Fidler, IJ; Kedar, D; Killion, JJ | 1 |
| Baselga, J; Cavalli, F; Conte, PF; Deplanque, G; Harris, AL; Hoekman, K; Huisman, H; Kuenen, BC; Madhusudan, S; Pfanner, E; Scigalla, P; Seeber, S; Tabernero, J | 1 |
| Baker, C; Doucet, M; Fidler, IJ; Kim, SJ; Price, JE; Weber, KL | 1 |
| Buckley, P; Doroshow, JH; Frankel, P; Galvin, I; Gandara, DR; Gosselin, R; Gumerlock, PH; Lara, PN; Lenz, HJ; Longmate, J; Mack, PC; Margolin, K; Meyers, FJ; Quinn, DI; Rao, J; Turrell, C; Valk, P; Wun, T | 1 |
| Doucet, M; Price, JE; Weber, KL | 1 |
| Fujimoto, E; Fukumoto, K; Hagiwara, H; Hagiwara, K; Negishi, E; Sato, H; Shirai, S; Ueno, K; Yamasaki, H; Yano, T | 1 |
| Desai, AA; Stadler, WM | 1 |
| Motzer, RJ; Rini, BI; Sosman, JA | 1 |
| Baker, B; Engel, JB; Gaiser, T; Halmos, G; Keller, G; Nagy, A; Schally, AV | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 1 |
| Baker, B; Engel, JB; Halmos, G; Keller, G; Nagy, A; Schally, AV | 1 |
| Vogelzang, NJ | 1 |
| Baum, CM; Bello, CL; DePrimo, SE; Figlin, RA; George, DJ; Ginsberg, MS; Hudes, GR; Kim, ST; Li, JZ; Michaelson, MD; Motzer, RJ; Redman, BG; Rini, BI; Theuer, CP; Wilding, G | 1 |
| Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
| Autenrieth, M; Blum, P; Gschwend, J; Herkommer, K; Hofer, M; Kuefer, R; Merseburger, A; Ringhoffer, M; Rinnab, L | 1 |
| Kanetake, H; Koga, S | 1 |
| Atkins, M; Jones, CA; Kirkpatrick, P | 1 |
| Ayame, H; Fujii, Y; Hiraoka, M; Huang, LE; Iwai, A; Kageyama, Y; Kihara, K; Kizaka-Kondoh, S; Sugiyama, H | 1 |
| Bacik, J; Baum, CM; Bukowski, RM; Curti, BD; George, DJ; Ginsberg, MS; Hudes, GR; Kim, ST; Margolin, KA; Merchan, JR; Michaelson, MD; Motzer, RJ; Redman, BG; Rini, BI; Wilding, G | 1 |
| Pasche, B | 1 |
| Chew, K; Fong, K; Jaeger, E; Rini, BI; Sein, N; Simko, J; Small, EJ; Waldman, FM; Weinberg, V | 1 |
| Hampton, T | 1 |
| Eto, M; Naito, S | 1 |
| Reddy, K | 1 |
| Bukowski, RM; Rini, BI; Shaheen, PE | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Biedrzycki, BA | 1 |
| King, CR | 1 |
| Bankhead, C | 1 |
| Ginsberg, MS; Kondagunta, GV; Motzer, RJ; Ronnen, EA; Russo, P | 1 |
| Stadler, W | 1 |
| Desch, CE | 1 |
| Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG | 1 |
| Vollmer, H | 1 |
| Gascón, P; Mellado, B | 1 |
| Bacik, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Reuter, V; Ronnen, EA; Russo, P; Spodek, L | 1 |
| Cardinal, E; Gallina, A; Karakiewicz, PI; Perrotte, P; Saad, F; Trinh, QD | 1 |
| Wetherbee, SL | 1 |
| Deeks, ED; Keating, GM | 1 |
| Bukowski, RM; Motzer, RJ | 1 |
| Chang, JW; Hong, HS; Kuo, TT; Tsai, KY; Yang, CH | 1 |
| Culine, S; Pouessel, D | 3 |
| Chadalavada, RS; Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
| Bukowski, RM; Dreicer, R; Garcia, J; Reddy, S; Rini, BI; Salas, R; Shaheen, P; Tamaskar, I; Wood, L | 1 |
| Baum, CM; Bukowski, RM; Bycott, PW; Chen, I; Figlin, RA; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rixe, O; Szczylik, C; Tomczak, P | 1 |
| Brugarolas, J | 1 |
| Dagher, R; Goodman, V; Jiang, JX; Justice, R; Mahjoob, K; Morse, D; Pazdur, R; Rock, EP; Verbois, SL | 1 |
| Ashendel, CL; Chan, TC; Chang, CJ; Chang, JY; Chen, SF; Chen, TS; Chou, KM; Fu, KC; Hong, PC; Hsu, CL; Hsu, KS; Hsu, PC; Huang, CW; Huang, L; Juang, SH; Kuo, CC; Li, YC; Lin, MJ; Lung, CC; Shiah, HS; Wang, YC | 1 |
| Chen, I; Kim, ST; Rini, BI; Rosenberg, JE; Shaw, V | 1 |
| Dreicer, R | 1 |
| Creel, P; George, D; Speca, J; Yenser, S | 1 |
| George, DJ | 1 |
| Senior, K | 1 |
| Chow, LQ; Eckhardt, SG | 1 |
| Abraham, S; Booth, BP; Chidambaram, N; Dagher, R; Gobburu, JV; Goodman, VL; Jiang, JX; Justice, R; Liang, CY; Mahjoob, K; Morse, DE; Pazdur, R; Ramchandani, RP; Rock, EP; Tang, S; Verbois, SL | 1 |
| Fukata, S; Iiyama, T; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Shuin, T | 1 |
| Dumez, H; Schöffski, P; Wolter, P | 1 |
| Kruck, S; Kuczyk, M; Merseburger, AS | 1 |
| Linehan, WM; Novakovic, KR; Pinto, PA; Vira, MA | 1 |
| De Mulder, PH; Mulder, SF; van Spronsen, DJ | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
| Boven, E; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Davis, ID; Nicholaou, T; Wong, R | 1 |
| Davis, PJ; Garfield, DH; Hercbergs, A | 1 |
| Feldman, DR; Martorella, AJ; Motzer, RJ; Robbins, RJ | 1 |
| Di Lorenzo, G | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L | 1 |
| Billemont, B; Izzedine, H; Rixe, O | 1 |
| Baum, CM; Bello, CL; Deprimo, SE; Michaelson, MD; Motzer, RJ; Rini, BI; Smeraglia, J; Spinella, D | 1 |
| Flaherty, KT; Stein, MN | 1 |
| Rini, BI; Unnithan, J | 1 |
| Chouhan, JD; Grabinski, JL; Lai, PH; Oramasionwu, CU; Zamarripa, DE | 1 |
| Billemont, B; Izzedine, H; Rixe, O; Thibault, F | 1 |
| Billemont, B; Rixe, O; Thibault, F | 1 |
| Albers, P; Bergmann, L; Geschwend, JE; Jäger, E; Jakse, G; Marschner, N; Miller, K | 1 |
| Goldspiel, BR; Grandinetti, CA | 1 |
| Jewett, MA; Neill, MG; Wei, AC | 1 |
| Bodrogi, I | 1 |
| Kibble, A; Shumoogam, J | 1 |
| Belcaceres, JL; Cojocarasu, O; Halimi, P; Medioni, J; Oudard, S | 1 |
| Bellido, L; Cruz, JJ; Martín, G | 1 |
| Nishida, T | 1 |
| Chorianopoulos, E; Frey, N; Jäger, D; Katus, HA | 1 |
| George, D; Medioni, J; Motzer, R; Oudard, S | 1 |
| Dettori, M; Fazio, N; Lorizzo, K | 1 |
| Adams, VR; Leggas, M | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Bukowski, RM; Curti, BD; George, DJ; Hudes, GR; Margolin, KA; Michaelson, MD; Motzer, RJ; Redman, BG; Rosenberg, J; Wilding, G | 1 |
| Barkhof, F; Boven, E; Hoekman, K; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Fiedler, W; Grünwald, V; Heinzer, H | 1 |
| Bjelogrlic, SK; Radulovic, S | 1 |
| Polyzos, A | 1 |
| Irani, J | 1 |
| Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L | 1 |
| Baccala, A; Fergany, A; Gilligan, T; Hedgepeth, R; Kaouk, J; Magi-Galluzzi, C | 1 |
| Audet, P; Ghosn, P; Jeldres, C; Karakiewicz, PI; Patard, JJ; Perrotte, P; Suardi, N | 1 |
| Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N | 1 |
| Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M | 1 |
| Boven, E; Droogendijk, H; Haanen, JG; Helgason, HH; Mallo, HA; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Azizi, M; Chedid, A; Oudard, S | 1 |
| Khurana, A | 1 |
| Hiles, JJ; Kolesar, JM | 1 |
| Holen, KD; Loconte, NK; Mulherin, B | 1 |
| Cohen, AF; Dubois, EA; Osanto, S; van Bronswijk, H | 1 |
| Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Yoshida, J | 1 |
| Bukowski, RM; Garcia, J; Heng, DY; Rini, BI; Wood, L | 1 |
| Bletard, N; Bonbled, F; Duck, L; Jacquet, L; Machiels, JP; Pirenne, P | 1 |
| Motzer, RJ; O'Brien, MF; Russo, P | 1 |
| Brändle, M; Cerny, T; Gillessen, S; Templeton, A | 1 |
| Kataja, V; Kellokumpu-Lehtinen, PL; Martikainen, JA; Purmonen, T; Soini, EJ; Vuorinen, RL | 1 |
| Brown, JE; Hall, PS; Kancherla, K; Sastry, PS | 1 |
| de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE | 1 |
| Kasper, KA; Kuzel, TM; Meeks, JJ; Smith, ND; Yang, X | 1 |
| Davis, ID; Desai, J; Grossmann, M; Premaratne, E | 1 |
| Pinthus, J | 1 |
| Athar, U; Gentile, TC | 1 |
| Hariharan, S; Lowry, S | 1 |
| Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
| Bex, A; Boven, E; de Gast, G; Haanen, JB; Meijerink, MR; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Fisher, GA; Srinivas, S; Telli, ML; Witteles, RM | 1 |
| Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
| Staehler, M | 1 |
| Bitker, MO; Boostan, H; Comperat, E; Meric, JB; Mozer, P; Renard-Penna, R; Richard, F; Rixe, O; Thibault, F | 1 |
| Halmos, G; Hebert, F; Kiaris, H; Nagy, A; Plonowski, A; Schally, AV | 1 |
218 review(s) available for pyrroles and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Topics: Biomarkers; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2023 |
Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.
Topics: Adult; Aged; Antineoplastic Agents; Arabs; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Saudi Arabia; Sunitinib | 2020 |
[New therapeutic schedules of Sunitinib: Current evidence regarding the 2:1 scheme.]
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Protocols; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate | 2017 |
Immunotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Bevacizumab; Cancer Vaccines; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney Neoplasms; Longevity; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib | 2017 |
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Randomized Controlled Trials as Topic; Spain; Sunitinib; Survival Rate; Treatment Outcome | 2018 |
Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Comorbidity; Drug Interactions; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indazoles; Indoles; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib | 2018 |
Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
Adjuvant treatment in renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2018 |
Do targeted agents offer clinical benefit as presurgical therapy?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Nephrectomy; Preoperative Care; Prognosis; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib | 2013 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Side-effects associated with targeted therapies in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Systemic treatment options for untreated patients with metastatic clear cell renal cancer.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
[Medical treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Sirolimus; Societies, Medical; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Advanced kidney cancer: treating the elderly.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Kidney cancer: Temsirolimus fails to expand its role in patients with mRCC.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus | 2014 |
A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Dendritic Cells; Electroporation; Everolimus; Humans; Immunotherapy, Active; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyrroles; Quinolines; RNA, Neoplasm; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2014 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Sunitinib re-challenge in advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Retreatment; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis | 2014 |
Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
[Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2014 |
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Prognosis; Pyrroles; Signal Transduction; Sunitinib; Tumor Microenvironment | 2015 |
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2015 |
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.
Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for
Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Europe; Humans; Imidazoles; Indazoles; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Analysis; Treatment Outcome | 2015 |
Renal cell carcinoma metastatic to the tongue: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Follow-Up Studies; Glossectomy; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Multimodal Imaging; Neoplasm Invasiveness; Palliative Care; Positron-Emission Tomography; Pyrroles; Recombinant Proteins; Sunitinib; Tomography, X-Ray Computed; Tongue Neoplasms | 2015 |
Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2015 |
Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.
Topics: Animals; Cancer Vaccines; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Immunotherapy; Indoles; Precision Medicine; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Signal Transduction; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Metastasectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2016 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2015 |
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Practice Patterns, Physicians'; Prognosis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2016 |
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Forecasting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Weight; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Racial Groups; Sex Factors; Sunitinib | 2016 |
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2016 |
Systemic therapy in metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Kidney cancer: Power couple: reovirus meets sunitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Orthoreovirus, Mammalian; Pyrroles; Sunitinib | 2016 |
Sunitinib Possible Sex-Divergent Therapeutic Outcomes.
Topics: Animals; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome | 2016 |
[Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Tongue Neoplasms | 2016 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Gene Frequency; Genetic Variation; Genotype; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; White People | 2017 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Sunitinib in kidney cancer: 10 years of experience and development.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survival Rate | 2017 |
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Sunitinib | 2017 |
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Research Design; Sunitinib | 2017 |
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult | 2017 |
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Management; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2017 |
[Value of targeted therapies for renal cell cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2008 |
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Diffusion of Innovation; Humans; Incidence; Indoles; Interferon-alpha; Interleukin-2; Molecular Biology; Neoplasm Staging; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rare Diseases; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
An update on the medical therapy of advanced metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Severity of Illness Index; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Targeted therapy in renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
New therapies in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
[Molecular basis of targeted therapy in metastatic renal cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Hypertension; Indoles; Kidney Diseases; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Congresses as Topic; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targeting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Exploring the role of novel agents in the treatment of renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recombinant Proteins; Sirolimus; Sorafenib; Sunitinib | 2008 |
Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Systemic therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytotoxins; Disease-Free Survival; Drug Therapy, Combination; Everolimus; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Stem Cell Transplantation; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Homologous | 2008 |
Pre-surgical targeted molecular therapy in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2009 |
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Incidence; Indoles; Kidney Neoplasms; Paresthesia; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sunitinib | 2009 |
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Design; Europe; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Interferons; Kidney Neoplasms; Palliative Care; Patient Selection; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; United States | 2009 |
Tolerability of first-line therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Renal Cell; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypothyroidism; Indoles; Interferons; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sunitinib; Wound Healing | 2009 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors | 2009 |
[Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
Topics: Animals; Antineoplastic Agents; Capsules; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Interferon-gamma; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome | 2009 |
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Prognostic markers and new, innovative treatments in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sunitinib in solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Molecular Structure; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2009 |
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2009 |
Sunitinib in renal-cell carcinoma: expanded indications.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2009 |
Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Prostatic Neoplasms; Pyrroles; Sunitinib | 2009 |
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Pyrroles; Risk Assessment; Sunitinib | 2009 |
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sirolimus; Stem Cell Transplantation; Sunitinib; Transplantation, Homologous | 2009 |
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Humans; Hypercalcemia; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paraneoplastic Syndromes; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2010 |
Metastatic renal cell carcinoma: current standards of care.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Carcinoma, Renal Cell; Endpoint Determination; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukocyte Count; Linear Models; Male; Middle Aged; Neoplasms; Neutrophils; Nonlinear Dynamics; Population; Pyrroles; Sunitinib | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neoplasms; Pyrroles; Sunitinib | 2010 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2010 |
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Drug Delivery Systems; Drugs, Investigational; Evidence-Based Medicine; Germany; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate | 2010 |
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2010 |
[First-line therapy of metastatic renal cell carcinoma--update 2009].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Evidence-Based Medicine; Germany; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Prognosis; Pyrroles; Sirolimus; Sunitinib; Survival Rate | 2010 |
Update on systemic therapies of metastatic renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biopsy, Needle; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Everolimus; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2010 |
Sunitinib for the management of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Pyrroles; Sunitinib | 2010 |
[Treatment of locally advanced renal tumors].
Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sorafenib; Sunitinib | 2010 |
Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
Topics: Carcinoma, Renal Cell; Consensus; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Evidence-Based Medicine; Fatigue; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mouth Diseases; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Skin Diseases; Sunitinib; Treatment Outcome | 2010 |
Present state of target therapy for disseminated renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Sunitinib for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2011 |
Sunitinib for metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2010 |
[A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Sunitinib; Vascular Neoplasms; Vena Cava, Inferior | 2010 |
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms | 2010 |
[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Europe; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib and other targeted therapies for renal cell carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Pyrroles; Sunitinib | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Posterior Leukoencephalopathy Syndrome; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Topics: Asthenia; Carcinoma, Renal Cell; Diarrhea; Dose-Response Relationship, Drug; Erythema; Exanthema; Fatigue; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Standard of Care; Sunitinib | 2011 |
[Current status in molecular-targeted therapy and IFNα for renal cell carcinoma in Japan].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Interferon-alpha; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib | 2011 |
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Patient Selection; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2011 |
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Follow-Up Studies; Heart Failure; Humans; Incidence; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biotransformation; Carcinoma, Renal Cell; Cell Hypoxia; Clinical Trials as Topic; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Multicenter Studies as Topic; Neoplasm Proteins; Neovascularization, Pathologic; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Receptors, Growth Factor; Retrospective Studies; Risk Factors; Severity of Illness Index; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Heart failure associated with sunitinib: lessons learned from animal models.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiotoxins; Disease Models, Animal; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Kidney Neoplasms; Mitochondria; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Signal Transduction; Sunitinib | 2011 |
Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Systemic treatment of renal cell carcinoma - recent update].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
New insights into molecular mechanisms of sunitinib-associated side effects.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Models, Biological; Pigmentation Disorders; Pyrroles; Signal Transduction; Sunitinib | 2011 |
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Current treatment considerations in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2012 |
Sunitinib malate for the treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vena Cava, Inferior | 2012 |
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrroles; Sunitinib | 2013 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Burden | 2013 |
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.
Topics: Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2013 |
Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
Topics: Adult; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Pre-Eclampsia; Pregnancy; Pyrroles; Sunitinib; Ventricular Dysfunction, Left | 2013 |
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
SU11248 and AG013736: current data and future trials in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2005 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Clinical Trials as Topic; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Protein Biosynthesis; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
[Progress in therapeutic strategy for renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2006 |
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Molecular targeting therapy for renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2006 |
Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2006 |
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Molecular biology of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Exons; Humans; Indoles; Kidney Neoplasms; Molecular Biology; Mutation; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2006 |
New weapons to snuff out kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2006 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Forecasting; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2006 |
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans; Indoles; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Phenotype; Platelet-Derived Growth Factor; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib: from rational design to clinical efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2007 |
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; United States; United States Food and Drug Administration | 2007 |
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Approval; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Leiomyomatosis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; von Hippel-Lindau Disease | 2007 |
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
The role of targeted therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
New challenges in kidney cancer therapy: sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Forecasting; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2007 |
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Growth Factor; Sorafenib; Sunitinib | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Treatment options in renal cell carcinoma: past, present and future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytokines; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2007 |
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lactation; Lung Neoplasms; Neuroendocrine Tumors; Pregnancy; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2007 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2008 |
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Guillain-Barré syndrome after treatment with sunitinib malate?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Guillain-Barre Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Interferon-beta; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Liposomes; Mitochondrial Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Sunitinib therapy in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
177 trial(s) available for pyrroles and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Necrosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor C | 2022 |
Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2023 |
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2023 |
Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Everolimus; Female; Humans; Hypercholesterolemia; Hyperglycemia; Indoles; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Protein Kinase Inhibitors; Proteinuria; Pyrroles; Pyrrolidines; Survival Analysis | 2020 |
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Lymphokines; Placenta Growth Factor; Pyrroles; Treatment Outcome | 2021 |
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cross-Over Studies; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2017 |
Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Markers; Genotype; Germ-Line Mutation; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Pharmacogenomic Variants; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypoalbuminemia; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Models, Biological; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2017 |
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Transplantation; Nephrectomy; Neutrophils; Prospective Studies; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib; Survival Rate | 2017 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proportional Hazards Models; Pyrroles; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2018 |
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Volume; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Predictive Value of Tests; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2018 |
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyrroles; Quality of Life; Risk; Sunitinib; Survival Analysis; Survival Rate | 2018 |
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Patient Selection; Postoperative Complications; Prognosis; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis | 2018 |
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Topics: Aged; Anemia; Benzodiazepines; Carcinoma, Renal Cell; CD27 Ligand; Edema; Fatigue; Female; Humans; Immunoconjugates; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Thrombocytopenia | 2019 |
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2013 |
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome | 2013 |
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sulfonamides; Sunitinib; Survival Rate; Treatment Failure | 2014 |
Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Catheter Ablation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib | 2013 |
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Pyrroles; Republic of Korea; Sunitinib | 2013 |
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biotransformation; Carcinoma, Renal Cell; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Postprandial Period; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma; Young Adult | 2013 |
Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Fluorocarbons; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Ultrasonography | 2014 |
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Famitinib in metastatic renal cell carcinoma: a single center study.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Survival; Treatment Outcome | 2014 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult | 2014 |
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires | 2014 |
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
Topics: Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Review Literature as Topic; Sunitinib; Survival Rate | 2014 |
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Biomarkers; Carcinoma, Renal Cell; Diffusion Magnetic Resonance Imaging; Female; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Pyrroles; Radiography; Sunitinib; Treatment Outcome | 2014 |
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2014 |
Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Models, Statistical; Neoplasm Metastasis; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2014 |
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Memory; Middle Aged; Neoplasm Metastasis; Neuropsychological Tests; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2014 |
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Preference; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires | 2014 |
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Cell Line, Tumor; Comparative Genomic Hybridization; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Pyrroles; Reproducibility of Results; RNA Interference; Sunitinib; Time Factors; Tissue Array Analysis; Transfection; Treatment Outcome; Up-Regulation; Vascular Endothelial Growth Factor A | 2014 |
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib; Thalidomide; Treatment Outcome | 2014 |
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Angiopoietin-2; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 2; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3; Von Hippel-Lindau Tumor Suppressor Protein | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Sunitinib still fi rst-line therapy for metastatic renal cancer.
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Prognosis; Pyrroles; Risk Assessment; Sirolimus; Sunitinib; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2014 |
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Female; Gene Expression; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Lymphocyte Count; Macrophages; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Singapore; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Compassionate Use Trials; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Dysgeusia; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Neutropenia; Pyrroles; Stomatitis; Sunitinib; Thrombocytopenia; Treatment Outcome | 2015 |
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Renal Cell; China; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A | 2015 |
Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Australia; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2015 |
Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Young Adult | 2015 |
A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Drug Administration Schedule; Female; Humans; Indoles; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Recombinant Fusion Proteins; Sunitinib | 2015 |
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Treatment Outcome | 2015 |
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2015 |
[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal c
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2015 |
[In Process Citation].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Germany; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Nivolumab; Prognosis; Pyrroles; Societies, Medical; Sunitinib; Urology | 2015 |
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Withholding Treatment | 2015 |
The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Female; Glucose Clamp Technique; Humans; Hypoglycemia; Indoles; Insulin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Time Factors | 2016 |
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2015 |
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Early Termination of Clinical Trials; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2016 |
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Topics: Adolescent; Adult; Aged; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Drug Monitoring; Female; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Observer Variation; Patient Positioning; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Treatment Outcome; Ultrasonography | 2016 |
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Benefits of pazopanib over sunitinib for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Patient Safety; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Sensitivity and Specificity; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cytokines; Everolimus; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Young Adult | 2016 |
Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cluster Analysis; DNA Methylation; DNA Mutational Analysis; Epigenesis, Genetic; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Promoter Regions, Genetic; Pyrroles; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Male; Neoplasm Metastasis; Peptides, Cyclic; Pyrroles; Receptors, CXCR4; Sunitinib | 2016 |
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Topics: Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proteinuria; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2016 |
[First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion")
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Selection; Pyrroles; Research Design; Sunitinib; Treatment Outcome; Young Adult | 2016 |
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Body Surface Area; Carcinoma, Renal Cell; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neoplasm Metastasis; Nonlinear Dynamics; Polymorphism, Genetic; Pyrroles; Sunitinib | 2016 |
Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Topics: Aged; Aged, 80 and over; Algorithms; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Middle Aged; Prospective Studies; Pyrroles; Quality of Life; Response Evaluation Criteria in Solid Tumors; Software; Sunitinib; Surveys and Questionnaires; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Vascular Neoplasms | 2016 |
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2016 |
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Aged; Cancer Vaccines; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2016 |
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Prospective Studies; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Prospective Studies; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; von Hippel-Lindau Disease | 2016 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2017 |
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Pyridines; Pyrroles; Risk Factors; Sunitinib | 2017 |
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Risk Factors; Sunitinib | 2008 |
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Placenta Growth Factor; Pregnancy Proteins; Prospective Studies; Pyrroles; Sunitinib; Time Factors; Treatment Failure; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3 | 2008 |
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
Topics: Administration, Oral; Antineoplastic Agents; Australia; Brazil; Canada; Carcinoma, Renal Cell; Drug Administration Schedule; Europe; Female; Health Status Indicators; Humans; Indoles; Injections, Subcutaneous; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quality of Life; Russia; Sunitinib; Surveys and Questionnaires; Treatment Outcome; United States | 2008 |
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cellulitis; Diarrhea; Drug Eruptions; Female; Humans; Indoles; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sirolimus; Stomatitis; Sunitinib; Thrombocytopenia; Treatment Outcome | 2009 |
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2009 |
Compassionate use of sorafenib in patients with advanced renal cell cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Renal Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Injections, Subcutaneous; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Probability; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Europe; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires | 2009 |
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2009 |
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sunitinib; Time Factors; Treatment Outcome; United States | 2009 |
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Geography; Health Status; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Research Design; Sunitinib; Surveys and Questionnaires | 2010 |
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Republic of Korea; Sunitinib; Thrombocytopenia; Treatment Outcome | 2010 |
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Preoperative Care; Prospective Studies; Pyrroles; Sunitinib | 2010 |
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; New York City; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2012 |
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Topics: Aged; Angiotensin II; Animals; Blood Pressure; Bradykinin; Carcinoma, Renal Cell; Cells, Cultured; Coronary Circulation; Endothelial Cells; Endothelin-1; Female; Gastrointestinal Stromal Tumors; Heart; Heart Rate; Humans; Hypertension; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Rats; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Renin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2010 |
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotropin; Time Factors; Treatment Outcome | 2012 |
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Topics: Acute Kidney Injury; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colitis; Death, Sudden; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2011 |
The effect of sunitinib on immune subsets in metastatic clear cell renal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colloids; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nanoparticles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival Analysis; Treatment Failure; United States | 2012 |
A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Indoles; Interleukins; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Recombinant Proteins; Sunitinib; Treatment Failure | 2011 |
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2011 |
[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy ov
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Germany; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Prevalence; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Topics: Aged; Antibodies, Neoplasm; Cancer Vaccines; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Vaccines, DNA | 2011 |
[Use of sunitinib in metastatic renal cell carcinoma patients with poor prognosis].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2011 |
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2011 |
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; International Agencies; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Tissue Distribution; Treatment Outcome | 2012 |
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sirolimus; Sunitinib | 2011 |
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Hypoxia; Cohort Studies; Disease Progression; Humans; Indoles; Kidney Neoplasms; Middle Aged; Misonidazole; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination | 2011 |
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Gland; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Probability; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Nomograms; Predictive Value of Tests; Pyrroles; Republic of Korea; Risk Factors; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sirolimus; Sunitinib | 2012 |
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2012 |
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Zoledronic Acid | 2011 |
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dideoxynucleosides; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Indoles; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyrroles; Sunitinib; Treatment Failure | 2011 |
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Hemangioblastoma; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pilot Projects; Pyrroles; Radiography; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease; Young Adult | 2011 |
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antigens; Female; Forkhead Transcription Factors; Humans; Indoles; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2012 |
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2012 |
[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Germany; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Patient Selection; Pyrroles; Sunitinib | 2012 |
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Remission Induction; Sunitinib; Survival Rate; Treatment Outcome | 2012 |
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2012 |
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Young Adult | 2012 |
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2012 |
Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal canc
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sunitinib; Survival Analysis; United Kingdom; Withholding Treatment; Young Adult | 2012 |
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2013 |
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Topics: Angiogenesis Inhibitors; Blood Coagulation; Blood Platelets; Carcinoma, Renal Cell; Cell Division; Cell Membrane Permeability; Cell Movement; Drug Administration Schedule; Endothelium, Vascular; Fibrinolysis; Hemostasis; Humans; Indoles; Kidney Neoplasms; Melanoma; Neovascularization, Pathologic; Protein C; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Thrombin; Vascular Endothelial Growth Factor Receptor-1 | 2002 |
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Indoles; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Sarcoma; Skin Neoplasms; Treatment Outcome | 2003 |
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Recombinant Proteins; Time Factors; Tomography, Emission-Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quality of Life; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2006 |
Sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2006 |
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sunitinib | 2007 |
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cluster Analysis; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Middle Aged; Neoplasm Proteins; Pyrroles; Solubility; Sunitinib; Time Factors; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Vascular Endothelial Growth Factors | 2007 |
Sunitinib efficacy against advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Single-Blind Method; Sunitinib; Survival Rate; Treatment Outcome; United States | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
[Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
1063 other study(ies) available for pyrroles and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Colitis; Diarrhea; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2022 |
Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Kidney Neoplasms; Nivolumab; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2022 |
Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort.
Topics: Administration, Oral; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2022 |
Effect of Sunitinib Treatment on Skin Sodium Accumulation in Patients With Renal Cancer: a Pilot Study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Pilot Projects; Pyrroles; Sodium; Sunitinib | 2022 |
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Humans; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2022 |
Time trends for drug specific adverse events in patients on sunitinib; implications for remote monitoring.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; COVID-19; COVID-19 Drug Treatment; Humans; Indoles; Kidney Neoplasms; Pandemics; Pyrroles; Retrospective Studies; Sunitinib | 2022 |
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.
Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2022 |
Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Child; Erythrocyte Indices; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sunitinib | 2022 |
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Renal Cell; Glycerophospholipids; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2022 |
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2023 |
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2023 |
Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib; Thyroid Gland | 2020 |
C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; China; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Progression-Free Survival; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2019 |
Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Fumarate Hydratase; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Glutaminase; Glycolysis; Humans; Kidney Neoplasms; Lactate Dehydrogenase 5; Lactones; Leiomyomatosis; Mice; Mice, Nude; Neoplastic Syndromes, Hereditary; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrroles; Sequestosome-1 Protein; Signal Transduction; Skin Neoplasms; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Topics: Adenocarcinoma; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Female; Indoles; Male; Neoplasm Recurrence, Local; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2021 |
BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Kidney Neoplasms; Mice; Nuclear Proteins; Organic Chemicals; Oxazoles; Pyridines; Pyrroles; Xenograft Model Antitumor Assays | 2020 |
"Hand foot genital syndrome": Proposition of a new term, induced by Sunitinib in a patient of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2021 |
Editorial Comment from Dr Hatakeyama and Dr Ohyama to Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib; Tomography | 2021 |
Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Habits; Humans; Kidney Neoplasms; Northern Territory; Pyrroles; Sunitinib | 2021 |
Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Prognosis; Pyrroles; Retrospective Studies; Sunitinib | 2022 |
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.
Topics: Aged; Carcinoma, Renal Cell; Cardiovascular Agents; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2021 |
Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles | 2021 |
Camrelizumab plus famitinib to treat RCC.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles | 2021 |
Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Renal Cell; Cell Movement; Cell Survival; HEK293 Cells; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Structure-Activity Relationship; Sunitinib; Tumor Cells, Cultured | 2017 |
Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2017 |
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib | 2017 |
LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cholesterol; Cholesterol, LDL; Drug Interactions; Elafin; Endothelial Cells; Female; Humans; Indoles; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Renal Cell; Female; Follow-Up Studies; Genetic Association Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; STAT3 Transcription Factor; Stomatitis; Sunitinib | 2017 |
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult | 2017 |
Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Retrospective Studies | 2017 |
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Kaplan-Meier Estimate; Male; MicroRNAs; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; ROC Curve; Signal Transduction; Sunitinib | 2017 |
Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2017 |
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Pyrroles; Quality-Adjusted Life Years; Registries; Regression Analysis; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Renal Cell; Female; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indoles; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib | 2017 |
Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Pyrroles; Sunitinib | 2017 |
Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Contrast Media; Dextrans; Drug Resistance, Neoplasm; Female; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, SCID; Microscopy, Fluorescence; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Cytokines; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Models, Biological; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Pyrroles; Ribonucleoproteins, Small Nuclear; Sunitinib; Ubiquitination | 2017 |
Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Young Adult | 2017 |
Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Heart Failure; Humans; Hypertension, Pulmonary; Indoles; Liver Neoplasms; Male; Pyrroles; Sunitinib | 2017 |
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis | 2017 |
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Rate; United Kingdom | 2017 |
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Circulating Tumor DNA; Combined Modality Therapy; Humans; Indoles; Kidney; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Nephrectomy; Programmed Cell Death 1 Receptor; Pyrroles; Radiosurgery; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate; Time Factors | 2017 |
Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Caveolin 1; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Pyrroles; Sunitinib; Young Adult | 2017 |
Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiogenic Proteins; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Inflammation Mediators; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; ROC Curve; Sunitinib; Treatment Outcome | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Rural Population; Sulfonamides; Sunitinib | 2017 |
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Everolimus; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Luminescent Measurements; Mice; Molecular Imaging; Molecular Targeted Therapy; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Pyrroles; Signal Transduction; Stromal Cells; Sunitinib; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Continuous remission of renal cell carcinoma with tumour thrombus after severe adverse events following short-term treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrroles; Remission Induction; Sunitinib; Thrombosis; Vena Cava, Inferior | 2017 |
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Sunitinib | 2017 |
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Neutrophils; Niacinamide; Nutritional Status; Phenylurea Compounds; Preoperative Period; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2017 |
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib | 2017 |
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2018 |
Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2018 |
Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Cell-Free Nucleic Acids; Combined Modality Therapy; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2017 |
Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Base Sequence; Carcinogenesis; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Mutagenesis; Nuclear Proteins; Pyrroles; RNA Interference; RNA, Small Interfering; Sequence Alignment; Sunitinib; Transcription Factors; Transplantation, Heterologous; Up-Regulation | 2017 |
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Health Expenditures; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States | 2017 |
Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib; Transcriptome; Treatment Outcome | 2018 |
Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Heterografts; Humans; Indoles; Magnetic Resonance Imaging; Male; Mice; Molecular Imaging; Molecular Targeted Therapy; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Lingual metastasis as an initial presentation of renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tongue Neoplasms | 2017 |
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2017 |
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis | 2018 |
[Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Humans; Indoles; Kidney Neoplasms; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Proto-Oncogene Proteins c-akt; Pyrroles; RNA Interference; Sunitinib; TOR Serine-Threonine Kinases | 2016 |
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Mutation; Pyrroles; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2018 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2018 |
Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2018 |
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Krukenberg Tumor; Peritoneal Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2018 |
Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Skull Base Metastasis From Occult Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Neoplasms, Unknown Primary; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Skull Base Neoplasms; Sorafenib; Sunitinib | 2018 |
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Second Primary; Pancreas; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A | 2018 |
AR involved in sunitinib resistance.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phosphorylation; Pyrroles; Sunitinib | 2018 |
Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Count; Female; Fluorescent Antibody Technique; Humans; Indoles; Kidney Neoplasms; Neoplastic Cells, Circulating; Pyrroles; Sunitinib | 2018 |
Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Prognosis; Pyrroles; ROC Curve; Sensitivity and Specificity; Sunitinib; Treatment Outcome | 2018 |
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Health Care Costs; Health Resources; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Patient Acceptance of Health Care; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome; United States | 2018 |
Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Survival Rate; Treatment Failure | 2018 |
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2019 |
[A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Japan; Kidney Neoplasms; Markov Chains; Molecular Targeted Therapy; Monte Carlo Method; Pyrroles; Quality-Adjusted Life Years; Sunitinib | 2018 |
Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Registries; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
Sunitinib Alone or after Nephrectomy in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Sunitinib Alone or after Nephrectomy in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Sunitinib Alone or after Nephrectomy in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2018 |
Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2019 |
Re: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2019 |
[A Case of Metastatic Clear Cell Renal Cell Carcinoma Showing Long-Term Complete Response after the Discontinuation of Tyrosine Kinase Inhibitor].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Pyrroles | 2018 |
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2019 |
Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Lymphocytes; Neutrophils; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2019 |
Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2019 |
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2021 |
[A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
Editorial comment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Keratosis, Actinic; Kidney Neoplasms; Lung Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Renal cell cancer treated with a single-edged sword.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2013 |
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Body Mass Index; Carcinoma, Renal Cell; Female; Forecasting; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sarcopenia; Sunitinib | 2013 |
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; G1 Phase; Indoles; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pyrroles; Signal Transduction; Sunitinib; Up-Regulation; Xanthones; Xenograft Model Antitumor Assays | 2012 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Renal Cell; CD11b Antigen; Cell Line; Cell Proliferation; Chemokine CXCL12; Drug Resistance, Neoplasm; Endostatins; Female; Gene Knockdown Techniques; Humans; Indoles; Mice; Myeloid Cells; Procollagen-Proline Dioxygenase; Proto-Oncogene Proteins c-mdm2; Pyrroles; Spiro Compounds; Sunitinib; Transplantation, Heterologous; Tumor Burden; Tumor Suppressor Protein p53 | 2013 |
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cytoskeleton; Ethanolamines; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Tubules, Proximal; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mitochondria; Neoplasm Metastasis; Neovascularization, Pathologic; Oxidation-Reduction; Pyrroles; Rats; Sunitinib; Transcription, Genetic; Vascular Endothelial Growth Factor Receptor-1; Wound Healing | 2013 |
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2012 |
[A case of myocardiac metastasis of clear cell renal carcinoma successfully treated with sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; ras Proteins; Signal Transduction; Sunitinib; Transcriptome | 2013 |
Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
Topics: Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Disease Progression; DNA Damage; G1 Phase; Humans; Indoles; Interleukins; Kidney Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-raf; Pyrroles; S Phase; Sunitinib; Tumor Necrosis Factor Decoy Receptors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2013 |
The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyoderma Gangrenosum; Pyrroles; Sunitinib | 2013 |
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2013 |
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrimidines; Pyrroles; Sirolimus; Stearoyl-CoA Desaturase; Sulfonamides; Sunitinib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Pyrroles; Risk Assessment; Sunitinib | 2013 |
Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Pyrroles; Sunitinib | 2013 |
Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Hematologic Tests; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutrophils; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2013 |
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Survival Rate; Young Adult | 2013 |
Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality Therapy; eIF-2 Kinase; Endoribonucleases; Female; Immunity, Innate; Indoles; Kidney Neoplasms; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Prostatic Neoplasms; Pyrroles; Sunitinib; Vesiculovirus | 2013 |
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Hypoxia; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; RNA, Messenger; Sunitinib; Survival; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.
Topics: Ablation Techniques; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Radiosurgery; Sunitinib | 2013 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Function Tests; Kidney Neoplasms; Liver Function Tests; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Patient Preference; Phenylurea Compounds; Population Surveillance; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2013 |
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; European Union; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Pyrroles; Sunitinib; Survival Analysis | 2013 |
[Case of multiple lung metastases of renal cell carcinoma failing to respond to Interferon-alpha (IFN-alpha) and sunitinib but markedly responding to everolimus].
Topics: Carcinoma, Renal Cell; Endoscopy; Everolimus; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pneumonectomy; Pyrroles; Sirolimus; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2013 |
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Growth Processes; Everolimus; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Random Allocation; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
[Hematologic adverse effects in patients with renal cell carcinoma treated with sunitinib].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2013 |
[A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Lung; Male; Pneumatosis Cystoides Intestinalis; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2013 |
Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Gene Expression Profiling; Graft Survival; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Neoplasm Metastasis; Pyrroles; Sequence Homology, Amino Acid; Sunitinib; Transplantation, Heterologous; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2014 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Young Adult | 2013 |
Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Topics: Animals; Carcinoma, Renal Cell; Cyclooxygenase 2; Female; Humans; Indoles; Kidney Neoplasms; Pyrazoles; Pyrroles; Sulfonamides | 2013 |
[Is the same tyrosine kinase inhibitor still effective after development of brain metastases? A Case report].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Renal Cell; Cell Adhesion; Cell Division; Cell Proliferation; Female; Humans; Imidazoles; Immunoenzyme Techniques; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nylons; Prognosis; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Young Adult | 2013 |
Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Indoles; Kidney Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib | 2014 |
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Mice, Knockout; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Kidney cancer: Comparing first-line treatments for mRCC.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Severe exacerbation of Crohn's disease during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Crohn Disease; Disease Progression; Fatal Outcome; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyrroles; Recurrence; Risk Factors; Severity of Illness Index; Sunitinib; Treatment Outcome | 2014 |
Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Oral Hygiene; Pain; Periodontal Index; Pyrroles; Sunitinib; Surveys and Questionnaires; Tooth Migration; Treatment Outcome | 2013 |
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2014 |
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Shrinkage of prostate volume in sunitinib-treated patients with renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dysuria; Endosonography; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Pyrroles; Quality of Life; Sunitinib; Tomography, X-Ray Computed; Urination | 2013 |
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Basigin; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Indoles; Kidney; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Tumor Cells, Cultured | 2013 |
Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Nomograms; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Survival Rate | 2013 |
Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; DNA Mutational Analysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Ki-67 Antigen; Kidney Neoplasms; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Proportional Hazards Models; Pyrroles; Sunitinib; Time Factors; Tissue Array Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
[Pre- surgical therapy with sunitinib for adrenal metastasis from renal cell carcinoma : a case report].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Preoperative Care; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neoplasm Invasiveness; Phosphoric Diester Hydrolases; Pyrroles; Signal Transduction; Sunitinib; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Sunitinib-induced severe hypoglycemia in a diabetic patient.
Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Severity of Illness Index; Sunitinib | 2014 |
Sunitinib-related interstitial pneumonia after treatment with temsirolimus: a case of possible recall phenomenon.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Pyrroles; Radiography; Sirolimus; Sunitinib | 2014 |
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Belgium; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2013 |
Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.
Topics: Aged; Blood Pressure Determination; Carcinoma, Renal Cell; Disease Management; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Compliance; Prognosis; Pyrroles; Sunitinib | 2013 |
Pazopanib versus sunitinib in renal cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Pazopanib versus sunitinib in renal cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Pazopanib versus sunitinib in renal cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Pazopanib versus sunitinib in renal cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Everolimus; Health Care Costs; Humans; Indoles; Kidney Neoplasms; Markov Chains; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Serbia; Sirolimus; Sunitinib; Survival Rate | 2013 |
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States | 2014 |
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib | 2014 |
Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Sunitinib | 2013 |
All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Hypertension; Immunohistochemistry; Indoles; Kidney Failure, Chronic; Kidney Glomerulus; Kidney Neoplasms; Male; Middle Aged; Proteinuria; Pyrroles; Registries; Retrospective Studies; Sunitinib; Syndrome; Vascular Endothelial Growth Factor A | 2014 |
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cohort Studies; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Quality of Life; Skin; Sunitinib | 2014 |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2014 |
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Smoking; Sunitinib; Treatment Outcome; Young Adult | 2014 |
[Sunitinib-induced pyoderma gangrenosum].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pyoderma Gangrenosum; Pyrroles | 2013 |
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Dramatic effect of sunitinib with rapid but transient improvement for psoriasis in a patient with metastatic renal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Remission Induction; Sunitinib | 2013 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Registries; Renal Insufficiency; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Targeted therapies: Juggling combinations--not the way forward.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus | 2014 |
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
[Exploratory analysis of the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Nephrogenic epistaxis.
Topics: Adult; Carcinoma, Renal Cell; Chemoradiotherapy; Diagnosis, Differential; Epistaxis; Humans; Indoles; Kidney Diseases; Male; Neoplasm Metastasis; Nose; Nose Neoplasms; Positron-Emission Tomography; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2014 |
Pazopanib outscores sunitinib on tolerability.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib | 2014 |
Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib | 2014 |
[Brain metastasis which appeared during complete response of lung metastatic lesion by sunitinib treatment in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Remission Induction; Sunitinib | 2013 |
NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Topics: Acute-Phase Proteins; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cells, Cultured; Drug Resistance, Neoplasm; Indoles; Kidney Neoplasms; Lipocalin-2; Lipocalins; Male; Mice; Mice, Nude; Proto-Oncogene Proteins; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Extensive necrotizing fasciitis associated with sunitinib therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fasciitis, Necrotizing; Gram-Positive Bacterial Infections; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Subcutaneous Fat; Sunitinib | 2014 |
[The changes in complete blood count in patients treated with sunitinib malate for metastatic clear cell renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Sunitinib | 2013 |
Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; MicroRNAs; Middle Aged; Models, Biological; Neoplasm Metastasis; Paracrine Communication; Prognosis; Pyrroles; Reproducibility of Results; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Kidney cancer: Sunitinib has similar efficacy irrespective of age in mRCC.
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2014 |
Kidney cancer: sunitinib has similar efficacy irrespective of age in mRCC.
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2014 |
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphopenia; Male; Neoplasm Staging; Neutropenia; Prognosis; Pyrroles; Risk Factors; Sunitinib; Treatment Outcome | 2014 |
Maturing of renal cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2014 |
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Sunitinib does not block thyroid peroxidase in patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Kidney Neoplasms; Perchlorates; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotropin | 2014 |
A collecting duct carcinoma producing carcinoembryonic antigen and Ca-125 in a 29-year-old woman.
Topics: Adult; Antineoplastic Agents; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Neoplasm Invasiveness; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2014 |
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2014 |
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Proteinuria; Pyrroles; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Sunitinib; Treatment Outcome | 2014 |
Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Organ Specificity; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.
Topics: Aged; Carcinoma, Renal Cell; Exome; Genome, Human; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins | 2014 |
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?
Topics: Adult; Aged; Aged, 80 and over; Antacids; Carcinoma, Renal Cell; Disease-Free Survival; Drug Interactions; Female; Gastric Acid; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2015 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Tissue Inhibitor of Metalloproteinase-2; Treatment Outcome | 2014 |
Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed | 2017 |
How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years.
Topics: Acute Disease; Angiogenesis Inhibitors; Aortic Aneurysm; Aortic Dissection; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lymphatic Metastasis; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Proto-Oncogene Proteins c-sis; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Superior vena caval syndrome secondary to metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pulmonary Embolism; Pyrroles; Radiotherapy; Sunitinib; Superior Vena Cava Syndrome | 2014 |
Kidney cancer: in crossover study, patients and physicians prefer pazopanib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
[A case of pneumatosis cystoides intestinalis secondary to sunitinib treatment for renal cell carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2014 |
[A case of adrenal metastasectomy in renal cell carcinoma after neoadjuvant therapy with sunitinib].
Topics: Adrenal Gland Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2014 |
[Metastatic collecting duct carcinoma with relatively long-term survival treated with sunitinib: a case report].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Pyrroles; Sunitinib | 2014 |
Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2014 |
Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian
Topics: Carcinoma, Renal Cell; Catheter Ablation; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Staging; Pyrroles | 2014 |
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Endpoint Determination; Humans; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2014 |
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Microvessels; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Phosphoproteins; Proportional Hazards Models; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Discontinuation of the tyrosine kinase inhibitor sunitinib in patients with metastatic renal cell carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Sunitinib | 2014 |
Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Disease-Free Survival; Europe; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Female; Genotype; Humans; Indoles; Japan; Kidney Neoplasms; Male; Metabolic Clearance Rate; Models, Biological; Neoplasm Proteins; Pyrroles; Sunitinib | 2014 |
Metastatic involvement of the maxillary antrum from an uncommon source.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Embolization, Therapeutic; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Maxillary Sinus Neoplasms; Nephrectomy; Niacinamide; Palatal Neoplasms; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2014 |
Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrotic Syndrome; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2014 |
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2014 |
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyponatremia; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Serum Albumin; Sodium; Sorafenib; Sunitinib; Survival Rate | 2015 |
[The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib | 2014 |
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Decreased toxicity with 2 weeks on and 1 week off schedule of sunitinib in metastatic renal cell carcinoma: is it a mirage or an oasis?
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2014 |
Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Editorial comment from Dr Yokomizo to efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2014 |
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Confidence Intervals; Cytoreduction Surgical Procedures; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms, Multiple Primary; Nephrectomy; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
Topics: Adult; Aged; Bone Marrow Cells; Carcinoma, Renal Cell; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Benzoates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pyrroles; Sunitinib; Telmisartan; Xenograft Model Antitumor Assays | 2014 |
Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol. In press. htt
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrases; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A | 2014 |
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2014 |
Editorial comment from Dr Yuasa to efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2014 |
Leukopenia as a biomarker of sunitinib outcome in advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2014 |
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L).
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Membrane Potential, Mitochondrial; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thiazolidines | 2014 |
Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Colon, Sigmoid; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radiography; Rectum; Retropneumoperitoneum; Sunitinib | 2014 |
Skin rash, a kidney mass and a family mystery dating back to World War II.
Topics: Adult; Alleles; Carcinoma, Renal Cell; Chromosome Deletion; Combined Modality Therapy; Drug Delivery Systems; Exanthema; Fumarate Hydratase; Genetic Counseling; Humans; Indoles; Kidney Medulla; Kidney Neoplasms; Leiomyomatosis; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Microfluidic Analytical Techniques; Multiplex Polymerase Chain Reaction; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Multiple Primary; Nephrectomy; New South Wales; Oligonucleotide Array Sequence Analysis; Precision Medicine; Pyrroles; Rod Opsins; Skin; Skin Neoplasms; Sunitinib; World War II | 2014 |
Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Germ-Line Mutation; Humans; Indoles; Kidney Neoplasms; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Pedigree; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Fatigue; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Pyrroles; Randomized Controlled Trials as Topic; Self Report; Sunitinib; Treatment Outcome | 2014 |
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cohort Studies; Europe; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis | 2014 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Israel; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2014 |
The use of sunitinib in renal cell carcinoma: where are we now?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Sunitinib | 2014 |
Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2014 |
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
Topics: Actin Cytoskeleton; Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Everolimus; Hedgehog Proteins; Humans; Indoles; Inhibitory Concentration 50; Kidney Neoplasms; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Micrometastasis; Nuclear Proteins; Paxillin; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Receptors, G-Protein-Coupled; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Smoothened Receptor; Sunitinib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2014 |
Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Renal Cell; Cell Hypoxia; Cell Movement; Drug Resistance, Neoplasm; Gene Expression; Humans; Hyaluronan Receptors; Immunohistochemistry; Indoles; Kidney Neoplasms; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Tumor Necrosis Factor-alpha | 2015 |
Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report.
Topics: Adult; Carcinoma, Renal Cell; Humans; Indoles; Kidney; Kidney Neoplasms; Kidney Transplantation; Male; Neoplasm Recurrence, Local; Postoperative Care; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Use of three-dimensional time-resolved phase-contrast magnetic resonance imaging with vastly undersampled isotropic projection reconstruction to assess renal blood flow in a renal cell carcinoma patient treated with sunitinib: a case report.
Topics: Adult; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Imaging, Three-Dimensional; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Nephrectomy; Pyrroles; Renal Circulation; Sunitinib; Time Factors | 2014 |
Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sunitinib | 2014 |
Racial disparity in metastatic renal cell cancer: the pharmaco-anthropology of sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2014 |
Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Vessels; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Nephrectomy; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiac Tamponade; Diagnosis, Differential; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2014 |
Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Belgium; Carcinoma, Renal Cell; Diarrhea; Edema; Female; Follow-Up Studies; Humans; Incidence; Indoles; Intestines; Kidney Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Pyrroles; Retrospective Studies; Sunitinib | 2015 |
Word of wisdom. Re: clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2014 |
Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Treatment Outcome | 2016 |
[Successful sunitinib treatment of a patient with Stauffer's syndrome].
Topics: Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; gamma-Glutamyltransferase; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Paraneoplastic Syndromes; Peritoneal Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
[Therapeutic significance of sunitinib-induced "off-target" side effects].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Stomatitis; Sunitinib; Treatment Outcome | 2014 |
Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; Mice; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
PISCES trial: the end does not always justify the means.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Reply to S. Barni et Al and M. Sun et Al.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Reply to S. Barni et Al and M. Sun et Al.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides | 2014 |
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Rapid involution of choroidal metastasis secondary to renal cell carcinoma with oral sunitinib.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Choroid Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Ultrasonography; Visual Acuity | 2015 |
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radiography; Retrospective Studies; Sunitinib; von Hippel-Lindau Disease | 2015 |
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium-Binding Proteins; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Membrane Proteins; Mice; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Differentiation; Drug Administration Schedule; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Sirolimus; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Health Expenditures; Health Services; Humans; Imidazoles; Indazoles; Indoles; Markov Chains; Models, Econometric; Pyrroles; Quality-Adjusted Life Years; Sunitinib; United States | 2015 |
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2015 |
Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cholesterol; Female; Humans; Hyperlipidemias; Hypothyroidism; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Triglycerides | 2015 |
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Kinetics; Membrane Transport Modulators; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Sunitinib; Tetrahydroisoquinolines | 2015 |
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice, Inbred C57BL; Mice, Nude; Muscle Proteins; Muscle, Skeletal; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Time Factors; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Protein Ligases; Weight Loss; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Withholding Treatment | 2015 |
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological Transport; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radioactive Tracers; Radioisotopes; Radionuclide Imaging; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Zirconium | 2015 |
Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Gadolinium DTPA; Humans; Image Enhancement; Indoles; Kidney Neoplasms; Magnetic Resonance Spectroscopy; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tyrosine | 2014 |
Stem cells increase in numbers in perinecrotic areas in human renal cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Necrosis; Neoplastic Stem Cells; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Prospective Studies; Pyrroles; Singapore; Sunitinib | 2015 |
Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib | 2014 |
Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Female; Gene Frequency; Genotype; Humans; Indoles; Japan; Kidney Neoplasms; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2014 |
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice, SCID; Microvessels; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib | 2015 |
Sunitinib and improved diabetes control.
Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Indoles; Insulin; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].
Topics: Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Genotype; Humans; Indoles; Polymorphism, Genetic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thrombocytopenia; Treatment Outcome | 2014 |
Sunitinib-induced thyrotoxicosis - a not so rare entity.
Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Thyrotoxicosis | 2015 |
Inhibition of placental growth factor in renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Sunitinib; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Europe; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2015 |
Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2015 |
Health care costs among renal cancer patients using pazopanib and sunitinib.
Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Health Services; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; United States | 2015 |
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Pyrimidines; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis; United States | 2015 |
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Mutation; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Risk; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2015 |
Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sunitinib | 2015 |
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Kidney Neoplasms; Male; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Inactivating STAT3: bad for tumor, good for muscle.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Muscle Proteins; Muscle, Skeletal; Protein Kinase Inhibitors; Pyrroles; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2015 |
p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Indoles; Interleukin-6; Mice; Mice, Nude; NF-kappa B; p21-Activated Kinases; Phosphorylation; Pyrroles; RNA Interference; Sunitinib | 2015 |
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis; Young Adult | 2015 |
Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Gene Frequency; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiotensins; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Renin-Angiotensin System; Sirolimus; Sunitinib; Treatment Outcome | 2015 |
Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Heterografts; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib | 2015 |
Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; Blood Platelets; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Indoles; Intestinal Absorption; Japan; Male; Middle Aged; Models, Biological; Platelet Count; Pyrroles; Sunitinib; Thrombocytopenia | 2015 |
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Artifacts; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Reproducibility of Results; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Egypt; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2015 |
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2016 |
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Indoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Coculture Techniques; Drug Resistance, Neoplasm; Female; Hepatitis A Virus Cellular Receptor 2; Heterografts; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Prognosis; Pyrroles; Sirolimus; Sunitinib; Tumor Cells, Cultured | 2015 |
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Renin-Angiotensin System; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Sunitinib 2 weeks on, 1 off: strengths and weaknesses.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2015 |
Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2015 |
Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quality of Life; Sunitinib; Treatment Outcome | 2015 |
Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Prognosis; Pyrroles; Registries; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Potential role of anti-VEGF targeted therapies in cervical artery dissection: A case report.
Topics: Angiogenesis Inhibitors; Aphasia; Bone Neoplasms; Carcinoma, Renal Cell; Carotid Artery, Internal, Dissection; Combined Modality Therapy; Endovascular Procedures; Hematoma; Humans; Hyperhomocysteinemia; Indoles; Infarction, Middle Cerebral Artery; Inflammation; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nephrectomy; Paresis; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy, Adjuvant; Stents; Sunitinib; Vasa Vasorum; Vascular Endothelial Growth Factor A; Vitamin B 12 Deficiency | 2015 |
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Disease Progression; Disease-Free Survival; Female; Haplotypes; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Netherlands; Ohio; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Spain; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides | 2016 |
Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Kidney cancer: SWITCHing inconsequential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles | 2015 |
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early Termination of Clinical Trials; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Treatment Outcome | 2015 |
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States | 2015 |
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; B7-H1 Antigen; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Heterografts; Humans; Immune Tolerance; Indoles; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Nude; Neoplasm Transplantation; Pyrroles; Sunitinib; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Tumor Microenvironment; Up-Regulation | 2015 |
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Cluster Analysis; Comparative Genomic Hybridization; DNA-Binding Proteins; Drug Design; Female; Gene Expression Profiling; Genotype; Humans; Hypoxia; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Nephrectomy; Nuclear Proteins; Pilot Projects; Protein Array Analysis; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Sunitinib; Transcription Factors; Von Hippel-Lindau Tumor Suppressor Protein | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Endoscopy, Gastrointestinal; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome | 2016 |
Precision medicine in oncology needs to integrate pharmacogenetic profiling.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Kidney Neoplasms; Male; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrroles | 2015 |
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Young Adult | 2015 |
[Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2015 |
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome | 2015 |
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indoles; Interleukin-13 Receptor alpha2 Subunit; Kidney Neoplasms; Mice, Inbred BALB C; Mice, SCID; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Kidney Neoplasms; Male; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrroles | 2015 |
Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery.
Topics: Bariatric Surgery; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Indoles; Kidney Neoplasms; Male; Obesity; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2015 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2015 |
miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Middle Aged; Models, Statistical; Neovascularization, Pathologic; Prognosis; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Transforming Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension.
Topics: Acetylcholine; Adult; Aged; Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Endothelium, Vascular; Forearm; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mesenteric Arteries; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroprusside; Pyrroles; Rats; Regional Blood Flow; Sunitinib; Vascular Endothelial Growth Factor A; Vasodilation; Vasodilator Agents | 2015 |
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Topics: Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Dysgeusia; Dyspepsia; Fatigue; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Mucositis; Nausea; Pyrroles; Stomatitis; Sunitinib; Time Factors | 2016 |
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2015 |
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult | 2015 |
Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Female; Glucocorticoid-Induced TNFR-Related Protein; Immunotherapy; Indoles; Kidney Neoplasms; Killer Cells, Natural; Lymphocyte Activation; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Sunitinib | 2016 |
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Singapore; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Signal Transduction; Sunitinib | 2015 |
Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib.
Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
Topics: Angiogenesis Inhibitors; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Lysosomes; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism.
Topics: Antineoplastic Agents; Ascites; Carcinoma, Renal Cell; Fatal Outcome; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Pyrroles; Sunitinib | 2016 |
Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Survival Analysis; Treatment Outcome | 2015 |
Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Turkey | 2015 |
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Drug Costs; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medicare; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United States; Young Adult | 2015 |
A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Metabolome; Middle Aged; Pyrroles; Serum; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2015 |
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2016 |
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
Topics: Aged; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Interleukin-13; Interleukin-8; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Survival Rate | 2015 |
Kidney cancer: Sunitinib: 2/1 is superior to 4/2.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Male; Pyrroles | 2015 |
[PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed | 2015 |
Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Indoles; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tissue Array Analysis | 2015 |
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Topics: Adult; Aged; Antineoplastic Agents; Autoantibodies; Autoimmunity; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Thyroglobulin; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States | 2016 |
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pilot Projects; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nevus, Spindle Cell; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2015 |
Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Fluorescent Antibody Technique; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Microscopy, Confocal; Pyrroles; RNA, Small Interfering; Signal Transduction; Stress, Physiological; Sunitinib; Transfection; Xenograft Model Antitumor Assays | 2015 |
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Pyrroles; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2016 |
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom | 2016 |
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2015 |
More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis.
Topics: Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles | 2016 |
Kidney cancer: TKIs associated with stroke risk.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles | 2015 |
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Metastatic renal cell carcinoma without evidence of a renal primary.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diagnosis, Differential; Diagnostic Imaging; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymph Node Excision; Male; Pyrroles; Sunitinib | 2016 |
The Authors Respond.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
The Authors Respond.
Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2016 |
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Topics: Animals; Antineoplastic Agents; Axitinib; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2016 |
More colors to the palette.
Topics: Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles | 2016 |
Comparing Everolimus to Sunitinib in Non-clear-cell Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2016 |
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Drug therapy: Preclinical oncology - reporting transparency needed.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Clinical Trials as Topic; Evidence-Based Medicine; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Medical Oncology; Meta-Analysis as Topic; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Pyrroles; Research Design; Research Report; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2016 |
Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment | 2016 |
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Sorafenib; Sunitinib | 2016 |
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chi-Square Distribution; Cytochrome P-450 CYP3A; Disease-Free Survival; Europe; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hypertension; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Ohio; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2017 |
Sunitinib activates Axl signaling in renal cell cancer.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Gene Ontology; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Inhibitory Concentration 50; Kidney Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib | 2016 |
Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Tumor Burden | 2016 |
Kidney cancer: Sunitinib versus everolimus for non-clear-cell renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2016 |
Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Erythrocyte Indices; Erythrocytes; Female; Hemoglobins; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome | 2016 |
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles | 2016 |
The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study.
Topics: Aged; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Hypertension; Incidence; Indoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease Progression; Female; Humans; Indoles; Inflammation; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2016 |
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Cross-Over Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib | 2017 |
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Case-Control Studies; Female; Genetic Association Studies; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Thrombocytopenia | 2016 |
In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Delayed-Action Preparations; Drug Synergism; Female; High-Energy Shock Waves; High-Intensity Focused Ultrasound Ablation; Indoles; Kidney Neoplasms; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Pyrroles; Sunitinib | 2016 |
Lethal acute liver failure in a patient treated with sunitinib.
Topics: Acute Kidney Injury; Aged; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Failure, Acute; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2016 |
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?
Topics: Aged; Antineoplastic Agents; Capsule Endoscopy; Carcinoma, Renal Cell; Diarrhea; Endoscopy, Gastrointestinal; Female; Humans; Indoles; Intestinal Mucosa; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2016 |
Adjuvant therapy for renal-cell carcinoma: settled for now.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles | 2016 |
Yellowish nail pigmentation caused by sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Nail Diseases; Pigmentation Disorders; Pyrroles; Risk Assessment; Sunitinib | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
Topics: Adenoma, Islet Cell; Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2016 |
Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Microscopy, Confocal; Middle Aged; Neovascularization, Pathologic; Nerve Tissue Proteins; Pyrroles; RNA, Messenger; RNA, Small Interfering; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Platelet Count; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2016 |
[Successful Management by Immunoglobulin for Sunitinib-Induced Thrombocytopenia in a Patient with Advanced Metastatic Renal Cell Carcinoma].
Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Humans; Immunoglobulins; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib; Thrombocytopenia | 2016 |
Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sarcopenia; Sunitinib | 2016 |
[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Systemic therapy of metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2016 |
[Sunitinib inhibits the expressions of co-stimulatory molecule ligands on dendritic cells].
Topics: B7-1 Antigen; B7-2 Antigen; B7-H1 Antigen; Carcinoma, Renal Cell; Cells, Cultured; Dendritic Cells; Down-Regulation; Female; Humans; Indoles; Ligands; Male; Monocytes; Programmed Cell Death 1 Ligand 2 Protein; Pyrroles; Sunitinib | 2016 |
Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immunoenzyme Techniques; Indoles; Ki-67 Antigen; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vesicular Transport Proteins | 2016 |
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker.
Topics: Aged; Calcium Channel Blockers; Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2016 |
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Blotting, Northern; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Exosomes; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Neoplasm; Signal Transduction; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glycolysis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Mice, Nude; Phenotype; Pyrroles; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Coculture Techniques; Drug Resistance, Neoplasm; Endothelial Cells; Fibroblasts; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Mice; Paracrine Communication; Pyrroles; Receptors, Fibroblast Growth Factor; Sunitinib; Tumor Cells, Cultured | 2016 |
Kidney cancer: Exosome transmission of sunitinib resistance.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2016 |
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Registries; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retreatment; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
[Dosing Schedules and Outcomes in Patients Treated with First-Line Sunitinib for Advanced Renal Cell Carcinoma].
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Topics: Adaptive Immunity; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Oncolytic Virotherapy; Oncolytic Viruses; Pyrroles; Reoviridae; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Topics: Aged; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Netherlands; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Young Adult | 2016 |
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; CD28 Antigens; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Nephrectomy; Preoperative Period; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Exome Sequencing; Female; Fumarate Hydratase; GRB2 Adaptor Protein; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74.
Topics: Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2017 |
Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Mastication; Neoplasm Metastasis; Nivolumab; Pain; Pyrroles; Sunitinib; Treatment Outcome; United States | 2016 |
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle Proteins; Class Ia Phosphatidylinositol 3-Kinase; Class Ib Phosphatidylinositol 3-Kinase; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoproteins; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Retrospective Studies; Ribosomal Protein S6 Kinases, 70-kDa; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2017 |
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer.
Topics: Carcinoma, Renal Cell; Diagnosis, Differential; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Orchiectomy; Pyrroles; Sunitinib; Testicular Neoplasms; Thrombectomy; Treatment Outcome; Venous Thrombosis | 2017 |
Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Female; Health Care Costs; Humans; Indazoles; Indoles; Male; Middle Aged; Prescription Fees; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2016 |
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Indoles; Kidney Neoplasms; Male; Metformin; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors | 2016 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; MicroRNAs; Pyrroles; RNA, Small Interfering; Sunitinib; Transcriptome; Treatment Failure; Ubiquitin-Protein Ligases | 2016 |
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib | 2016 |
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Prospective Studies; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tissue Array Analysis; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Egypt; Female; Follow-Up Studies; Hospitals, University; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2016 |
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides | 2016 |
Sunitinib uptake inhibits platelet function in cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Coagulation; Blood Platelets; Carcinoma, Renal Cell; Case-Control Studies; Female; Healthy Volunteers; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Pyrroles; Signal Transduction; Sunitinib | 2016 |
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Registries; Retrospective Studies; Sunitinib; Time-to-Treatment | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Pancreatic Neoplasms; Prognosis; Pyrroles; Sunitinib | 2016 |
Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Topics: Adrenomedullin; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Kidney Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Preoperative Care; Pyrroles; Retrospective Studies; Sunitinib; Thrombosis; Vascular Neoplasms; Vena Cava, Inferior | 2016 |
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Topics: Adult; Animals; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrroles; Receptors, Interleukin-2; Sunitinib; Tumor Burden; Tumor Escape; Xenograft Model Antitumor Assays | 2016 |
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2017 |
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Erythrocyte Indices; Erythrocytes; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2016 |
Targeting renal cell carcinoma with a HIF-2 antagonist.
Topics: Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Basic Helix-Loop-Helix Transcription Factors; Binding Sites; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Erythropoietin; Female; Gene Expression Regulation, Neoplastic; Humans; Indans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Mutation; Pyrroles; Reproducibility of Results; Sulfones; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retreatment; Risk Factors; Sunitinib; Treatment Outcome | 2017 |
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib | 2016 |
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden | 2017 |
Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Regression Analysis; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Indoles; Iodine; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; DNA-Binding Proteins; Everolimus; Female; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Nuclear Proteins; Prognosis; Proportional Hazards Models; PTEN Phosphohydrolase; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult | 2017 |
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Rate | 2017 |
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Sunitinib as adjuvant therapy for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2016 |
[Efficacy and the multivariate analysis of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2016 |
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2017 |
The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diabetes Insipidus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Pyrroles; Sunitinib | 2016 |
Gene expression profile of renal cell carcinomas after neoadjuvant treatment with sunitinib: new pathways revealed.
Topics: Adult; Aged; Carcinoma, Renal Cell; Chemokine CCL20; Chemokine CXCL6; DNA Methylation; Female; Fibrinogen; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Insulin-Like Growth Factor Binding Protein 1; Male; Middle Aged; Neoadjuvant Therapy; Pyrroles; Signal Transduction; Sunitinib; Transcriptome | 2017 |
An impedimetric biosensor for the diagnosis of renal cell carcinoma based on the interaction between 3-aminophenyl boronic acid and sialic acid.
Topics: Animals; Biosensing Techniques; Boronic Acids; Carcinoma, Renal Cell; Cattle; Cell Line; Cell Line, Tumor; Dielectric Spectroscopy; Electrodes; Equipment Design; Humans; Kidney Neoplasms; N-Acetylneuraminic Acid; Polymers; Pyrroles; Sensitivity and Specificity; Serum Albumin, Bovine; Silver | 2017 |
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Disease-Free Survival; Everolimus; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium Channel Blockers; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib | 2016 |
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Neoplasm Transplantation; Pyrroles; STAT3 Transcription Factor; Sunitinib; T-Lymphocytes, Regulatory | 2017 |
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Europe; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Practice Guidelines as Topic; Pyrroles; Societies, Medical; Sunitinib; Urology | 2017 |
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, Neoplasm; Becaplermin; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Cyclin D1; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Proto-Oncogene Proteins c-sis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Elongin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Mutation, Missense; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sunitinib; Transfection; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Mixed Results for Sunitinib in Renal Cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors.
Topics: Carcinoma, Renal Cell; Developing Countries; Geography; Humans; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Ilium; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Nephrectomy; Pyrroles; Rectal Neoplasms; Sunitinib | 2017 |
TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR.
Topics: Animals; Animals, Zoo; Carcinoma, Renal Cell; Carnivora; Female; Indoles; Kidney Neoplasms; Lung Neoplasms; Pyrroles | 2016 |
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk; Risk Assessment; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2017 |
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Commentary on: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
Topics: Biomarkers; Carcinoma, Renal Cell; Everolimus; Genomics; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Car
Topics: Biomarkers; Carcinoma, Renal Cell; Everolimus; Genomics; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2017 |
CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Pyrroles; Radiographic Image Enhancement; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Cyclooxygenase 2; Disease-Free Survival; Female; Gene Frequency; Genetic Association Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Genetic; Multivariate Analysis; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polypeptide N-acetylgalactosaminyltransferase; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2017 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2017 |
Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma after Nephrectomy.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Sunitinib | 2017 |
Intermittent sunitinib for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Prognosis; Pyrroles; Sunitinib | 2017 |
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Cluster Analysis; Cytokines; Disease Progression; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2017 |
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prealbumin; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Serum Albumin, Human; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Humans; Indazoles; Indoles; Italy; Kidney Neoplasms; National Health Programs; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis | 2017 |
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Mucins; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Tumor Cells, Cultured | 2017 |
Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Costs; Drug Dosage Calculations; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2017 |
Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Up-Regulation | 2017 |
Adjuvant Sunitinib in Renal-Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles | 2017 |
Adjuvant Sunitinib in Renal-Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles | 2017 |
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
Topics: Antibodies, Monoclonal, Humanized; Aspergillosis, Allergic Bronchopulmonary; Carcinoma, Renal Cell; Humans; Immunocompromised Host; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Pyrroles; Sunitinib | 2017 |
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Cell Surface; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
[Knockdown of ATG5 enhances the sensitivity of human renal carcinoma cells to sunitinib].
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Carcinoma, Renal Cell; Cell Line, Tumor; Gene Knockout Techniques; Humans; Indoles; Pyrroles; Sunitinib | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Prognosis; Pyrroles; Sunitinib | 2008 |
Severe gastrointestinal hemorrhage due to metastatic renal cell carcinoma to the pancreas successfully controlled by transarterial embolization and adjuvant administration of Sunitinib Malate.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Embolization, Therapeutic; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2008 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Pneumatosis Cystoides Intestinalis; Pyrroles; Radiography; Sunitinib | 2009 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report.
Topics: Adult; Biopsy, Needle; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Staging; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythrocyte Indices; Female; Hematologic Tests; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib | 2008 |
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyroid Gland; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine; Triiodothyronine | 2008 |
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
Sunitinib-related fulminant hepatic failure: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Failure, Acute; Pyrroles; Sunitinib | 2008 |
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Thyroid Function Tests | 2008 |
[Targeted therapy - point blank or single shot].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome; Young Adult | 2008 |
[New therapeutic regimes in metastasic renal-cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetic Angiopathies; Drug Eruptions; Foot; Foot Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Necrosis; Paresthesia; Pyrroles; Skin; Sunitinib | 2008 |
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Managed Care Programs; Markov Chains; Models, Economic; Neoplasm Metastasis; Pyrroles; Quality-Adjusted Life Years; Sunitinib; Survival Rate | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Sample Size; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nomograms; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2008 |
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proctocolitis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Major treatment improvements encourage kidney cancer researchers to seek further gains.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD1; Carcinoma, Renal Cell; Cell Lineage; Dendritic Cells; Disease-Free Survival; Female; Glycoproteins; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Myeloid Cells; Pyrroles; Sunitinib | 2008 |
[Renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Pharmacokinetics of sunitinib in hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Renal Dialysis; Renal Insufficiency; Sunitinib; Young Adult | 2009 |
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Diseases; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Sunitinib-induced acute hemolysis without hypertension: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Hemolysis; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
[Systemic therapy of metastasizing renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2008 |
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Female; Humans; Indoles; Insulin-Like Growth Factor I; Kidney Neoplasms; Male; Middle Aged; NF-kappa B; Pyrroles; Retrospective Studies; Sunitinib | 2008 |
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Dental Fistula; Humans; Indoles; Jaw Diseases; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Sunitinib | 2009 |
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Case-Control Studies; CD3 Complex; CD4-Positive T-Lymphocytes; Female; Humans; Immunosuppression Therapy; Indoles; Interferon-gamma; Interleukin-4; Kidney; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recombinant Proteins; Sunitinib; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells | 2008 |
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Withholding Treatment | 2009 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2009 |
Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pain Management; Palliative Care; Pyrroles; Quality of Life; Sunitinib; Zoledronic Acid | 2008 |
Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
Topics: Acute Disease; Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephritis, Interstitial; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis | 2009 |
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Preoperative Care; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Pain; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Treatment of hemodialyzed patient with sunitinib.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Artery Bypass; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Indoles; Male; Middle Aged; Nausea; Nephrectomy; Pyrroles; Remission Induction; Renal Dialysis; Sunitinib; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyrotoxicosis | 2009 |
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2009 |
Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.
Topics: Aged; Biopsy, Needle; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Topics: Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib | 2009 |
Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Pyrroles; Renal Dialysis; Skin Neoplasms; Sunitinib | 2009 |
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase C; Protein Kinase C beta; Pyridines; Pyrroles; Ribosomal Protein S6 Kinases; Signal Transduction; Sorafenib; Sunitinib | 2009 |
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cohort Studies; Data Interpretation, Statistical; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Surveys and Questionnaires; Time Factors; Urology | 2009 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Time Factors | 2009 |
Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Diuretics; Drug Therapy, Combination; Electrocardiography; Female; Furosemide; Gated Blood-Pool Imaging; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Metoprolol; Pyrroles; Sunitinib; Treatment Outcome; Troponin | 2009 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib | 2009 |
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Renal Cell; Endothelial Cells; Erythropoietin; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Indoles; Kidney Neoplasms; Kinetics; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
Topics: Acalculous Cholecystitis; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
From theoretical synergy to clinical supra-additive toxicity.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug Synergism; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Indoles; Kidney Neoplasms; Mice; Neovascularization, Pathologic; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Peritoneal Dialysis; Peritonitis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-gamma; Kidney Neoplasms; Male; Middle Aged; Myeloid Cells; Pyrroles; Sunitinib; Suppressor Factors, Immunologic; T-Lymphocytes, Regulatory | 2009 |
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Humans; Indoles; Interleukin-12; Kidney Neoplasms; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Monocytes; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation.
Topics: Aged; Amputation, Surgical; Angiogenesis Inhibitors; Anti-Bacterial Agents; Carcinoma, Renal Cell; Cutis Laxa; Debridement; Foot Dermatoses; Forefoot, Human; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Stevens-Johnson Syndrome; Sunitinib; Treatment Outcome; Wound Healing | 2009 |
Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Nephrotic Syndrome; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Dose Fractionation, Radiation; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pleural Neoplasms; Pyrroles; Radiation-Sensitizing Agents; Sunitinib | 2009 |
Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib | 2009 |
Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Heart Neoplasms; Humans; Indoles; Male; Middle Aged; Poland; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Compassionate Use Trials; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib | 2010 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Expanding the boundaries of clinical practice: building on experience with targeted therapies.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2009 |
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Intestinal Neoplasms; Intestine, Small; Kidney Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma.
Topics: Aged; Bursitis; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Olecranon Process; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Sequential sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Remission Induction; Remission, Spontaneous; Sunitinib | 2009 |
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Disease; Female; Heart; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Stroke Volume; Sunitinib; Ventricular Function, Left | 2009 |
Effective therapy for metastatic renal cancer, whither to now.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Gynecomastia; Humans; Indoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2009 |
Sunitinib-aggravated hypertension.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2009 |
The nasal septum: an unusual presentation of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Nasal Septum; Nose Neoplasms; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult | 2009 |
Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
Topics: Aged; Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Prospective Studies; Pyrroles; Sunitinib | 2009 |
Surgical resection of renal cell carcinoma after targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2009 |
Sunitinib-induced thyrotoxicosis.
Topics: Aged; Antineoplastic Agents; Carbimazole; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Prednisone; Propranolol; Pyrroles; Sunitinib; Thyroid Hormones; Thyrotoxicosis | 2009 |
Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Nephrectomy; Pyrroles; Sunitinib | 2009 |
Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Sunitinib; Treatment Outcome | 2009 |
Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Renal Dialysis; Sunitinib | 2009 |
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Medical Audit; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; United Kingdom | 2009 |
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium DTPA; Humans; Hypoxia; Immunoprecipitation; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
[Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib | 2009 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Topics: Benzamides; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Sunitinib | 2009 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Peritoneal Dialysis; Pyrroles; Renal Dialysis; Sunitinib | 2009 |
A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Indoles; Karyotyping; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Translocation, Genetic | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2009 |
Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypopigmentation; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2009 |
Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Pyrroles; Sirolimus; Sunitinib | 2010 |
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cohort Studies; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Therapy for metastatic RCC--questions remain.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Data Interpretation, Statistical; Female; Health Status Indicators; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Sunitinib; Surveys and Questionnaires | 2009 |
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain-Derived Neurotrophic Factor; Carcinoma, Renal Cell; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Sunitinib; Survival Rate; Tumor Necrosis Factor-alpha | 2009 |
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; France; Gastrointestinal Diseases; Germany; Health Care Costs; Hematologic Diseases; Hospital Costs; Hospitalization; Humans; Hypertension; Indoles; Interferon alpha-2; Interferon-alpha; Italy; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom; Venous Thrombosis | 2010 |
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Benzenesulfonates; Carcinoma, Renal Cell; Cooperative Behavior; Data Collection; Drug Delivery Systems; Drug Utilization; Germany; Humans; Immunotherapy; Indoles; Interdisciplinary Communication; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Medical Oncology; Niacinamide; Patient Care Team; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Urology | 2010 |
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Prognosis; Pyrroles; Sunitinib | 2009 |
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Time Factors | 2010 |
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Prognosis; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome | 2010 |
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Regional Health Planning; Sorafenib; Sunitinib; Survival Rate; United Kingdom | 2009 |
Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Remission Induction; Sunitinib | 2009 |
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
Topics: Antineoplastic Agents; Arteries; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Enalapril; Glomerulosclerosis, Focal Segmental; Humans; Indoles; Kidney; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Thrombotic Microangiopathies | 2010 |
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
SUN vs BEVthornIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Computer Simulation; Confidence Intervals; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Models, Theoretical; Probability; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
Effect of sunitinib on renal cell carcinoma cutaneous metastasis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Skin Neoplasms; Sunitinib | 2009 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib | 2010 |
Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cells, Cultured; Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neoplasm Proteins; Proteoglycans; Pyrroles; Sunitinib; Umbilical Cord; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Neutralizing; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Interleukin-8; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2010 |
Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Topics: Adult; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thrombosis | 2010 |
Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.
Topics: Adrenalectomy; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Treatment Outcome | 2010 |
Renal cell carcinoma: complete response.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Radiography; Smoking; Sunitinib; Thrombocytopenia; Treatment Outcome | 2010 |
Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.
Topics: Adult; Antineoplastic Agents; Bronchial Fistula; Bronchial Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Mediastinal Neoplasms; Pyrroles; Sunitinib | 2010 |
[Renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Organ Size; Pyrroles; Sunitinib; Thyroid Gland | 2010 |
Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Prognosis; Pyrroles; Sunitinib; Ultrasonography | 2010 |
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2010 |
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Gelatinases; Humans; Indoles; Kidney; Kidney Neoplasms; Lipocalins; Neoplasms; Neutrophils; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2010 |
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Carcinoma, Renal Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Everolimus; Female; Gene Fusion; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Research Report; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2010 |
[The introduction of targeted drugs].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Delivery Systems; Evidence-Based Medicine; Germany; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2010 |
[Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Approval; Drug Delivery Systems; Drugs, Investigational; Germany; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate | 2010 |
[Monitoring of metastatic renal cell carcinoma--standards and challenges].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drug Monitoring; Drugs, Investigational; Follow-Up Studies; Germany; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Survival Rate; Tomography, X-Ray Computed | 2010 |
[Outlook: Future therapy of renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Everolimus; Evidence-Based Medicine; Forecasting; Germany; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Prognosis; Pyrroles; Sirolimus; Sunitinib | 2010 |
Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.
Topics: Aged; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Natriuretic Peptide, Brain; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombosis | 2010 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Recombinant Proteins; Sunitinib | 2010 |
How does sunitinib cause hypothyroidism?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2010 |
Sunitinib induces hypothyroidism with a markedly reduced vascularity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Middle Aged; Organ Size; Pyrroles; Sunitinib; Thyroid Gland | 2010 |
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Necrosis; Neoplasm Metastasis; Pneumothorax; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Tomography, X-Ray Computed | 2010 |
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2010 |
Current and predicted cost of metastatic renal cell carcinoma in Finland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Finland; Health Care Costs; Humans; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Odds Ratio; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2010 |
Prognostic factors in patients treated with VEGF-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors | 2010 |
The promise of biomarkers for personalized renal cancer care.
Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasms; Nervous System Neoplasms; Patients; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Nephrons; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Osteonecrosis of the jaw related to sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Molar; Neoplasm Recurrence, Local; Nephrectomy; Osteonecrosis; Postoperative Complications; Pyrroles; Sunitinib; Tooth Extraction | 2011 |
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
Topics: Animals; Carcinoma, Renal Cell; CD11b Antigen; CD8-Positive T-Lymphocytes; Female; Humans; Immunologic Factors; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Pyrroles; Sunitinib; Suppressor Factors, Immunologic; T-Lymphocyte Subsets | 2010 |
[Renal cell carcinoma management and therapies in 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Everolimus; Humans; Indoles; Interferons; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Metabolic Networks and Pathways; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Digestive System; Heart; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Injury; Mucous Membrane; Muscle Fatigue; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
[Advanced renal carcinomas with special situations. How to treat them?].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Sunitinib | 2010 |
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2010 |
Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Pyrroles; Radiotherapy Dosage; Sunitinib; Tomography, X-Ray Computed | 2010 |
[Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Mesoderm; Mice; Mice, Nude; Microvessels; Pericytes; Phenotype; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2010 |
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Protein Isoforms; Pyrroles; RNA, Messenger; Solubility; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Fatigue; Humans; Indoles; Kidney Neoplasms; Medical History Taking; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Sunitinib | 2010 |
Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib | 2010 |
Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Drug Synergism; Humans; Imidazoles; Indoles; Infusions, Intravenous; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Neoplasm Staging; Osteonecrosis; Pyrroles; Sacrum; Spinal Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Neoplasm Metastasis; Pyrroles; Sunitinib | 2010 |
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Approval; Everolimus; Humans; Indoles; Kidney Neoplasms; Practice Guidelines as Topic; Pyrroles; Sirolimus; Sunitinib; United Kingdom | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Renal Cell; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pulmonary Alveoli; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.
Topics: Angiogenesis Inhibitors; Capillaries; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Palliative Care; Pyrroles; Skin; Sunitinib | 2010 |
Three cases of severe ulcerative esophagitis induced by SUTENT®.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Esophagitis; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Pyrroles; Sunitinib; Ulcer | 2012 |
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Carcinoma; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Metastatic collecting duct carcinoma of the kidney responded to sunitinib.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Ribs; Sunitinib | 2011 |
Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Diphosphonates; Humans; Indoles; Injections, Intravenous; Kidney Neoplasms; Mandibular Diseases; Middle Aged; Mucositis; Osteonecrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Risk Factors; Stomatitis; Sunitinib; Tooth Extraction | 2010 |
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Hypercholesterolemia; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Salvage Therapy; Sirolimus; Sunitinib | 2011 |
[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Middle Aged; Prevalence; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Hormones; Thyrotropin | 2010 |
Renal cell carcinoma: ten years of significant advances.
Topics: Angiogenesis Inhibitors; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Drug Discovery; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Medical Oncology; Neoplasm Metastasis; Pyrroles; Sunitinib | 2010 |
Evidence-based urology in practice: randomized controlled trials stopped early for benefit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Evidence-Based Medicine; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Recall pneumonitis during systemic treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphocytes; Mediastinal Neoplasms; Middle Aged; Neoplasms, Radiation-Induced; Pneumonia; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles; Renal Dialysis; Rhabdomyolysis; Sunitinib; Treatment Outcome | 2010 |
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?
Topics: Blood Pressure; Carcinoma, Renal Cell; Endothelin-1; Gastrointestinal Stromal Tumors; Heart Rate; Humans; Hypertension; Indoles; Kidney Neoplasms; Models, Biological; Proteinuria; Pyrroles; Receptor Protein-Tyrosine Kinases; Renin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Hyperthyroidism; Hypothyroidism; Indoles; Japan; Male; Middle Aged; Organ Size; Protein Kinase Inhibitors; Pyrroles; Regional Blood Flow; Sunitinib; Thyroid Gland; Thyroiditis; Thyrotoxicosis | 2010 |
Recurrent scrotal hemangiomas during treatment with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Genital Neoplasms, Male; Hemangioma; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recurrence; Scrotum; Skin Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cytokines; Disease Progression; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Palliative Care; Protein Kinase Inhibitors; Pyrroles; Quality-Adjusted Life Years; Spain; Sunitinib | 2010 |
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrroles; Sunitinib | 2010 |
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyrotropin; Treatment Outcome | 2011 |
Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2011 |
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Feasibility Studies; Female; Humans; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Progression of intramedullary metastasis during perioperative cessation of sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Spinal Neoplasms; Sunitinib | 2010 |
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom | 2010 |
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2010 |
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Tumor Burden; Young Adult | 2011 |
Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Topics: Acute Kidney Injury; Angioplasty, Balloon, Coronary; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Agents; Coronary Stenosis; Fatal Outcome; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multiple Organ Failure; Protein Kinase Inhibitors; Pyrroles; Renal Dialysis; Sunitinib; Treatment Outcome | 2010 |
The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Indoles; Interleukin-2; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Recombinant Fusion Proteins; Sunitinib | 2010 |
Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Papilledema; Pyrroles; Sunitinib | 2011 |
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factors | 2011 |
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Constitutive Androstane Receptor; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib | 2011 |
Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Retrospective Studies; Sunitinib | 2010 |
Lower limbs erosions induced by sunitinib.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Infective Agents, Local; Carcinoma, Renal Cell; Foot Ulcer; Hand; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrroles; Skin Ulcer; Sunitinib; Treatment Outcome | 2011 |
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Retreatment; Retrospective Studies; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Tubulocystic renal carcinoma: a clinical perspective.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
[Multimodal interventional therapy of a large renal cell carcinoma in a patient with high anesthesia risk - a case report].
Topics: Anesthesia, General; Antineoplastic Agents; Biopsy, Needle; Brachytherapy; Carcinoma, Renal Cell; Catheter Ablation; Chemotherapy, Adjuvant; Combined Modality Therapy; Conscious Sedation; Contraindications; Embolization, Therapeutic; Follow-Up Studies; Health Status Indicators; Humans; Image Processing, Computer-Assisted; Indoles; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasm Staging; Pulmonary Emphysema; Pyrroles; Radiology, Interventional; Radiotherapy, Adjuvant; Respiratory Insufficiency; Sunitinib; Tomography, X-Ray Computed | 2011 |
Kidney cancer: Does hypothyroidism predict clinical outcome?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Medical Oncology; Neoplasm Metastasis; Palliative Care; Pyrroles; Radiation-Sensitizing Agents; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Indoles; Kidney Neoplasms; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2011 |
Blue toe syndrome and sunitinib.
Topics: Antineoplastic Agents; Blue Toe Syndrome; Carcinoma, Renal Cell; Heparin, Low-Molecular-Weight; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2011 |
Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Brain Neoplasms; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Radiosurgery; Spinal Neoplasms; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Gland; Tomography, X-Ray Computed | 2011 |
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.
Topics: Adult; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Pyrroles; Sunitinib; Translocation, Genetic | 2011 |
Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; DNA Fingerprinting; Everolimus; Female; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Polymorphism, Single Nucleotide; Pyrroles; Sirolimus; Sunitinib; Transfection; Tumor Cells, Cultured; von Hippel-Lindau Disease; Xenograft Model Antitumor Assays | 2011 |
Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases.
Topics: Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Sunitinib | 2010 |
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Immunoglobulin E; Indoles; Kidney Neoplasms; Mast Cells; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Rhinitis, Allergic, Seasonal; Sunitinib | 2011 |
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Monocytes; Neoplastic Cells, Circulating; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Survival Rate; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Pyoderma gangrenosum with the use of sunitinib.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Prednisone; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrroles; Skin; Sunitinib; Treatment Outcome | 2011 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Retrospective Studies; Sunitinib; Treatment Outcome | 2011 |
Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2011 |
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Models, Animal; Drug Interactions; Female; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Lymphatic Vessels; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Pyrroles; Stromal Cells; Sunitinib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Von Hippel-Lindau Tumor Suppressor Protein | 2011 |
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2011 |
Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Palliative Care; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2011 |
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States | 2011 |
Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Nose Neoplasms; Pyrroles; Skull Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2011 |
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2012 |
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Boston; Carcinoma, Renal Cell; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Observer Variation; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Pyrroles; Reproducibility of Results; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antigens, Ly; Carcinoma, Renal Cell; CD11b Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Sunitinib; Tumor Burden; Tumor Escape | 2011 |
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Ventricular Function, Left | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
A proof of concept phase II non-inferiority criterion.
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Confidence Intervals; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Research Design; Sirolimus; Sunitinib | 2011 |
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder | 2013 |
Editorial comment to "Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature".
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2011 |
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Patient Selection; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Radiography; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Texas; Thrombectomy; Time Factors; Treatment Outcome; Tumor Burden; Vena Cava, Inferior; Venous Thrombosis | 2011 |
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Substrate Specificity; Sunitinib; Swine; Transfection | 2011 |
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cell Proliferation; Collagen Type I; Disease Models, Animal; Female; Humans; Indoles; Kidney Neoplasms; Macrophage Colony-Stimulating Factor; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Osteoclasts; Peptides; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Pyrroles; Renal Dialysis; Sunitinib | 2012 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2011 |
Targeted caval cytoreduction: solid foundations or shifting sands?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Patient Selection; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Thrombectomy; Time Factors; Treatment Outcome; Tumor Burden; Vena Cava, Inferior; Venous Thrombosis | 2011 |
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Osteotomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Prognosis; Pyrroles; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; Carcinoma, Renal Cell; Community Health Services; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; United States | 2012 |
Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Dedifferentiation; Combined Modality Therapy; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Rhabdoid Tumor; Sunitinib | 2011 |
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sunitinib; Treatment Outcome | 2011 |
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyrans; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Ethanolamines; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Irbesartan; Male; Middle Aged; Nebivolol; Prevalence; Pyrroles; Reproducibility of Results; Sunitinib; Tetrazoles; Time Factors; Treatment Outcome | 2011 |
[Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tumor Lysis Syndrome | 2011 |
Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Renal Cell; Contrast Media; Evidence-Based Medicine; Female; Fluorocarbons; Humans; Indoles; Kidney Neoplasms; Male; Microbubbles; Middle Aged; Neoplasm Metastasis; Pyrroles; Reproducibility of Results; Statistics, Nonparametric; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Ultrasonography | 2011 |
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Remission Induction; Sunitinib; Treatment Outcome | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2011 |
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
Topics: Aged; Angiogenesis Inhibitors; Angiotensins; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Renin-Angiotensin System; Retrospective Studies; Sunitinib; Treatment Outcome | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2011 |
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Health Care Costs; Humans; Indoles; Interferon-alpha; Italy; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2011 |
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Incidence; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Nephrectomy; Organ Sparing Treatments; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Sunitinib prior to planned cytoreductive nephrectomy: is this the new litmus test for metastatic renal cell carcinoma?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Rare Diseases; Sunitinib | 2012 |
Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Lung Neoplasms; Male; Opportunistic Infections; Pulmonary Aspergillosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quinolones; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Sunitinib-induced acute psychosis: case report.
Topics: Aged; Bipolar Disorder; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Psychotic Disorders; Pyrroles; Sunitinib | 2011 |
Metastatic collecting duct carcinoma of the kidney treated with sunitinib.
Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Diagnosis, Differential; Fatal Outcome; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Ribs; Sunitinib | 2011 |
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Survival Rate; Texas; Time Factors; Treatment Outcome; Tumor Burden; Young Adult | 2011 |
Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Topics: Benzodioxoles; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; Treatment Failure | 2011 |
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Topics: Aged; Animals; Antineoplastic Agents; Body Weight; Capillaries; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Rats; Rats, Inbred WKY; Regional Blood Flow; Regression Analysis; Retrospective Studies; Stomach Neoplasms; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2011 |
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; International Cooperation; Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Time Factors | 2011 |
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Humans; Hypertension; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Indazoles; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Pyrroles | 2011 |
Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Humans; Indoles; Kidney Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pyrroles; Renal Dialysis; Sunitinib | 2011 |
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cathepsin K; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 6; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Interferons; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Pyrroles; Sirolimus; Sunitinib; Translocation, Genetic | 2011 |
Determining the optimal dose and schedule of sunitinib: some answers, more questions.
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2012 |
Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sirolimus; Sunitinib | 2012 |
Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Female; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Peritonitis; Pyrroles; Sunitinib | 2012 |
The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Protein Kinase C-epsilon; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sunitinib; Wound Healing | 2011 |
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2013 |
Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Calcium; Carcinoma, Renal Cell; Female; Humans; Hyperparathyroidism; Hypophosphatemia; Indoles; Kidney Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2012 |
Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Combined Modality Therapy; Female; Gene Fusion; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Nephrectomy; Nephrotic Syndrome; Pyrroles; Sunitinib; Translocation, Genetic; Treatment Outcome | 2011 |
Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Radiography; Sirolimus; Sunitinib | 2011 |
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; HCT116 Cells; HT29 Cells; Humans; Indoles; Kidney Neoplasms; Lysosomes; Mice; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2011 |
Improved curve fits to summary survival data: application to economic evaluation of health technologies.
Topics: Algorithms; Antineoplastic Agents; Biomedical Technology; Carcinoma, Renal Cell; Computer Simulation; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Models, Statistical; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Sunitinib; Survival Analysis; Treatment Outcome | 2011 |
Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biotransformation; Calibration; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Dealkylation; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Limit of Detection; Protein Kinase Inhibitors; Pyrroles; Reproducibility of Results; Sunitinib; Sweat; Tandem Mass Spectrometry | 2011 |
Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Survival Analysis; Turkey | 2011 |
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Disease-Free Survival; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Patient Selection; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Spain; Sunitinib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
Targeted therapy for patients with renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2011 |
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-pim-1; Pyridazines; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib | 2011 |
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Count; Disease Progression; Disease-Free Survival; Epidemiologic Methods; Female; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pyrroles; Sunitinib; Young Adult | 2012 |
PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Indoles; Kidney Neoplasms; Melanoma; Protein Serine-Threonine Kinases; Pyrroles; Ribosomal Protein S6 Kinases, 90-kDa; RNA Interference; RNA, Small Interfering; Sunitinib | 2012 |
Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2011 |
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib | 2011 |
Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Receptors, FSH; Retrospective Studies; Sensitivity and Specificity; Sunitinib | 2012 |
[Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sarcoma; Sunitinib | 2011 |
Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Female; Health Status; Humans; Indoles; Japan; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2013 |
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Remission Induction; Retrospective Studies; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2012 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sunitinib | 2012 |
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Pyrroles; Sunitinib; Time Factors | 2012 |
Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Genital Diseases, Male; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Scrotum; Skin Diseases; Sunitinib; Vulvar Diseases | 2012 |
An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
Topics: Algorithms; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Indoles; Kidney Neoplasms; Proportional Hazards Models; Pyrroles; Rare Diseases; Research Design; Sample Size; Sirolimus; Sunitinib; Survival | 2012 |
Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Scleroderma, Diffuse; Sunitinib | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2012 |
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Chemoradiotherapy; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Palliative Care; Pyrroles; Sunitinib | 2012 |
Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Prognosis; Proteasome Endopeptidase Complex; Pyrroles; Sunitinib; Survival Analysis | 2012 |
Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyridines; Pyrroles | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2012 |
Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Blood Glucose; Carcinoma, Renal Cell; Diabetes Mellitus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2012 |
Second-line treatment for renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Retreatment; Sulfonamides; Sunitinib | 2012 |
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Hormones | 2012 |
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Editorial comment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoadjuvant Therapy; Pyrroles; Sunitinib | 2012 |
Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2013 |
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrroles; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Chi-Square Distribution; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Receptors, CXCR4; Risk Assessment; Risk Factors; RNA, Messenger; Sunitinib; Time Factors; Treatment Outcome | 2012 |
Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC).
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Postoperative Complications; Pyrroles; Risk Assessment; Risk Factors; Sunitinib | 2012 |
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Female; Humans; Indoles; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotoxicosis | 2012 |
Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report.
Topics: Aged; Antibodies; Carcinoma, Renal Cell; Female; Humans; Indoles; Iodide Peroxidase; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroglobulin; Thyroiditis, Autoimmune; Tomography, X-Ray Computed | 2012 |
Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplastic Cells, Circulating; Pyrroles; Sunitinib; Vena Cava, Inferior; Venous Thrombosis | 2012 |
Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Blood Loss, Surgical; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Length of Stay; London; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Postoperative Complications; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2012 |
Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2012 |
Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gingival Hemorrhage; Humans; Indoles; Kidney Neoplasms; Mandibular Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Taste Disorders | 2012 |
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Topics: Adult; Aged; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Genotype; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Sunitinib; Young Adult | 2012 |
Sunitinib related osteonecrosis of jaw: a case report.
Topics: Actinomyces; Actinomycosis; Amoxicillin; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Clavulanic Acid; Female; Humans; Indoles; Kidney Neoplasms; Mandible; Mandibular Diseases; Middle Aged; Molar, Third; Osteonecrosis; Pyrroles; Sunitinib; Tooth Extraction; Tooth Socket | 2012 |
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Management of bone metastases from advanced renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles | 2012 |
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokines; Female; Humans; Immunotherapy; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Drug Administration Schedule; Everolimus; Female; Indoles; Kidney Neoplasms; Luciferases; Luminescent Measurements; Mice; Mice, Inbred BALB C; Pyrroles; Random Allocation; Sirolimus; Sunitinib | 2012 |
Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Nephrectomy; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2012 |
Management of antiangiogenic therapy-induced hypertension.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lisinopril; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment | 2012 |
How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shift.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2012 |
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib | 2012 |
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2013 |
[Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Image Interpretation, Computer-Assisted; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Organ Sparing Treatments; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Topics: Aged; Angiogenesis Inhibitors; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Risk Factors; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Child; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Translocation, Genetic | 2013 |
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Gland; Thyroid Hormones | 2012 |
The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Erythropoietin; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indoles; Kidney Neoplasms; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrroles; Receptors, Erythropoietin; Recombinant Proteins; Signal Transduction; Sunitinib | 2012 |
Tyrosine kinase inhibitor induced pancreatitis.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib | 2013 |
Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Pyrroles; Severity of Illness Index; Sunitinib | 2013 |
Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Topics: Adult; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Drug Resistance; Fatal Outcome; Female; Hormone Replacement Therapy; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Liver Neoplasms; Pyrroles; Severity of Illness Index; Sunitinib; Thyroid Gland; Thyroxine | 2012 |
Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiopulmonary Bypass; Contraindications; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Failure; Male; Middle Aged; Pyrroles; Sunitinib | 2013 |
[A case of interstitial lung disease due to sunitinib].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib | 2012 |
[Cardiac tamponade due to pericardial metastasis from renal cell carcinoma : a case report].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiac Tamponade; Echocardiography; Heart Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pericardiocentesis; Pericardium; Pyrroles; Sunitinib | 2012 |
Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; China; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Humans; Indoles; Kidney Neoplasms; Limit of Detection; Linear Models; Pyrroles; Reproducibility of Results; Sunitinib; Tandem Mass Spectrometry | 2013 |
Conditional survival of patients with metastatic renal-cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2012 |
[A case of advanced renal cell carcinoma with inferior vena cava thrombus treated with sunitinib as neoadjuvant therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Thrombosis; Vena Cava, Inferior | 2012 |
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Hepatocyte Growth Factor; Humans; Indoles; Interleukin-6; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Humans; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Hypoxia; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Indoles; Kidney Neoplasms; MicroRNAs; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2013 |
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
[Management of sunitinib-associated adverse events].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Pyrroles; Sunitinib | 2012 |
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Sweden; Young Adult | 2013 |
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States | 2013 |
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Remission, Spontaneous; Sunitinib | 2013 |
Early onset recall pneumonitis during targeted therapy with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Prednisolone; Protein Kinase Inhibitors; Pulse Therapy, Drug; Pyrroles; Radiation Dosage; Radiation Pneumonitis; Spinal Neoplasms; Sunitinib; Thoracic Vertebrae; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Esophagitis; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tetrazoles; Valine; Valsartan | 2013 |
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Pyrroles; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2013 |
Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemoradiotherapy; Enzyme Inhibitors; Fistula; Gastric Fistula; Heart Diseases; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pericardium; Pleural Diseases; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Renal Cell; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; ROC Curve; Statistics, Nonparametric; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2013 |
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Indoles; Kidney Neoplasms; Mice; Pyrazoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Retrospective Studies; Sunitinib; Survival; Treatment Outcome | 2013 |
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Kidney; Lung; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Carcinoma, Renal Cell; Cell Division; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Recombinant Proteins; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Renal Cell; ErbB Receptors; Kidney Neoplasms; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Tumor Cells, Cultured | 2003 |
Cytotoxic effect of the Her-2/Her-1 inhibitor PKI-166 on renal cancer cells expressing the connexin 32 gene.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Connexins; Dose-Response Relationship, Drug; ErbB Receptors; Gap Junction beta-1 Protein; Genes, erbB-1; Growth Inhibitors; Humans; Kidney Neoplasms; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2005 |
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Topics: Animals; Antineoplastic Agents; Binding Sites; Blotting, Western; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; DNA, Complementary; Doxorubicin; Humans; Immunohistochemistry; Kidney; Kidney Neoplasms; Kinetics; Male; Mice; Mice, Nude; Neoplasm Transplantation; Peptides; Protein Binding; Pyrroles; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bombesin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Transplantation; Chemokines, CC; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Receptors, Bombesin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Treatment options in metastatic renal carcinoma: an embarrassment of riches.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2006 |
Sunitinib maleate.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element.
Topics: Base Sequence; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Hypoxia; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Models, Biological; Molecular Sequence Data; Nylons; Protein Binding; Pyrroles; Response Elements; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2006 |
A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2006 |
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2006 |
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Interleukin-2; Karnofsky Performance Status; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Nurse's Role; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Assessment; Safety Management; Sorafenib; Sunitinib; Survival Analysis | 2006 |
Three new drugs available to fight kidney cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lapatinib; Multicenter Studies as Topic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Long-term response with sunitinib for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Remission Induction; Sunitinib; Time Factors | 2006 |
New therapeutic options for renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
We have a new treatment, but you can't afford it.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Costs and Cost Analysis; Drug Costs; Humans; Indoles; Kidney Neoplasms; Male; Medicare; Physician's Role; Pyrroles; Sunitinib | 2006 |
New hope for RCC patients.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lapatinib; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2006 |
[Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2006 |
Treatment outcome for metastatic papillary renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Papillary; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2006 |
Sunitinib relieves renal cell carcinoma spinal cord compression.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Spinal Cord Compression; Spinal Neoplasms; Sunitinib | 2007 |
Good news for metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2006 |
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dermatitis, Seborrheic; Erythema; Foot; Hand; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Syndrome | 2006 |
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Hormones | 2007 |
Renal-cell carcinoma--molecular pathways and therapies.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Approval; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Safety; Sunitinib; United States; United States Food and Drug Administration | 2007 |
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Renal Cell; Cell Cycle Proteins; DNA Adducts; DNA Damage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; HeLa Cells; Heterocyclic Compounds, 3-Ring; HT29 Cells; Humans; Male; Mice; Mice, Nude; Organoselenium Compounds; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein Serine-Threonine Kinases; Pyrroles; Reactive Oxygen Species; S Phase; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2007 |
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Pyrroles; Sunitinib | 2006 |
Fatigue with sunitinib-induced hypothyroidism.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
Two new drugs for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
Topics: Animals; Bone and Bones; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Indoles; Kidney; Kidney Neoplasms; Loss of Heterozygosity; Mice; Mutation; Oxindoles; Propionates; Pyrroles; Radiography; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Newly approved therapies for RCC and their effect on the standard of care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Interferons; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Sunitinib and hypothyroidism.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Hypothyroidism; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrroles; Safety; Sunitinib; Treatment Outcome | 2007 |
Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Tumor Lysis Syndrome | 2007 |
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Hormone Replacement Therapy; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroid Hormones | 2007 |
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Thyroid Function Tests; Thyroid Hormones | 2007 |
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Survival Rate | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Hypertension as a predictive factor of Sunitinib activity.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2007 |
Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2007 |
Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome | 2007 |
Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2007 |
Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Pyrroles; Seizures; Sunitinib; Syndrome; Treatment Outcome | 2007 |
[Imatinib . Sunitinib].
Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate | 2007 |
Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiomyopathies; Contraindications; Echocardiography; Female; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Severity of Illness Index; Sunitinib; Ventricular Dysfunction, Left | 2007 |
Temsirolimus for advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2007 |
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cognition Disorders; Dementia, Vascular; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Sunitinib | 2007 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Humans; Indoles; Male; Necrosis; Pyrroles; Sunitinib | 2007 |
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Thrombosis; Diagnosis, Differential; Female; Heart Atria; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Brain metastases in patients with renal cell cancer receiving new targeted treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Home blood-pressure monitoring in patients receiving sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Heart Rate; Home Nursing; Humans; Hypertension; Indoles; Kidney Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Telemedicine | 2008 |
Allergic interstitial nephritis possibly related to sunitinib use.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Eosinophilia; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Nephrectomy; Nephritis, Interstitial; Proteinuria; Pyrroles; Sunitinib | 2007 |
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Nephrectomy; Protein Kinases; Pyrazoles; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Time Factors | 2007 |
Acute cardiac failure after sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
Remission of diabetes while on sunitinib treatment for renal cell carcinoma.
Topics: Antineoplastic Agents; Blood Glucose; Carcinoma, Renal Cell; Dendritic Cells; Diabetes Complications; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Indoles; Insulin; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cytokines; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Finland; Health Care Costs; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Markov Chains; Models, Economic; Palliative Care; Protein Kinase Inhibitors; Pyrroles; Quality-Adjusted Life Years; Sunitinib; Time Factors; Treatment Failure | 2008 |
Severe epistaxis with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Epistaxis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
Metastatic renal cell carcinoma with partial response to sunitinib complicated by ureteral obstruction from necrotic tumor.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Middle Aged; Necrosis; Pyrroles; Sunitinib; Ureteral Obstruction | 2009 |
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyrotoxicosis; Thyrotropin; Thyroxine | 2008 |
Editorial comment on: Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Movement; Humans; Indoles; Kisspeptins; Matrix Metalloproteinase Inhibitors; Molecular Biology; Neoplasm Invasiveness; Pyrroles; Receptors, G-Protein-Coupled; Receptors, Kisspeptin-1; Sunitinib; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
Cardiotoxicity associated with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2008 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Probability; Protein-Tyrosine Kinases; Pyrroles; Registries; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Stroke Volume; Sunitinib; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Heart Diseases; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Pyrroles; Sunitinib; Thrombosis | 2008 |
[Neoadjuvant therapy for renal cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Cell Division; Doxorubicin; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microsatellite Repeats; Neoplasm Transplantation; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Cells, Cultured | 2000 |